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Drinking Water Public Health Goals
 
Pesticide and Environmental Toxicology Section
 
Office of Environmental Health Hazard Assessment
 
California Environmental Protection Agency
 
This Public Health Goal (PHG) technical support document provides information on health 
effects from contaminants in drinking water.  PHGs are developed for chemical contaminants 
based on the best available toxicological data in the scientific literature.  These documents and 
the analyses contained in them provide estimates of the levels of contaminants in drinking water 
that would pose no significant health risk to individuals consuming the water on a daily basis 
over a lifetime. 
The California Safe Drinking Water Act of 1996 (amended Health and Safety Code, Section 
116365) requires the Office of Environmental Health Hazard Assessment (OEHHA) to perform 
risk assessments and adopt PHGs for contaminants in drinking water based exclusively on public 
health considerations.  The Act requires that PHGs be set in accordance with the following 
criteria: 
1.	  PHGs for acutely toxic substances shall be set at levels at which no known or anticipated 
adverse effects on health will occur, with an adequate margin of safety. 
2.	  PHGs for carcinogens or other substances which can cause chronic disease shall be 
based solely on health effects without regard to cost impacts and shall be set at levels 
which OEHHA has determined do not pose any significant risk to health. 
3.	  To the extent the information is available, OEHHA shall consider possible synergistic 
effects resulting from exposure to two or more contaminants. 
4.	  OEHHA shall consider the existence of groups in the population that are more 
susceptible to adverse effects of the contaminants than a normal healthy adult. 
5.	  OEHHA shall consider the contaminant exposure and body burden levels that alter 
physiological function or structure in a manner that may significantly increase the risk of 
illness. 
6.	  In cases of insufficient data to determine a level of no anticipated risk, OEHHA shall set 
the PHG at a level that is protective of public health with an adequate margin of safety. 
7.	  In cases where scientific evidence demonstrates that a safe dose-response threshold for a 
contaminant exists, then the PHG should be set at that threshold. 
8.	  The PHG may be set at zero if necessary to satisfy the requirements listed above. 
9.	  OEHHA shall consider exposure to contaminants in media other than drinking water, 
including food and air and the resulting body burden. 
10.	  PHGs adopted by OEHHA shall be reviewed every five years and revised as necessary 
based on the availability of new scientific data. 
PHGs adopted by OEHHA are for use by the California Department of Health Services (DHS) in 
establishing primary drinking water standards (State Maximum Contaminant Levels, or MCLs). 
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regard to economic cost considerations, drinking water standards adopted by DHS are to consider 
economic factors and technical feasibility.  Each standard adopted shall be set at a level that is as 
close as feasible to the corresponding PHG, placing emphasis on the protection of public health. 
PHGs established by OEHHA are not regulatory in nature and represent only non-mandatory 
goals.  By federal law, MCLs established by DHS must be at least as stringent as the federal 
MCL if one exists. 
PHG documents are used to provide technical assistance to DHS, and they are also informative 
reference materials for federal, state and local public health officials and the public.  While the 
PHGs are calculated for single chemicals only, they may, if the information is available, address 
hazards associated with the interactions of contaminants in mixtures.  Further, PHGs are derived 
for drinking water only and are not to be utilized as target levels for the contamination of other 
environmental media. 
Additional information on PHGs can be obtained at the OEHHA web site at www.oehha.ca.gov. 
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IN DRINKING WATER
 
SUMMARY 
A Public Health Goal (PHG) of 0.0008 mg/L (0.8 ppb) was developed for trichloroethylene 
(TCE) in drinking water.  The current California Maximum Contaminant Level (MCL) is 0.005 
mg/L (5 ppb) for TCE in drinking water.  The PHG was based on the occurrence of 
hepatocellular carcinomas and adenocarcinomas in mice in two studies, in both sexes, by 
inhalation and oral routes of administration, and a linear dose-response approach.  The 
carcinogen slope factor (CSF) of 0.013 (mg/kg-day)
-1 was based on a geometric mean of four 
values using the pharmacokinetic dose metric of TCE metabolized dose (AMET).  A nonlinear 
approach yielded a value of 0.005 mg/L (5 ppb).  Semi-quantitative estimates of health-protective 
water concentrations based on the occurrence of kidney cancers in TCE-exposed cardboard 
workers and limited exposure data were similar, ranging from 0.3 to 1.3 ppb TCE.  The PHG was 
set at a level providing a de minimis theoretical lifetime excess individual cancer risk (10
-6) 
through typical ingestion of tap water.  It also includes an allowance for inhalation and dermal 
exposures to TCE via showering, flushing of toilets, and other typical household uses of tap 
water that may contain TCE.  A health-protective value for noncancer toxicity was also 
developed.  Based on the benchmark dose (BD10) for kidney nephropathy in an oral chronic study 
in rats, and a 100-fold uncertainty factor, a value of 1.0 mg/L (1 ppm) was derived for TCE. 
INTRODUCTION 
The purpose of this document is to develop a PHG for trichloroethylene.  The document is based 
on earlier Office of Environmental Health Hazard Assessment (OEHHA) assessments for water 
(DHS, 1988) and air (DHS, 1990) and particularly a health risk assessment performed by the 
Lawrence Livermore National Laboratory under contract to OEHHA (Bogen et al., 1988).  [Note: 
prior to the establishment of the California Environmental Protection Agency in 1991 OEHHA 
was a division of the California Department of Health Services (DHS)]. 
Trichloroethylene (TCE) is a volatile organic compound (VOC) which has been extensively used 
as a metal degreaser, a solvent in adhesives, textile manufacturing, paint stripping, and dry 
cleaning etc.  Production in the United States was estimated as about 130,000 metric tons/year 
(U.S. EPA, 1985; Davidson and Beliles, 1991).  There are currently two U.S. manufacturers of 
TCE with a combined capacity of 145,000 metric tons/year (ATSDR, 1997).  Due to widespread 
use, TCE is a common environmental contaminant.  The primary public health concern from 
chronic low level exposures via contaminated drinking water is the probability of cancer 
induction. 
Rodent cancer bioassays have shown that oral administration of TCE in corn oil leads to an 
increased incidence of hepatocellular carcinoma in B6C3F1 mice (NCI, 1976; NTP, 1983, 1988, 
1990; Maltoni et al., 1986a).  In parallel studies, TCE did not induce hepatocellular carcinoma in 
Osborne-Mendel rats (NCI, 1976), Fischer 344 rats (NTP, 1983), and Sprague-Dawley rats 
(Maltoni et al., 1988).  Fukuda et al. (1983) reported lung tumors in B6C3F1 mice after TCE 
inhalation exposure.  The metabolism of TCE is thought to play a key role in its carcinogenic 
effects (Buben and O’Flaherty, 1985).  Metabolites of TCE, chloral hydrate (CH), trichloroacetic 
acid (TCA), and dichloroacetic acid (DCA) induced hepatocellular tumors in B6C3F1 mice when 
TRICHLOROETHYLENE in Drinking Water 
California Public Health Goal (PHG)  1  February 1999 administered in drinking water (Herrn-Freund et al., 1987; Bull et al., 1993; DeAngelo et al., 
1991; Daniel et al., 1992; Pereira, 1996).  Similar administration of TCA and DCA to rats did not 
result in liver tumors (Herrn-Freund et al., 1987; Bull et al., 1990; Daniel et al., 1992).  Other 
metabolites such as trichloroethanol (TCOH), its glucuronide (TCOG), and related metabolites 
may also play a role in the overall mode of action. 
CHEMICAL PROFILE 
Chemical Identity 
Trichloroethylene (TCE) is a volatile, chlorinated hydrocarbon compound that has been widely 
used as a degreasing solvent. Information on the identity of TCE is provided in Table 1. 
Physical and Chemical Properties 
Trichloroethylene is a colorless liquid. It is miscible with common organic solvents and is 
slightly soluble in water.  It has a vapor pressure of 50 mm Hg at 20° C and boils at 87° C. Other 
information on the physical and chemical properties of TCE is provided in Table 2. 
Production and Uses 
U.S. production of trichloroethylene has decreased in recent years due to restrictions on 
emissions and substitution by other solvents. In 1982 U.S. production totaled 340 million kg (748 
million pounds) (Chemical Marketing Reporter, 1983); in 1985 U.S. production was only 178 
million pounds due to industry recycling (Storck, 1987).  In 1990 U.S. production was 138 
million pounds (IARC, 1995).  A minimum purity of 99.85% is required of commercial grades of 
TCE for use as a chemical reagent (World Health Organization, 1985).  Contaminants that have 
been found in commercial TCE include epichlorohydrin, carbon tetrachloride, 1,2­
dichloroethane, trans-1,2-dichloroethylene, cis-1,2-dichloroethylene, pentachloroethane,1,1,1,2­
and 1,1,2,2-tetrachloroethane, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1-dichloroethylene, 
tetrachloroethylene, bromodichloromethane, bromodichloroethylene, chloroform , and benzene 
(Verschueren, 1983; IARC, 1995).  Commercial grades of TCE require stabilizers (up to 2%) in 
the form of antioxidants or acid-receptors.  Natural production of TCE has been reported in 
temperate, subtropical and tropical algae and in one red microalga (Abrahamson et al., 1995). 
TCE is widely used as an industrial solvent primarily for the vapor degreasing and cold cleaning 
of fabricated metal parts.  It is also used in textile cleaning and solvent extraction processes.  Of 
the total TCE used in the U.S. in 1982, 66% was used in vapor degreasing, 22% for export, 7% 
as chemical intermediates, and 5% for miscellaneous uses (Chemical Marketing Reporter, 1983). 
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Table 1.  Chemical Identity of trichloroethylene 
Chemical name:  Trichloroethylene 
Synonyms: TCE, TRI, ethylene trichloride, acetylene trichloride, ethinyl trichloride, 1,1,2­
trichloro-ethylene, trichloraethen (German), trichloroaethylene (German), trichloretene (Italian), 
tricloroetilene (Italian), trielina (Italian), 1-chloro-2,2-dichloroethylene, 1,1-dichloro-2 
chloroethylene, 1,1,2-trichloroethylene, 1,1,2-trichloroethene, 1,2,2-trichloroethylene. 
Registered trade names: Alglyen, Anamenth, Benzinol, Blacosolv, Cecolene, Chlorilen, 
Chlorylea, Chlorylen, Circosolv, Crawhaspol, Densinfluat, Dow-Tri, Dukerom, Fleck-Flip, 
Flock-Flip, Fluate, Gemalgene, Germalgen, Lanadin, Lethurin, NCI-CO4546, Narcogen, 
Narkigen, Narkosoid, Nialk, Perm-Trial, Perm-a-chlor, Petzinol, Philex, Threthylen, Threthylene, 
Trethylen, Trethylene, Triad, Trial, Tri-Clene, Tri-Plus, Tri-Plus M,Triasol, Trichloran, 
Trichloren, Triclene, Trielene, Trielin, Trilen, Trilene, Triline, Trimar, Triol, Vestrol, Vitran, 
Westrosol. 
Chemical formula: C2HCl3 
Identification numbers: 
Chemical Abstracts Service (CAS) Registry number:  79-01-06 
NIOSH Registry of Toxic Effects of Chemical
 Substances (RTECS)® number:  KX4550000 
U.S. EPA Hazardous Waste number:  U228 
Oil and Hazardous Materials/Technical Assistance
 Data System (OHM/TADS) number:  7216931 
Hazardous Substances Data Bank (HSDB) number:  133 
DOT/UN/NA/IMCO shipping:  UN1710 
National Cancer Institute (NCI) number:  NCI-C04546 
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Table 2. Physical and Chemical Properties of Trichloroethylene 
Property  Value  References 
Molecular weight  131.39 g/mol   IARC (1995) 
Color  Clear, colorless 
Physical state  Mobile liquid 
Odor  Chloroform-like  Budavari (1989) 
Odor threshold in water  10.0 mg/L   Verschueren (1983) 
Boiling point  87° C  Lide (1993) 
Melting point  -73° C  Lide (1993) 
Solubility
 Water  1.07 g/L (20
0 C)  McNeill (1979)
 Organic solvents  Soluble in ethanol, 
diethyl ether, acetone 
and chloroform 
Specific Gravity  1.4642 g/cm
3 (20° C)  Lide (1993) 
Partition coefficients
 Octanol-water (Kow)
 Log Kow  2.42  Leo (1983) 
2.29  Callahan et al. (1979) 
2.61  Hansch et al. (1995) 
Vapor pressure  100 mm Hg (31.4 
0 C)  Lide (1993) 
Henry's law constant  0.020  atm-m
3/mol (20° C)  MacKay & Shiu (1981) 
0.011 atm-m
3/mol (25° C)  Hine & Mookerjee (1975) 
Conversion factor: Air at 25°C  1 ppm = 5.37 mg/m
3  IARC (1995) 
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Trichloroethylene released to the environment tends to partition to the atmosphere.  It has been 
estimated that 60% to 90% of the annual world production of TCE is released to the environment 
(WHO, 1985).  The environmental degradation of TCE primarily involves atmospheric 
photooxidation.  The key properties of TCE that affect its movement in the environment are its 
high vapor pressure and relatively low solubility in water. 
Air 
TCE in the atmosphere is subject to relatively rapid chemical or photochemical degradation.  In 
the troposphere, it is removed by scavenging mechanisms, primarily with hydroxyl free radicals 
(•OH).  Dahlberg (1969) observed the degradation products of atmospheric TCE decay to 
include phosgene and dichloroacetyl chloride.  Gay et al. (1976) also observed formyl chloride 
when TCE was photooxidized in the presence of nitrogen dioxide.  McNeill (1979) lists the 
decomposition products of TCE, due to autooxidation catalyzed by free radicals, to include 
hydrochloric acid (HCl), dichloroacetyl chloride, phosgene, carbon monoxide, and 
hexachlorobutane.  The persistence of TCE in the atmosphere is dependent on the concentration 
of hydroxyl free radicals (•OH) and the extent of vertical and horizontal mixing.  A literature 
review by the U.S. Environmental Protection Agency (U.S. EPA, 1985a) gave 11 days to two 
weeks as the range of the atmospheric residence time of TCE. 
The widespread use and volatile characteristics of TCE, combined with its persistence and 
transport in the atmosphere, make this chemical a global ambient air contaminant. Highest 
ambient air concentrations are found in urban environments and near point-sources.  Singh et al. 
(1981) measured mean TCE concentrations of 339 – 302 parts per trillion by volume (pptv) in 
Los Angeles, CA, and 188 – 270 pptv in Oakland, CA, during 1979.  Singh et al.  (1982) 
measured ground-level average TCE atmospheric concentrations in seven U.S. cities (in 1980) 
ranging from 96 – 93 pptv to 225 – 298 pptv.  They estimated a background TCE concentration 
of 15 pptv based on global surface level measurements, but primarily represented by a Pacific 
marine site at Point Arena, CA (40
0N.).  The California Air Resources Board (Nystrom, 1986), 
from preliminary 1985 data, reports average ambient TCE concentrations for several California 
locations:  Los Angeles, 338 – 223 pptv; San Jose, 730 – 156 pptv; San Francisco, 348 – 106 
pptv; Stockton, 296 – 63 pptv; Santa Barbara, 219 – 123 pptv; and Simi Valley, 116 – 54 pptv. 
Industrial releases of TCE into the environment in the U.S. were 53.75 million pounds in 1988, 
49.5 million pounds in 1989, 38.9 million pounds in 1990, and 35.1 million pounds in 1991 
(U.S.EPA, 1993).  Indoor air concentrations of TCE can increase when TCE contaminated water 
is used domestically. A community water supply with 40 ppm (mg/L) of TCE was estimated to 
contribute 40 mg/m
3 to bathroom air during showering resulting in a 48 mg inhalation dose/wk (1 
hr showering) compared to 42 mg through ingestion (Andelman, 1985). 
Soil 
TCE in the soil can be lost through volatilization to the atmosphere, downward leaching, or 
sorption to organic material.  The sorption of TCE to soils appears to be correlated to its 
octanol/water partition coefficient, the organic carbon content of the soil, and the concentration 
of TCE in the liquid phase.  From the soil-water partition coefficient of 0.8 ppm by weight 
(Urano and Murata, 1985), it follows that TCE is only moderately hydrophobic and thus is 
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in experiments with trace organics in soil columns, that tetrachloroethylene (PCE) and related 
halogenated organics, including TCE, have the potential to leach rapidly through the soil. 
Many studies have indicated that TCE is transformed to 1,2-DCE in soils and aquifer systems. 
Parsons et al. (1984), Wood et al. (1985), Dresen and Hoffman (1986), Boateng et al. (1984), and 
Cline and Viste (1985) independently studied TCE or PCE spills in Florida, California, 
Washington, Connecticut, and Wisconsin.  1,2-DCE was found in the plumes from the spills 
although there was no known source for it.  A conclusion drawn from each study was that TCE 
was degrading to 1,2-DCE.  Proof that TCE microbially degrades to 1,2-DCE in soil was given 
by Kleopfer et al. (1985), who studied anaerobic degradation in soils taken at depths of 1 to 17 
feet from a Des Moines TCE spill-site.  They used soybean meal to assure anaerobic conditions. 
All soils spiked with [
13C]-1abeled TCE produced [
13C]-labeled 1,2-DCE after 6 wk of 
incubation.  None of their set of rigorous controls showed formation except for one that was 
thought to be incompletely sterilized.  The rate of transformation could not be determined 
because of volatilization.  Actual concentrations of TCE measured in soils range from 5.6 to 300 
ppb by weight in soi1 samples taken from the vicinity of industrial producers and consumers of 
TCE (U.S. EPA, 1985a). 
Water 
In surface waters TCE volatilizes rapidly into the atmosphere.  Wind speed, agitation of the 
water, and water and air temperatures affect evaporation rates.  Photodegradation and hydrolysis 
are slow decay processes and do not appear to be important in the overall removal of TCE 
(McNeill, 1979).  Dilling et al. (1975) observed TCE to have a slow decomposition rate in dilute 
aqueous solutions.  They measured a half-life of 10.7 months at ambient temperatures in the 
dark.  In the presence of sunlight, 75% of the TCE decomposed in 12 months, compared to a 
54% loss over the same period in the dark.  In contrast, Dilling et al. (1975) showed that 
the loss of TCE from agitated dilute aqueous solution occurs exponentially with an evaporation 
half-life of 21 – 3 min.  The U.S.EPA (1985a) summarized several studies of surface waters, 
including one by Zoeteman et al. (1980) who measured a half-life of TCE in the Rhine River of 1 
to 4 days and one by Smith et al. (1980) who estimated half-lives of TCE in surface waters 
ranging from 3 hr for rapidly moving shallow streams to 10 h or longer for ponds or lakes.  TCE 
concentrations in drinking water supplies from surface waters have been measured in 133 cities 
through federal surveys (U.S. EPA, 1985a).  Thirty-two percent of the treated drinking waters 
contained TCE concentrations ranging from 0.06 to 3.2 mg/L and averaging 0.47 mg/L.  Thirty 
percent of all systems sampled contained a TCE level below 1 mg/L and the remaining 2% 
contained TCE concentrations between 1 and 4 mg/L. 
In the groundwater TCE has been found to degrade slowly by microbial action.  Wood et al. 
(1985), Parsons et al. (1984, 1985), Dresen and Hoffman (1986), Boateng et al. (1984) and Cline 
and Viste (1985) independently studied TCE or perchloroethylene (PCE) spills in Florida, 
California, Washington, Connecticut and Wisconsin.  The plumes from the spills showed 
progressively less of the parent compounds (PCE and/or TCE) and progressively more 
dichloroethylene (DCE) in the form of cis-1,2-DCE and trans-l, 2-DCE.  Wood et al. (1985) 
measured the microbial half-lives of the parent compounds and possible degradation products 
under laboratory conditions and reported the values shown in Table 3.  These investigators 
interpret these data to support the hypothesis that PCE degrades to TCE, which then degrades to 
the three DCE isomers listed in Table 3.  The DCE isomers then degrade to vinyl chloride. 
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Table 3.  Microbial half-lives derived by Wood et al. (1985). 
_Compound  Half-life (d) 
Vinyl chloride  ND
a 
trans-l,2-Dichloroethylene (trans-l,2-DCE)  ND 
cis-1,2-Dichloroethylene (cis-l,2-DCE)  ND 
1,l-Dichloroethylene (1,l-DCE)  53 
Trichloroethylene (TCE)  43 
Tetrachloroethylene (PCE)  34 
a  ND = No detectable reduction in concentration during observations over periods 
averaging 30 to 60 d. 
The degradation products and relative degradation rates found by Wood et al. are supported by a 
number of laboratory “microcosm” studies intended to simulate groundwater aquifer conditions 
(Parsons et al., 1984, 1985; Barrio-Lage et al., 1986; Wilson et al., 1986; Bouwer and McCarty, 
1983; Vogel and McCarty, 1985). 
Field measurements were made by Roberts et al. (1980) (data reported in Bouwer et al., 1981) on 
the decrease in concentration of various volatile halogenated organic compounds present 
(initially at concentrations of 2 to 20 mg/L) in reclaimed tertiary effluent (i.e., treated sewage 
water) that was injected into an aquifer in Palo Alto, California.  Over the 11-month observation 
period the concentration of TCE decreased with a half-life of approximately 1 to 1.5 yr.  This 
half-life is similar to that calculated from their data for PCE and 1,1,1-trichloroethane, but longer 
than that of approximately 20 to 30 d observed for 4 trihalomethanes (CHBr3, CHClBr2, 
CHCl2Br, and CHC13; the reported concentration of CHCl3 declined only until 140 d after 
injection stopped, after which it remained constant at approximately 1 mg/L). 
Other field measurements of contamination showed that TCE degradation varies with the amount 
and type of local microorganisms.  Cline and Viste (1985) studied the products of organic solvent 
degradation in the groundwater plumes from solvent-recovery facilities and landfill leachate. 
Both 1,2-DCE isomers were detected in groundwater near solvent-recovery facilities that had soil 
organic matter or other carbon sources, but presence of TCE-degradation products was not 
detected in groundwater that passed beneath an undisclosed industrial site in an organic-poor 
environment. 
Hydrolytic loss of TCE was found to be either nonexistent or much slower in the sterile, control 
environments used in microcosm experiments than in test environments that were 
microbiologically active.  Parsons et al. (1984, 1985) reported no loss of TCE from sterile 
control microcosms in either 3- or l6-wk laboratory experiments.  Parson and Lage (1985) 
showed transformation of TCE in the sterilized controls containing TCE, water, and aquifer 
sediment in 8-wk experiments.  They concluded that the hydrolytic processes were much slower 
than the microbial ones.  Dilling et al. (1975) measured the disappearance of TCE from aerated 
water that was purified by deionization followed by treatment with activated charcoal.  They 
calculated a half-life of 10.7 months for the disappearance of TCE.  These investigators ascribed 
the loss of TCE solely to hydrolysis. 
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were derived from a survey of large water utilities in California (i.e., utilities with more than 200 
service connections).  The survey was conducted by the California Department of Health 
Services (DHS, 1986).  From January 1984 through December 1985, wells in 819 water systems 
were sampled for organic chemical contamination.  The water systems use a total of 5550 wells, 
2947 of which were sampled.  TCE was found state-wide in 187 wells at concentrations up to 
440 mg/L, with a median concentration of 3.0 mg/L.  Generally, the most contaminated wells and 
the wells with the highest concentrations were found in the heavily urbanized areas of the state. 
Los Angeles County registered the greatest number of contaminated wells (i.e., 149). 
Food 
The average concentrations of TCE in food in the U.S. were: 0.9 (0-2.7) ppb in grain-based 
foods; 1.8 (0-12) ppb in ‘table-ready’ foods; 73.6 (1.6-980) ppb in butter and margarine; 3.8 (0­
9.5) ppb in cheese products; 0.5 (0-1.7) ppb in peanut butter; 3.0 (0-9.2) ppb in ready-to-eat 
cereal products; and 1.3 (0-4) ppb in highly processed foods (Heikes & Hopper, 1986; Heikes, 
1987).  Process waters in 3/15 food processing plants were found to contain 3-7.8 ppb TCE but 
no TCE was found in the food products (Uhler & Diachenko, 1987).  Daft (1989) detected TCE 
in 5/372 fatty and non-fatty food samples at concentrations of 2-94 ppb (mean, 49 ppb).  The 
concentrations of TCE in food in the U.K. were: 0.3-10 ppb in dairy products, 12-22 ppb in meat, 
non-detect (ND)-19 ppb in oils and fats, ND-60 ppb in beverages, ND-7 ppb in fruits and 
vegetables and 7 ppb in cereals. 
METABOLISM AND PHARMACOKINETICS 
Trichloroethylene is rapidly absorbed across the surface of the lungs and gastrointestinal tract. 
Although some TCE can be absorbed through the skin, the rate and extent of dermal absorption 
are limited in contrast with more lipophilic xenobiotic compounds. 
There is very little information on the distribution of TCE in humans; however, data from animal 
studies indicate that TCE distributes to all tissues.  The concentration of TCE in a given tissue 
depends on the route of exposure, partition coefficients of TCE in each tissue, and on the rates of 
metabolism and elimination.  Once in the blood, TCE is metabolized via cytochrome P450 
enzymes initially to chloral (trichloroacetaldehyde).  Chloral, following hydration to chloral 
hydrate (CH) undergoes additional metabolism and ultimately forms metabolites including 
trichloroethanol (TCOH), trichloroethanol glucuronide (TCOG), trichloroacetic acid (TCA), and 
dichloroacetic acid (DCA). 
Absorption 
Ingestion 
TCE is readily absorbed across the gastrointestinal (GI) tract of animals.  Data on GI absorption 
of TCE in humans is limited; however, case reports of poisoning after ingestion of TCE indicate 
that GI absorption in humans is also extensive. 
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Animal mass-balance studies with radiolabeled TCE have typically recovered most of the dose in 
excretion products as unchanged TCE or one of its metabolites.  In its review of GI absorption of 
TCE by animals, the EPA (U.S. EPA, 1985a) equated percent recovery of radiolabel with percent 
of TCE absorbed.  This approach assumes that the radioactivity recovered in the urine, feces, 
carcass, and cage air has been absorbed through the gut prior to its distribution and/or 
elimination by a given route.  However, it should be pointed out that this assumption may not be 
entirely correct.  For example, the TCE measured in cage air  (which presumably came from 
exhalation) may include TCE retained in material that passed through the digestive tract without 
systemic absorption.  In addition, mass-balance studies generally recover 2.0 to 4.0% of the 
radioactivity in the carcass.  These reports have not provided data on the specific disposition of 
radioactivity within the carcass (i.e., whether or not radioactivity remained in the gut), and it is 
possible that some of the carcass radioactivity is due to unabsorbed material. 
Mass-balance studies using radiolabeled TCE demonstrate that mice can metabolize 38 to 100% 
and rats can metabolize 15 to 100% of an oral dose of TCE administered in a corn-oil vehicle 
(Parchman and Magee 1982; Dekant et al., 1984; Prout et al., 1985; Mitoma et al., 1985; Buben 
and O'Flaherty, 1985; Rouisse and Chakrabarti, 1986).  For both species, the lower values were 
obtained after treatment with large doses (>1000 mg/kg).  In general, these data indicate that 
absorption of TCE through the GI tract is considerable, and at very low concentrations, nearly 
complete. 
Withey et al. (1983) examined the effect of different vehicles on the rate and extent of absorption 
of TCE in rats as measured by serial blood samples collected over a five-hr period. 
Gastrointestinal absorption of TCE was slowed significantly by the use of corn oil as a vehicle, 
compared with an aqueous solution.  After an 18 mg/kg IG dose of TCE in water, TCE reached a 
peak concentration in blood within 5.6 min.  When the same dose was given in corn oil, the 
blood concentration profile exhibited two distinct peaks, one within 5 to 10 min and a second 
peak at approximately 100 min after dosing.  Furthermore, the maximum concentration of TCE 
in blood was almost 15 times greater when TCE was administered in water (14.7 mg/mL) 
compared to oil (<1.0 mg/mL).  Likewise, the observed area under the blood concentration-time 
curve (AUC) was estimated to be 218 times greater with TCE administered in water (241.5 mg­
min/mL) rather than in oil (1.11 mg-min/mL).  Thus, a very significant decrease was observed in 
the rate and extent of GI uptake for TCE administered as an oil solution as compared with an 
aqueous solution.  When TCE is administered in corn oil, it appears that its high solubility in this 
vehicle slows its diffusion from the GI tract.  In any event, the results of the mass-balance studies 
referred to above demonstrate clearly that TCE administered orally in a vehicle is readily, albeit 
not necessarily rapidly, absorbed systemically. 
D'Souza et al. (1985) determined that the extent of absorption of TCE across the GI tract was 
dependent on whether test animals (male Sprague-Dawley rats) were fasted or non-fasted. 
Following an oral dose of 10 mg/kg TCE as a 50% aqueous suspension in a polyethylene glycol-
based dispersant (Pegosperse 400-MS), TCE was rapidly and extensively absorbed from the GI 
tract of fasted rats.  Arterial blood had measurable levels of TCE within 30 sec of treatment, and 
blood concentrations of TCE peaked within 6 to 10 min.  Although specific data were not given 
for non-fasted animals, the authors reported that the blood levels of TCE in fasted animals were 
two to three times greater than in non-fasted animals. 
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adult male and female mongrel dogs (8 to 12 kg body weight) with a surgically implanted 
intestinal circulation system.  Solutions containing 0.1, 0.25, or 0.5% TCE (weight/volume) were 
perfused through the jejunum, ileum, and colon of dogs anesthetized with 25 to 30 mg/kg sodium 
pentobarbital and placed on respirators.  Each TCE solution comprised 500 mL of an aqueous 
solution of TCE dissolved in Tween 80 (1:1 by volume).  The absorption of TCE was observed 
to be 50 to 70% of the administered TCE dose after 2 hr.  There were no significant differences 
in the absorption rates of TCE and water among the 3 intestinal regions studied and the 
absorption rate for TCE was observed to be constant over time. 
Human Studies 
No experimental studies have been conducted on humans to evaluate the extent of absorption 
following ingestion of TCE.  Defalque (1961) cited a number of cases of accidental poisoning 
from ingestion of TCE.  The U.S. EPA (1985a) listed several additional instances of poisoning, 
and observed that these reports suggest that absorption of TCE across the GI tract of humans is 
extensive. 
Dermal Absorption 
Animal Studies 
Tsurata (1978) applied 0.5 mL of pure TCE liquid to the (clipped) abdominal skin of mice for 
periods of 5 to 15 minutes; the TCE was contained on the skin by a small impermeable chamber 
glued to the skin patch studied.  The estimated percutaneous absorption rate ranged from 7.82 to 
12.1 mg/min-cm
2.  The corresponding dermal absorption rate measured during in vitro 
experiments (using excised mouse abdominal skin) was 1.125 mg/min-cm
2. 
Jakobson et al. (1982) monitored the concentration of TCE in the blood following administration 
of pure TCE liquid to the backs of guinea pigs; the TCE was contained on the skin by a small 
impermeable chamber glued to the skin patch studied.  TCE was absorbed rapidly and reached a 
peak concentration in the plasma (0.79 mg/mL) within 30 min.  Despite continued exposure, 
plasma levels of TCE decreased gradually after this time. 
Bogen et al. (1992) studied the dermal absorption of dilute aqueous TCE in hairless guinea pigs. 
The animals were exposed to 10-100 ppb solutions for 70 min.  The mean permeability constant 
kp (mL/cm
2-hr) was 0.23 – 0.04 with 10 min (initial) concentrations ranging from 19 to 110 ppb 
and radiolabel loss rates of 12-17%/hr over the 70 min observation period. 
McCormick and Abdel-Rahman (1991) observed a role for testosterone in dermal penetration of 
[
14C]TCE in rats.  TCE penetration was greater in female and castrated male rats than in 
untreated male Sprague-Dawley rats.  Female rats administered testosterone showed decreased 
penetration of TCE. 
Human Studies 
Stewart and Dodd (1964) estimated the rate of dermal absorption of TCE in humans by 
measuring the alveolar concentration of TCE in three subjects who immersed their thumbs in 
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ppmv) occurred within 30 minutes of exposure.  The relatively small amount of TCE present in 
exhaled breath indicates that absorption of TCE through the skin is limited.  Stewart and Dodd 
(1964) noted that there was considerable individual variation in the rate of absorption and 
concluded that the dermal absorption of TCE depended on the thickness and area of skin 
exposed. 
Sato and Nakajima (1978) also studied the characteristics of dermal absorption of liquid TCE in 
humans.  The extent of absorption was evaluated by measuring the concentration of TCE in 
blood and exhaled air of individuals who had immersed one hand in neat liquid TCE for 30 
minutes.  Measurements were made at the end of exposure, as well as intermittently over a 10-hr 
follow-up period.  The highest levels of TCE were found immediately after the end of exposure 
(203.11 mg/mL in blood, 28.66 mg/mL in breath) and decreased thereafter.  Sato and Nakajima 
(1978) noted that the conditions of this experiment did not represent a typical occupational 
exposure and that under average work conditions dermal contact with TCE would probably not 
result in the absorption of toxic quantities. 
Weisel and Jo (1996) investigated the multi-route exposure of 11 subjects to TCE in tap water. 
The TCE concentrations in exhaled breath were elevated in each subject after both inhalation and 
dermal exposures during showering.  Breath concentrations were also elevated after dermal 
exposure via bathing.  In contrast to ingestion, after inhalation and dermal exposure, the exhaled 
breath had elevated levels for extended time periods, indicating that TCE was distributed via the 
bloodstream prior to metabolism.  The concentrations of TCE in water were 20-40 mg/L.  The 
amount of TCE expired per mg/L of water after dermal exposure was 0.03 – 0.011 mg and after 
inhalation exposure was 0.074 – 0.08 mg.  The calculated internal dose from inhalation exposure 
ranged from 60 to 250 mg TCE.  The amount of TCE expired after inhalation and dermal shower 
exposures were similar, suggesting nearly equivalent internal doses for these two exposure 
routes.  Ingestion of 2 L of tap water containing the concentrations used in the study, assuming 
100% GI tract absorption, yields maximum internal dose estimates for TCE of 30-300 mg.  Thus 
for typical showering and drinking activities, each exposure route contributes similar internal 
doses, and the total internal dose from a 10-min shower or a 30-min bath is greater than that from 
ingesting 2 L of water.  It should be noted that this study addresses only showering and bathing 
exposures.  Other household activities such as flushing toilets, washing clothes etc. would be 
expected to add to these exposures particularly via the inhalation route.. 
Pulmonary Uptake 
The human blood/air partition coefficient of TCE has been estimated to be between 9.2 and 15, 
and TCE readily diffuses across the lungs into the capillaries of the alveoli (Eger and Larson, 
1964; Sato et al., 1977; Monster, 1979).  For a given concentration of TCE, pulmonary uptake 
depends on the solubility of TCE in blood and tissue, the volume and rate of perfusion of tissues, 
the rate of elimination; and on the rate of alveolar ventilation, i.e., that fraction of respiratory 
ventilation from which volatile organic compounds may be cleared by absorption into alveolar 
capillary blood (Fernandez et al., 1977; Astrand, 1975). 
Under non-steady-state conditions, the amount of TCE that initially enters arterial blood depends 
primarily on the concentration difference of TCE between alveolar and venous blood (Fernandez 
et al., 1977; Monster, 1979). Several studies have found that the uptake of TCE from the lungs is 
rapid during the first 30 to 60 minutes of exposure, but that the rate of uptake decreases 
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as TCE concentration in body tissues approaches steady state (Monster, 1979; Fernandez et al., 
1977). 
Under steady-state conditions, the net uptake (the difference between the ambient and alveolar 
air concentrations, multiplied by alveolar ventilation rate) is theoretically equal to the amount of 
TCE removed from the body by metabolism.  But experimental human studies of pulmonary 
uptake of TCE have generally not approximated steady-state conditions.  Because, prior to the 
attainment of a steady-state condition, net uptake (i.e., retention) varies as a function of time, 
generalizations that can be made from reported values of percent uptake are necessarily restricted 
to the specific exposure regime used. 
Animal Studies 
Andersen et al. (1980) exposed rats to TCE for 3 hr at concentrations that ranged from 30 to 
6000 ppmv.  The rate of pulmonary uptake in rats was concentration dependent; at the lowest 
exposure concentration (30 ppmv) the uptake of TCE was linear.  Uptake deviated from linearity 
at concentrations of TCE > 100 ppmv. 
Stott et al. (1982) evaluated the metabolism of TCE in rats and mice exposed to 10 or 600 ppmv 
14C-labeled TCE for 6 hr.  Radiolabel was recovered in expired air (as CO2 and unchanged TCE), 
as well as in the urine, feces, and carcass.  Pulmonary absorption of TCE was evident in both rats 
and mice, because radiolabeled CO2 and urinary metabolites were generated as a result of 
exposure.  However, the net uptake of TCE appeared to differ between species at the higher TCE 
concentration of 600 ppmv because the amount of unchanged TCE exhaled after exposure to this 
concentration, as a percent of total body burden of measured TCE, was (at 21.1%) 10 times 
greater than the corresponding percent (2.1%) observed after exposure to 10 ppmv TCE.  A 
similar change was not observed in mice, which exhaled unchanged from 1% to 2% of the 
measured TCE body burden at both concentrations. 
Human Studies 
Fernandez et al. (1977) simulated the uptake, distribution and elimination of TCE after inhalation 
exposure.  Their model separated the body into a pulmonary compartment, a compartment 
responsible for metabolism (the liver), and three tissue types, the muscle group, fat group, and 
vessel-rich group.  Fernandez et al. (1977) calculated the partial pressure of TCE in different 
tissues during an 8 hr exposure to 100 ppmv TCE.  In the well perfused vessel-rich and muscle 
groups, the concentration of TCE increased rapidly over the first two hours of exposure.  As the 
partial pressure of TCE equilibrated between tissues and inspired air, the rate of uptake 
diminished, and became relatively constant by the end of the 8 hr exposure period.  The 
concentration of TCE in the poorly perfused (fat) compartment increased much more slowly, and 
continued to increase for approximately one hour after the end of exposure. 
Various studies have reported the "percent retention" (i.e., net uptake as a percent of alveolarly 
ventilated amount) of TCE for experimental inhalation exposures.  These studies estimated 
percent uptake by measuring the TCE concentration in inhaled and alveolar-exhaled air, 
subtracting the ratio of the latter to the former from one, and multiplying by 100%.  As noted 
previously, under non-steady-state conditions these values will vary with the duration of 
exposure.  This variation is apparent in the broad range of values that have been reported for the 
percent of TCE retained.  For example, Soucek and Vlachova (1960) found that the percent of 
TCE retained varied from 58 to 70% in individuals exposed to 93 to 158 ppmv TCE for 5 hr. 
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and Nomiyama (1971, 1974) found that approximately 35% of a dose of TCE was retained in 
individuals exposed to 252 to 380 ppmv TCE for 2.7 hr.  Monster et al. (1976) measured the 
pulmonary uptake of TCE in six subjects exposed to 70 or 140 ppmv TCE for 4 hr.  Uptake was 
found to be rapid during the first 30 minutes of exposure, but after this time uptake became 
relatively constant and remained so for the duration of the experiment.  Subjects exposed to 70 
and 140 ppmv TCE retained 5.6 – 1.1 and 5.4 – 0.28 mg TCE/ppmv TCE in air.  Thus, percent 
retention of TCE was not affected significantly by exposure concentration in this study.  Monster 
et al. (1979) calculated the pulmonary uptake in five individuals exposed to 70 ppmv TCE, 4 hr/d 
for 5 days.  The average quantity of TCE retained during this exposure scenario was 450 – 51 
mg/d, which was approximately 44% – 5.5% of the estimated total alveolarly respired dose. 
The amount of TCE taken up by the body is affected by differences in alveolar ventilation rate. 
During exercise or work, the alveolar ventilation rate increases and exposure to TCE under these 
conditions results in a greater uptake of TCE.  When volunteers were exposed to 70 or 140 ppmv 
TCE while under a work load (2.5 hr x 100 watts) the uptake of TCE increased to approximately 
2.5 times what it was at rest (Monster et al., 1976).  Astrand and Ovram (1976) also reported that 
the uptake of TCE doubled in subjects under a 50- to 150-watt workload exposed to 100 or 200 
ppmv TCE in air compared to resting subjects who were similarly exposed. 
Wallace et al. (1997) studied the uptake of nine VOCs including TCE at environmentally 
relevant concentrations in five human subjects.  TCE concentrations in three experiments ranged 
from 800 to 1300 mg/m
3.  Uptake over 10 hr and elimination over an additional 24 hours were 
measured to within 5% precision in exhaled breath.  A four-compartment model was fitted to the 
data.  The mean residence times (t) for TCE in the four compartments were: 0.15; 0.68; 4.8; and 
29 hr, respectively.  The mean distributions in the body (a) for TCE in the four compartments 
were 21, 24, 19, and 31%, respectively. 
Pleil & Lindstrom (1997) evaluated the elimination of a number of VOCs including TCE with a 
“single breath canister” technique for sample collection and GC-MS analysis.  Seventeen 
subjects were studied following controlled four-hr chamber exposure to TCE at 550 mg/m
3.  The 
maximum blood concentrations ranged from 729 to 1749 mg/L.  The elimination data was fit to a 
three compartment model (blood, highly perfused, moderately perfused) with half-lives ranging 
from 0.5-4.1 min for blood, 15-62 min for the highly perfused compartment and 262-1146 min 
for the moderately perfused compartment.  In a subsequent chamber study six subjects were 
exposed to 100 ppm TCE for four hr followed by purified air for 20 hr (Pleil et al., 1998). 
Matched breath and blood samples were collected periodically.  The concentration data were 
modeled with respect to time course and the blood/breath relationship.  At equilibrium conditions 
at the end of the exposure, blood levels could be predicted using breath elimination curve 
calculations and a literature based partition coefficient with a mean calculated:measured ratio of 
0.98 – 0.12 SE across all subjects.  Blood/breath comparisons at equilibrium gave in vivo 
partition coefficients with a mean of 10.8 – 0.60 SE.  The authors found that about 78% of TCE 
entering the body during inhalation exposure is metabolized, stored, or excreted through routes 
other than exhalation. 
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TCE diffuses readily through blood and into body tissues.  Studies with experimental animals 
have measured TCE or its metabolites in most organs and tissues.  A combination of 
experimental and theoretical data indicate that TCE becomes widely distributed within the 
human body. 
Animal Studies 
Barrett et al. (1939) exposed dogs and rabbits to water vapor saturated with TCE (1.2 g/L) for 25 
to 28 minutes.  TCE and its metabolites were found in the blood, skeletal muscle, fat, liver, 
kidney, lungs, and heart of both species.  The highest concentrations were measured in the 
adipose tissue of these animals (44 to 48 mg/100 g).  In both rabbits and dogs, the lowest 
quantities of TCE occurred in the muscle (4 to 7 mg/l00 g).  TCE was detected in the cerebrum, 
cerebellum, blood, liver, lungs, and perirenal fat of rats 24 hr after the end of exposure (200 
ppmv TCE, 6 hr/d for 4 d).  The greatest amounts of TCE were measured in perirenal fat (55.9 to 
75.4 nmol/g) and the lowest amounts in liver (2.4 to 5.5 nmol/g) (Savolainen et al., 1977). 
Parchman and Magee (1982) found that some of the radioactivity from a dose of 
14C-labeled TCE 
(10 to 1000 mg/kg) was covalently bound to liver protein of rats and mice.  Low levels of 
radioactivity were also associated with the DNA fraction from both species.  However, Parchman 
and Magee (1982) were unable to distinguish whether it was TCE or a metabolite that was bound 
to DNA or whether the radioactivity in the DNA fraction was due to contamination with protein. 
Male rats given 10, 100, or 1000 mg/kg of TCE orally 5 d/wk for 6 wk had measurable levels of 
TCE, TCA, and trichloroethanol in the blood, heart, testes, vas deferens, seminal vesicles, 
prostate, epididymis, adrenals, fat, liver, kidneys, muscle, lungs, and brain (Zenick et al., 1984). 
In general, blood and tissue levels increased in a dose-dependent manner, indicating that TCE 
and its two major metabolites accumulate in tissue.  For example, animals that received 1000 
mg/kg of TCE had 30 to 50% more TCA in their reproductive organs than the 100 mg/kg group. 
The concentration of trichloroethanol in the epididymis and vas deferens did not change 
substantially with dose.  However, the concentration of trichloroethanol was three to seven times 
higher in the testes, prostate, and seminal vesicles of high-dose animals than in animals that 
received 100 mg/kg TCE. 
Pfaffenberger et al. (1980) dosed male rats by gavage with 1 to 10 mg/d of TCE for 25 d.  TCE 
levels were measured in fat and blood at nine separate times during the treatment period.  TCE 
was detected at very low levels (<1.0 mg/L) in serum, while the amount of TCE present in 
adipose tissue depended on dose.  Animals given 1.0 mg/d had an average concentration of 280.0 
ng/g TCE in their fat, while those that received 10.0 mg/d had an average of 20,000 ng/g. 
Measurements were also made three and six days after dosing was discontinued.  Animals from 
both treatment groups had an average of 1.0 ng/g of TCE in adipose tissue.  Serum 
concentrations of TCE were <1.0 mg/L (1.0 mg/d TCE) and 6.0 mg/L (10.0 mg/d TCE).  The 
values reported by Pfaffenberger et al. (1980) are mean values and are based on measurements 
from 12 animals taken over the course of the experiment.  The authors noted that there was 
considerable fluctuation in individual values, and that no steady increase in the 1evels of TCE 
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the 25 days of treatment indicate that some accumulation of TCE occurs with continued 
exposure. 
Human Studies 
TCE distribution depends on the partition coefficient, volume of distribution, and tissue-specific 
perfusion rate, as well as on the volume of venous blood in equilibrium with a given tissue type. 
After accounting for these variables the model of Fernandez et al. (1977) (discussed above in the 
subsection on Pulmonary Uptake) predicted that the body burden of TCE in the muscle and 
vessel-rich (well-perfused) tissue groups would increase only slightly with repeated inhalation 
exposure (100 ppmv, 6 hr/d, 5 d/wk).  Because of TCE’s high fat solubility and the limited 
perfusion of adipose tissue, TCE is eliminated slowly from fat, and repeated exposure is 
expected to cause a progressive accumulation of TCE in this tissue.  Under these conditions (100 
ppmv, 6 hr/d, 5 d/wk), TCE concentration is predicted by the Fernandez et al. model to reach 
equilibrium in adipose tissue in 5 to 7 d.  Once adipose tissue becomes saturated, this model 
predicts that the concentration of TCE in fat will remain relatively constant as long as exposure 
concentration remains constant. 
Bartonicek (1962) exposed eight volunteers to 194 ppmv TCE for 5 hr and measured the 
excretion of TCE and its metabolites TCA and trichloroethanol (TCOH) in feces, sweat, and 
saliva (on day 3 post-exposure) and in blood and urine (on days 2 to 22 post-exposure).  The 
measured metabolites were found in feces, sweat, and saliva on the third day after exposure at 
average concentrations of approximately 18, 4.2, and 0.27 mg TCA+TCOH/100 mL, 
respectively.  The metabolites excreted in feces represented about 8.4% of all measured 
metabolites excreted in feces and urine on day 3 after exposure.  Metabolites in blood and urine 
decreased exponentially by a factor of about 10 from day 2 to day 22 after exposure.  Intervening 
consumption of alcohol by the subjects appeared to influence the measurements of urinary 
metabolites by transiently increasing their concentration after consumption, particularly for 
TCOH. 
De Baere et al. (1997) evaluated tissue distribution of TCE and metabolites in one subject 
following a fatal ingestion of TCE mixed with beer.  The TCE concentrations found were: 
stomach contents, 95.7 mg/mL; blood, 210 mg/L; liver, 747 mg/g; kidney, 78.8 mg/g; and lung, 
9.25 mg/g. TCA concentrations in liver and kidney were 21.0 and 27.5 mg/g, respectively.  TCOH 
concentrations were: liver, 15.7 mg/g; kidney, 78.7 mg/g; lung, 4.0 mg/g.  The blood TCE 
concentration was high compared to the reported average fatal value of 27 mg/mL (range, 3 to 
110 mg/mL).  The liver TCE concentration of 747 mg/g is the highest ever reported (range of 
other values, 5 to 250 mg/g). 
Metabolism 
TCE is initially transformed by the cytochrome P450 dependent mixed function oxygenases 
(MFO) to an intermediate electrophilic epoxide, trichloroethylene oxide (TCE-oxide) (Byington 
and Leibman, 1965; Henschler, 1977; Bonse et al., 1975).  There is considerable speculation 
regarding this epoxide; it is not clear whether it is an obligate intermediate or if it exists in free 
form (available to bind cellular macromolecules) (Henschler, 1977; Henschler et al., 1979; Miller 
and Guengerich, 1982, 1983). 
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in which TCE-oxide rearranges spontaneously to chloral.  Chloral is then rapidly hydrated to 
form chloral hydrate.  Chloral hydrate undergoes oxidation to trichloroacetic acid (TCA), and 
some of the TCA contributes to the formation of dichloroacetic acid (DCA) and carbon dioxide 
(CO2).  Recent studies cast doubt on the importance of DCA as a TCE metabolite.  Toxipeus and 
Frazier (1998) used an isolated perfused rat liver and found that the DCA concentration in the 
perfusion medium decreased rapidly over the two-hour exposure period.  There was no DCA 
detectable in the liver following exposure to initial concentrations of 25 and 250 mM DCA.  Only 
5-10% of the initial DCA was found in the perfusion fluid and 0.2% in bile following exposure. 
Merdink et al. (1998) dosed male B6C3F1 mice i.v. with TCE, CH, TCOH, or TCA and orally 
with TCE only.  DCA was not detectable above the 1.9 mM detection limit in whole blood.  The 
authors conclude that DCA is likely formed as a short-lived intermediate metabolite.  Its rapid 
elimination relative to its formation from TCA prevents the accumulation of measurable 
concentrations in blood.  Moghaddam et al. (1997) observed that the intestinal microflora of mice 
played little or no role in the metabolism of TCE or CH to DCA. 
Conjugates of TCA (TCA-glucuronide and TCA-CoA) have also been identified.  Alternatively, 
chloral hydrate can be reduced to trichloroethanol (TCOH).  Most of the TCOH reacts with 
glucuronyl transferase to form trichloroethanol glucuronide (urochloralic acid, TCOG) (Barrett 
et al., 1939; Powell, 1945,1947; Butler, 1948; Byington and Leibman, 1965; Nomiyama and 
Nomiyama, 1971; Muller et al., 1972; Kimmerle and Eben, 1973a; Cole et al., 1975; Ikeda et al., 
1980a; Hathaway, 1980; Miller and Guengerich, 1982, 1983; Parchman and Magee, 1982; Stott 
et al., 1982; Costa and Ivanetich, 1984; Green and Prout, 1985; Dekant et al., 1984; Prout et al., 
1985).  The metabolism of TCE has been reviewed by IARC (1979), WHO (1985), and the U.S. 
EPA (1985a). 
Although TCA, TCOH, and trichloroethanol glucuronide (TCOG) are the principal metabolites 
formed, the isolation of a number of minor metabolites can only be explained by the presence of 
other metabolic paths.  Under certain conditions, TCE-oxide forms dichloroacetyl chloride; this 
rearranges to dichloroacetic acid (DCA) (Kline and Van Duuren, 1977; Hathaway, 1980; Dekant 
et al., 1984).  TCE-oxide can also undergo oxidation and hydrolysis to formic acid, glyoxylic 
acid, oxalic acid, CO2, and carbon monoxide (CO).  Monochloroacetic acid has been 
occasionally recovered, but little is known about its formation (Bonse et al., 1975; Hathaway, 
1980; Miller and Guengerich, 1982, 1983; Dekant et al., 1984; Fetz et al., 1978; Traylor et al., 
1977; Soucek and Vlachova, 1960; Bartonicek, 1962; Ogata and Saeki, 1974; Green and Prout, 
1985).  Recent isolation of N-(hydroxyacetyl)-aminoethanol (HAAE) indicates the presence of a 
fourth (and separate) biotransformation of TCE-oxide.  No details of HAAE formation have been 
characterized (Dekant et al., 1984). 
The formation of glutathione (GSH) conjugates is catalyzed by cytosolic and microsomal GSH S­
transferases.  Substantial nonenzymatic GSH S-conjugate formation may occur with highly 
electrophilic substrates.  S-(1,2-dichlorovinyl)glutathione (DCVG) is formed and goes through 
further metabolism to yield various metabolites, largely the mercapturic acids (Goeptar et al., 
1995).  N-Acetyl-S-(1,2-dichlorovinyl)-L-cysteine (Nac-DCVC) has been identified as a urinary 
metabolite in rats given an oral dose of 400 mg/kg of TCE.  The Nac-DCVC in urine accounted 
for only 0.1% of the administered dose (Dekant et al., 1986).  TCE is also metabolized in vivo to 
two isomeric mercapturic acids: 1,2-DCVC-Nac, and 2,2-DCVC-Nac.  Birner et al. (1993) have 
detected 1,2-DCVC- and 2,2-DCVC-Nac in the urine of humans occupationally exposed to TCE. 
Alkaline decomposition of TCE may also produce dichloroacetylene that can yield both 1,2­
DCVG and 1,2-DCVC.  So the role of GSH-conjugation in forming these metabolites is 
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shown to produce nephrotoxicity in vivo in rats as well as the identification of DCVC-Nac 
isomers as urinary metabolites of TCE in rats, mice, and humans suggests that these compounds 
play a role in the toxicity and carcinogenicity of TCE (Dekant et al., 1986, 1990; Commandeur & 
Vermeulen, 1990; Birner et al., 1993, 1997). 
Steel-Goodwin et al. (1996) detected a linear increase of free radicals with increasing TCE 
concentration in cut liver slices using an EPR/SPIN trapping method with a-phenyl t-butyl 
nitrone.  The TCE concentrations used were very high (2500 to 10,000 ppm).  Using 
immunochemical methods Halmes et al. (1996,1997) detected two TCE protein adducts at 50 and 
100 kDa in liver microsomal fractions from male B6C3F1 mice treated with TCE.  The amounts 
of TCE adducts were both dose and time dependent.  The data also suggest that one of the 
protein targets is cytochrome P450 2E1. 
Lipscomb et al. (1997) reported differences in cytochrome P450-dependent metabolism of TCE 
in human microsomal samples.  They found TCE metabolism was dependent on CYP 2E1 with 
minimal involvement of other forms (1A1, 1A2, 3A4).  Of 23 human hepatic microsomal 
samples, three groups could be identified based on the apparent Km values: low (12-20 mM); mid 
(26-37 mM); and high (> 46 mM).  The indicated variation in the capacity to metabolize TCE was 
less than 10-fold.  Channel and Pravecek (1998) studied the metabolism of TCE in B6C3F1 
mouse and human liver slices.  Both explants tolerated TCE concentrations up to 750 mM 
without evidence of cytotoxicity.  For the mouse apparent Vmax and Km values were 6.14 ng 
TCA generated/mg protein/min and 215 mM TCE, respectively.  The human explant showed only 
0.47 ng TCA/mg/min and 30.6 mM TCE, respectively, indicating a higher affinity but lower 
capacity than the mouse. 
Griffen et al. (1998) observed covalent binding of TCE metabolites to proteins in human and rat 
hepatocytes.  One of the targets is likely CYP 2E1 since the 50 kDa adduct in rat hepatocytes was 
found to comigrate in SDS-PAGE with a protein recognized by an antibody raised against 
cytochrome P450 2E1.  In the human hepatocyte the major TCE adduct migrated to a different 
position than CYP 2E1. 
Excretion 
Absorbed TCE is eliminated both by pulmonary release of unchanged TCE and by metabolic 
transformation into other products which are primarily excreted in urine.  There is a large amount 
of data on the kinetics of TCE metabolism and excretion in animals and humans, perhaps more 
for TCE than for any other volatile chlorinated organic compound.  These data are reviewed 
extensively in the U.S. EPA (l985a) health-risk assessment document for TCE. 
Animals 
Early experiments on rats exposed to TCE by inhalation established that TCA is a major 
metabolite which is excreted in urine and that unmetabolized TCE is excreted by exhalation 
through the lungs (Forssmann and Holmquest, 1953).  Kimmerle and Eben (1973a) studied 
excretion kinetics of TCE in SPF-Wistar-II rats to TCE by acute and subchronic inhalation. 
After rats were exposed to 49, 175 and 330 ppmv TCE for 4 hr, they showed an exponential 
decrease in TCE concentration in expired breath over an 8-hr observation period, as well as in 
amounts of TCA and trichloroethanol excreted in urine over a 4-d collection period.  During 
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of TCE metabolites averaged approximately 1.5 mg/kg-day.  The metabolites TCOH and chloral 
hydrate were found at fairly constant levels in blood, and TCE could not be detected in blood.  In 
Wistar rats given 3 to 15 mg/kg TCE by intravenous injection, Withey and Collins (1980) 
observed TCE concentrations to decrease in blood and perirenal fat with half-life (t1/2) values of 
about 4 min and 3.6 hr, respectively. 
TCE elimination from blood in mice and rats given a single oral dose of 1000 mg/kg TCE in corn 
oil was compared by Prout et al. (1985).  Peak blood concentrations of TCE occurred at 1 hr and 
3 hr for mice and rats, respectively, with corresponding decay (t1/2) values of about 1 hr and 3 hr, 
respectively.  While removal of TCE from mouse blood occurred more rapidly than from rat 
blood, blood concentrations of the TCE metabolite, TCA, were about 10 times greater in mice 
than in rats studied over a 48-hr post-exposure observation period.  Particularly given the 
cytotoxicity and possible carcinogenicity of TCA itself (Elcombe, 1985), the differential ability 
of mice and rats to convert TCE to TCA has been proposed to explain the differential 
hepatotoxicity and hepatocarcinogenicity of TCE observed in these species (Stott et al., 1982; 
Buben and O'Flaherty, 1985; Prout et al., 1985). 
The pharmacokinetics of inhaled TCE was investigated in Wistar rats (Filser and Bolt, 1979) and 
Fischer 344 rats (Andersen et al., 1980), using depletion of TCE at various original 
concentrations in a closed chamber to measure uptake and metabolism.  TCE metabolism in 
Wistar rats was found to saturate above 65 ppmv, where the maximum rate (Vmax) of metabolic 
elimination was observed to be 28 mg/kg-h.  In F344 rats, TCE metabolism was also found to be 
dose-dependent, saturating above 500 to 1000 ppmv where a Vmax of 24.3 mg/kg-h was 
observed, yielding a close agreement in estimates of Vmax, but not saturation concentrations, for 
Wistar and F344 rats. 
Mass-balance studies using radiolabeled TCE have been used to study the nature and extent of 
TCE metabolism in rodents and primates.  Daniel (1963) dosed rats with 40 to 60 mg/kg of TCE 
liquid by gavage and observed respiratory elimination of 80% of the dose (t1/2 = 5 hr) and 
elimination of the remainder via urinary metabolites.  Other gavage studies using TCE in a corn 
oil vehicle demonstrate a much greater degree of TCE metabolism in rodents.  Muller et al. 
(1982) gave intramuscular injections of 50 mg/kg TCE to chimpanzees, baboons, and Rhesus 
monkeys and observed that urinary plus fecal elimination of the (presumably metabolized) dose 
amounted to 40 to 60%, 11 to 28%, and 7 to 40%, respectively, of the administered dose.  Other 
recent studies of TCE metabolism in mice and rats provide further information on the extent of 
TCE metabolism in these species (Buben and O’Flaherty, 1985; Stott et al., 1982; Parchman and 
Magee, 1982; Dekant et al., 1984; Mitoma et al., 1985; Prout et al., 1985; Rouisse and 
Chakrabarti, 1986).  The extent of TCE metabolism in mice and rats measured in these studies is 
summarized in Tables 3-4 and 3-5, respectively, in terms of the total amount of TCE metabolized 
and the percent of this amount excreted in the form of urinary metabolites. 
Humans 
Many studies have been conducted using volunteers to assess the extent to which TCE is 
metabolized in humans.  Quantification of metabolism in these studies is done by collection of 
urinary metabolites and/or by calculating total exhaled TCE subsequent to a known TCE 
exposure.  Unmetabolized TCE is either distributed within body tissues, as discussed above in 
this section, where it remains available for subsequent excretion or metabolism, or it is excreted 
via exhalation with kinetics that parallel depletion of TCE concentration in blood after exposure 
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and in exhaled air as TCOH (Monster et al., 1976) in humans. 
Studies have demonstrated that in humans TCE is metabolized primarily to TCA, TCOH and 
TCOH-G, which are excreted in urine for the most part, although some TCOH and TCA may be 
metabolized further.  Studies of the kinetics of excretion of these urinary metabolites in 
volunteers have shown that subsequent to TCE exposure, urinary TCOH is first produced more 
quickly and in larger amounts than is urinary TCA, but that TCA production persists and 
eventually supersedes that for TCOH (Soucek and Vlachova, 1960; Nomiyama and Nomiyama, 
1971; Muller et al., 1974; Fernandez et al., 1975; Monster et al., 1979).  The observed distinction 
between TCOH and TCA after TCE exposure has played an important role in the development of 
strategies for biological monitoring of occupational TCE exposure (Guberan, 1977; Sato et al., 
1977; Fernandez et al., 1977; Monster and Houtkooper, 1979). 
In a number of studies the extent to which people metabolize TCE in response to a controlled 
respiratory exposure has been quantified by measuring total urinary metabolites generated after 
exposure or by measuring the total amount of unchanged TCE expired after an exposure for 
which an estimate of total retained TCE dose was available (Soucek and Vlachova, 1960; Ogata 
et al., 1971; Nomiyama and Nomiyama, 1971; Ertle et al., 1972; Muller et al., 1972; Monster et 
al., 1976; Fernandez et al., 1975,1977; Monster et al., 1979).  The reported values for average 
percent of retained dose metabolized (PRDM) range from 81% to 92%.  If only the studies by 
Monster et al. and Fernandez et al. involving a total of 18 males given respiratory exposures 
ranging from 280 to 1440 ppmv are considered, the reported values for average PRDM are 
remarkably consistent, ranging from 89% to 92% with a person-weighted average of 90.6 + 1.9% 
(C.V. = 2.1%) and a corresponding individual PRDM range of 87% to 93%.  These 18 individual 
PRDM values are not significantly correlated with either TCE exposure concentration or time-
integrated TCE exposure (in ppmv-hr). 
In contrast to the estimates of PRDM for humans, the values reported for percent of metabolized 
dose identified as urinary metabolites (PMDU) show a greater degree of inter-individual 
heterogeneity.  The 18 individual PMDU values from the Monster et al. and Fernandez et al. 
studies average 66.0% + 10.9% (C.V. = 16.6%).  This inter-individual heterogeneity is only 
partly due to differences in study methodology (e.g., regarding urinary metabolite identification 
efficiency, specificity, etc.), because the separate Monster et al. (1976), Fernandez et al. (1975, 
1977), and Monster et al. (1979) PMDU averages are 67.4% + 8.5% (C.V. = 12.6%), 54.9% + 
2.1% (C.V. = 3.9%) and 75.0% + 11.0% (C.V. = 14.7%), respectively.  The high PMDU values 
reported by Nomiyama and Nomiyama (1971) are not consistent with the other reported values, 
due partly to the fact that in this study the total urinary metabolite excretion was estimated 
beyond day six using a first-order decay assumption (with a half-life of 1.3 to 1.5 d), and also 
possibly to the fact that TCE retention was estimated to be only about 35% to 36% based 
(apparently) on a single post-exposure measurement for exposed individuals.  The fact that the 
PMDU values are in general significantly below 100% indicates that respired TCE is 
metabolized by humans either to products excreted in urine other than those considered, such as 
HAAE (see Dekant et al., 1984 ), or to expired products such as CO2.  Human values for PRDM 
and PMDU are similar to those obtained from mice and rats given oral (applied) TCE doses 
below 2000 mg/kg and 500 mg/kg, respectively.  This indicates that humans exposed to very low 
levels of TCE may metabolize almost all of the dose received as dose approaches zero, although, 
as is the case for animals, detailed human data on this point are entirely lacking.  However, 
results from a study of urinary metabolites excreted by 51 male Japanese workers regularly 
exposed to TCE in 10 different workshops indicate that certain TCE-metabolism or metabolite-
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study showed that while the concentration of total trichloro-compounds (TTC) and 
trichloroethanol (TCOH) in urine increased linearly with increasing exposure levels up to 200 
ppmv (8 hr/d, 6 d/wk), that of trichloroacetic acid (TCA) appears to saturate at about 200 mg/L 
in workers exposed to air concentrations of TCE greater than 100 ppmv. 
Kostrzewski et al. (1993) measured the kinetics of TCE elimination from blood in three subjects 
following acute occupational TCE exposures.  They also interpreted the earlier data of Monster 
and Sato described above deriving a tri-exponential equation for TCE elimination.  The half lives 
corresponding to the successive elimination phases were 0.1, 0.5, and 3.6 hr, but the observation 
period was limited to 16 hr.  For the three subjects studied the TCE elimination from venous 
blood, over a 128 hr observation period, was described by a one compartment model with a mean 
half-life of 21.7 hr.  On the basis of the two data sets the authors proposed a bi-exponential 
relation with t1/2 values of 0.5 and 21.7 hr for the early (first few hours) and later phases of 
elimination, respectively. 
Pharmacokinetics & PBPK Models 
Other studies of TCE metabolism in mice and rats provide further information on the extent of 
TCE metabolism in these species (Buben and O'Flaherty, 1985; Stott et al., 1982; Parchman and 
Magee, 1982; Dekant et al., 1984; Mitoma et al., 1985; Prout et al., 1985; Rouisse and 
Chakrabarti, 1986).  All of these studies are mass-balance studies, except the studies of Buben 
and O'Flaherty (1985) and Rouisse and Chakrabarti (1986) on urinary metabolites of TCE in 
mice and rats, respectively. 
The results of the studies indicate that total TCE metabolism in mice is not saturated at single 
gavage doses below 2000 mg/kg.  Furthermore, the relationship between applied and metabolized 
dose for mice appears to be approximately linear over most of the dose range below this point of 
metabolic saturation. The Prout et al. (1985) mouse data show a fairly linear relationship 
between applied gavage and total metabolized doses, with slope value estimated to be 0.788 
(conditional on an intercept-parameter value of 0) by linear regression (R = 0.995).  Thus, the use 
of a Michaelis-Menten relation to describe the mouse data may be inappropriate in the applied 
dose range below 2000 mg/kg, despite the fact that metabolic saturation occurs above this dose 
level.  Saturation kinetics does not necessarily imply Michaelis-Menten (or rectangular 
hyperbolic) kinetics (see Pang and Rowland, 1977; Andersen, 1981; O’Flaherty, 1985). 
However, the data of Prout et al. (1985) for both B6C3Fl and Swiss-Webster mice, as well as the 
B6C3Fl mouse data of Mitoma et al. (1985) and the NMRI mouse data of Dekant (1984), all 
indicate a deviation from linearity at low doses, implying an increased metabolic efficiency as 
applied dose approaches zero. 
Lee et al. (1996) evaluated the efficiency and dose dependency of presystemic elimination of 
TCE in rats surgically cannulated for carotid artery (CA), jugular vein (JV), and hepatic portal 
vein administration.  Sprague-Dawley rats (330-380 g) were dosed with TCE (0.17, 0.33, 0.71, 2, 
8, 16, 64 mg/kg) over 30 s into the CA, JV, portal vein or stomach.  Serial blood samples were 
collected for up to 12 hr and analyzed for TCE.  Pharmacokinetic analysis indicated that TCE 
was eliminated through dose-dependent nonlinear processes.  A three-compartment model with 
Michaelis-Menten and first order elimination was derived to fit the TCE blood data following JV 
administration.  Total presystemic elimination of TCE was inversely related to dose, ranging 
from ca. 60 to < 1%.  At doses below metabolic saturation, hepatic presystemic elimination of 
TCE accounted for approximately 45-55% of dose. 
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Physiologically-based pharmacokinetic (PBPK) models are based on data from many sources; 
they attempt to simulate actual body organs or tissue groups (e.g., liver, muscle, fat), and are 
essentially predictive.  These features are in contrast to classical or descriptive pharmacokinetic 
(PK) modeling that uses rather abstract compartments and interrelations to fit to specific data 
sets, usually for deriving pharmacokinetic constants and parameters.  PBPK modeling has been 
applied in many chemical risk assessments to correct for metabolic saturation of high bioassay 
doses, to derive improved internal dose metrics, and to improve inter-route and inter-species 
extrapolations.  Several PBPK models have been developed for TCE.  Most of the PBPK models 
describe only the pharmacokinetic behavior of the parent chemical (Andersen et al., 1987; Bogen 
et al., 1988; Koizumi, 1989; Opdam, 1989; Opdam and Smolders, 1989; Droz et al., 1989a,b; 
Dallas et al., 1991; Srivatsan et al., 1993; Yang et al., 1995; El-Masri et al., 1995, 1996a,b). 
Fisher and co-workers developed PBPK models for TCE and TCA in pregnant rats (Fisher et al., 
1989), lactating rats (Fisher et al., 1990), mice (Fisher et al., 1991), and humans (Allen and 
Fisher, 1993; Fisher and Allen, 1993).  Sato et al. (1991) investigated the effects of physiological 
factors such as body fat content in a human PBPK model for TCE and TCA.  More recent PBPK 
models have included additional metabolites such as TCOH and TCA (Clewell et al., 1995), CH, 
TCA, DCA, TCOH, and TCOG (Abbas and Fisher, 1997; Fisher et al., 1998), and chloral, 
dichlorovinylcysteine (DCVC), and DCA (Page et al., 1997).  Other model elaborations have 
involved enterohepatic recirculation of TCA and TCOH (Stenner et al., 1998). 
Lipscomb et al. (1998) compared TCE metabolic parameters from human microsomal 
suspensions (Lipscomb et al., 1997), whole hepatocytes, and PBPK model parameters of Allen 
and Fisher (1993).  The Vmax value for the microsomes was 1589 – 840 pmol/min/mg protein 
and for hepatocytes 16.1 – 12.9 nmol/hr/10
6 cells.  When adjusted to kg
-1 body weight these 
values were 6.8 – 3.6 and 6.9 – 5.0 mg/hr/kg, respectively.  The PBPK model Vmax was 14.9 
mg/hr/kg.  The similarity of these values may indicate that, once delivered to the liver, factors 
such as protein binding, competing enzymes, or sequestration by nonendoplasmic reticular lipids 
have little effect on cytochrome-dependent metabolism of TCE. 
PBPK models have been used to study potential effects of mixtures of chemical contaminants 
and effects on enzyme systems relevant to their metabolism and toxicity (Yang et al., 1995).  El 
Masri et al. (1996a,b) studied the interaction of TCE and 1,1-DCE with respect to binding and 
depletion of hepatic GSH in Fischer 344 rats.  To quantitatively resolve the interaction effects on 
GSH content from resynthesis effects they used physiologically based pharmacodynamic (PBPD) 
modeling.  The application of TCE to rats at higher than 100 ppm obstructed the ability of DCE 
to bind hepatic GSH via competitive inhibition.  TCE, at concentrations below 100 ppm, was not 
effective in inhibiting DCE from significantly depleting hepatic GSH.  Similar results were 
obtained for DCE-induced hepatic injury as indicated by serum aspartate aminotransferase 
activity.  The results indicate an interaction threshold at the pharmacokinetic level. 
TOXICOLOGY 
In this section, we review the toxic effects of TCE in animals and humans.  Previous reviews of 
the toxicity of TCE include those by Condie (1985), Kimbrough et al. (1985), U.S. EPA (1980; 
1984a,b; 1985a,b), World Health Organization (1985), Lauwerys (1983), National Research 
Council (1980), Cornish et al. (1977), Infante (1977), Van Duuren (1977), Waters and Black 
(1976), Waters et al. (1977), Walter et al. (1976), Huff (1971), Smith (1966), Defalque (1961), 
Atkinson (1960), and von Oettingen (1937, 1964).  This review is not intended to be exhaustive, 
but instead, to present a current summary and update of the available literature. 
TRICHLOROETHYLENE in Drinking Water 
California Public Health Goal (PHG)  21  February 1999  
Toxicological Effects in Animals and Plants 
Acute Toxicity 
The 14-d acute oral LD50s for TCE were 2400 mg/kg in the mouse (Tucker et al., 1982) and 
4920 mg/kg in the rat (Smyth et al., 1969).  Stott et al. (1982) examined the effects of orally 
administered TCE on rats and mice.  In one group of experiments, mice were given 2400 mg/kg 
of TCE by gavage daily for 3 d, or 5 d/wk for 3 wk.  The livers of animals from both groups 
exhibited altered hepatocellular morphology, centrilobular hepatocellular swelling, and necrosis. 
Statistically significant (p < 0.01) increases in liver weight and in hepatic DNA synthesis were 
observed, as well as a slight reduction in DNA content per gram of liver.  Stott et al. (1982) 
documented similar effects in mice that received oral doses of 250, 500, 1200, or 2400 mg/kg­
day of TCE daily for 3 wk.  Rats given 1100 mg/kg of TCE by gavage 5 d/wk for 3 wk had 
statistically significant (p < 0.01) increases in liver weight and in hepatic DNA synthesis. 
However there were no statistically significant changes in the livers of rats that received 1100 
mg/kg of TCE for 3 d. 
Tucker et al. (1982) conducted an experiment in which TCE was administered to mice by gavage 
at 24 and 240 mg/kg per day for 14 d.  A statistically significant increase in liver weight (p < 
0.05) was observed only in animals that received 240 mg/kg-day. 
In a study by Buben and O'Flaherty (1985), mice were given 100, 200, 400, 800, 1600, 2400, or 
3200 mg/kg of TCE by gavage 5d/wk for 6 wk.  All dose levels caused a statistically significant 
(p < 0.001) increase in the liver-weight/body-weight ratio.  Glucose-6-phosphatase (G-6-P) 
activity was significantly lower (p < 0.01) in the livers of animals that received doses of 800 
mg/kg or more.  Liver triglycerides increased significantly (p < 0.01) at 2400 mg/kg and serum 
glutamic pyruvic transaminase (SGPT) activity increased significantly (p < 0.05) after treatment 
with 2400 mg/kg or 3200 mg/kg.  The DNA content of hepatocytes from the 400 mg/kg and 1600 
mg/kg treatment groups were also observed to decrease significantly (p < 0.05 and p < 0.001, 
respectively). 
White and Carlson (1979) studied epinephrine-induced cardiac arrhythmias in rabbits and rats. 
Animals were pretreated with agents that induced (phenobarbital or Aroclor 1254) or inhibited 
(SKF 525A or Lilly 18947) microsomal enzymes.  Rabbits were exposed to 3000 ppmv TCE by 
inhalation for 7.5 to 60 min, while rats were exposed to 25,000 ppmv TCE for 10 to 60 min. 
Increasing doses of epinephrine (0.5 to 4.0 mg/kg) were administered intravenously.  Cardiac 
arrhythmias were not observed in rats treated with phenobarbital, Aroclor 1254, or Lilly 18947 
(and subsequently exposed to TCE and epinephrine).  However, rats pretreated with SKF 525A 
developed arrhythmias in response to TCE, and sensitivity to epinephrine became more 
pronounced over the course of an hour.  In rabbits, arrhythmias were observed in response to 
epinephrine in all treatment groups.  The effective dose of epinephrine varied with the 
pretreatment regimen and duration of exposure to TCE. 
In a later study White and Carlson (1981) examined the effect of ethanol on epinephrine-induced 
cardiac arrhythmias in rabbits exposed to TCE by inhalation.  A single dose of ethanol (1 g/kg, 
oral or intravenous) was given to rabbits 30 min before exposure to TCE (6000 ppmv, 1 hr). 
Epinephrine was then injected (0.5 to 3.0 mg/kg).  Rabbits treated orally with ethanol and TCE 
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developed epinephrine-induced cardiac arrhythmias sooner and at lower doses of epinephrine 
than control animals.  No cardiac arrhythmias occurred when TCE was administered alone. 
A single dose of ethanol (1 g/kg, oral or intravenous) was given to rabbits 30 min before 
exposure to TCE (6000 ppmv, 1 h).  Epinephrine was then injected (0.5 to 3.0 pg/kg) until 
arrhythmia developed.  Rabbits treated orally with ethanol and TCE developed epinephrine-
induced cardiac arrhythmias sooner and at lower doses of epinephrine than control rabbits. 
Ethanol administered by intravenous injection induced arrhythmias in rabbits more often than 
orally administered ethanol.  No cardiac arrhythmia occurred when TCE was administered alone. 
Soni et al. (1998) investigated tissue repair response as a function of dose during 
trichloroethylene hepatotoxicity.  Male Sprague-Dawley rats (10/dose group) were in injected 
intraperitoneally with 250, 500, 1250, 2500, and 5000 mg/kg TCE dissolved in corn oil. 
Lethality between days one and three was 100% in the top dose and 50% at 2500 mg/kg.  Smaller 
groups of 4-6 rats were similarly dosed with 0 (vehicle control), 250, 500, 1250, and 2500 mg/kg 
TCE in corn oil.  Hepatotoxicity and tissue repair were evaluated over a 96-hr period following 
TCE or oil administration.  Maximum liver cell necrosis was seen at 48 hr after TCE 
administration.  Measures of liver injury such as plasma sorbitol dehydrogenase and alanine 
aminotransferase did not show dose-related increases probably because of inhibition by the TCE 
metabolite TCA.  TCA was found to inhibit both enzymes in vitro.  Tissue regeneration response 
as measured by [
3H]thymidine incorporation into hepatocellular DNA was stimulated maximally 
at 24 hr after 500 mg/kg TCE administration.  At 250 mg/kg [
3H]thymidine incorporation peaked 
only after 48 hr indicating minimal injury.  At higher doses tissue repair was delayed and 
reduced resulting in greater liver injury. 
Subchronic Toxicity 
Kimmerle and Eben (1973a) evaluated the toxicity of TCE to rats after acute and subchronic 
inhalation exposure.  One group of animals was exposed to 49, 175 or 330 ppmv TCE for 4 hr, 
while another group was exposed to 55 ppmv of TCE 8 hr/d 5 d/wk for 14 wk.  At the end of 
treatment, liver- and kidney-function test results were within normal limits.  However, treated 
animals had a significant increase in relative and absolute liver weight (p < 0.01) compared to 
untreated animals. 
Continuous exposure to TCE at 150 ppmv by inhalation for 30 d caused a statistically significant 
increase (p < 0.05) in the liver weights of mice, rats, and gerbils (Kjellstrand et al., 1981). 
Kjellstrand et al. (1983a) used the same protocol to evaluate the effects of TCE on seven 
different strains of mice.  All strains had a significant increase in plasma butylcholinesterase 
activity (p < 0.001).  In a subsequent study by Kjellstrand et al. (1983b) mice were exposed to 
37, 75, 150, or 300 ppmv of TCE vapor continuously for 30 d.  Statistically significant increases 
(p < 0.05) in plasma butylcholinesterase activity were found in the males, and increases in liver 
weight were measured in both sexes at concentrations of TCE greater than 75 ppmv. 
Several animal studies have found no evidence of renal toxicity in mice or rats exposed to TCE 
(Nowill et al., 1954; Utesch et al., 1981; Stott et al., 1982.  In contrast to these reports, Tucker et 
al. (1982) found a significant increase (p < 0.05) in the kidney weights of mice that received 5.0 
mg/mL TCE in drinking water for 4 to 6 months (2.5 and 5.0 mg/mL).  In addition, high-dose 
females (5.0 mg/mL) and males in the two highest dosage groups (2.5 and 5.0 mg/mL) excreted 
greater amounts of protein and ketones in their urine than controls (specific data were not 
published). 
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the kidney.  For example, male and female gerbils exposed to 150 ppmv TCE continuously for 30 
d had a significant increase (p < 0.05) in kidney weight (Kjellstrand et al., 1981).  Continuous 
exposure of NMRI mice to TCE for 30 d (37, 75, 150, or 300 ppmv) caused a statistically 
significant increase (p < 0.05) in kidney weight at 75 ppmv (males) and >150 ppmv (females) 
(Kjellstrand et al., 1983b).  No differences in sensitivity to TCE-induced kidney toxicity were 
observed among seven strains of mice (Kjellstrand et al., l983a). 
Prendergast et al. (1967) conducted an extensive study on dogs, guinea pigs, rats, rabbits, and 
monkeys, in which he exposed the animals to TCE at 189 mg/m
3 (continuously for 90 d) or to 
3825 mg/m
3 8 hr/d, 5 d/wk for 6 wk.  No visible signs of toxicity were noted after exposure to 
189 mg/m
3.  All animals exposed to 3815 mg/m
3 (710 ppm) had non-specific inflammatory 
changes of the lung; some rats and guinea pigs also developed lung congestion. 
Haglid et al. (1981) studied the impact of TCE on the levels of the glial brain-specific protein 
(S100) in discrete areas of the brain.  Gerbils were exposed to 60 or 320 ppmv TCE continuously 
for 3 months.  A pronounced decrease in total soluble protein and a significant increase (p < 
0.05) in S100 protein were measured in the hippocampus, cerebellar vermis (posterior), and brain 
stem of exposed animals.  The DNA content of cells was significantly elevated (p < 0.05 to p < 
0.01) in the cerebellar vermis and sensory motor cortex in animals exposed to 320 ppmv. 
Savolainen et al. (1977) and Vainio et al. (1978) collaborated on a series of experiments in which 
rats were exposed to 200 ppmv TCE 6 hr/d for 5 d.  Both studies reported a decrease in the brain 
RNA content of treated animals (statistical significance was not given).  In addition, Savolainen 
et al. (1977) found that exposure to TCE had no significant effect on brain protein content, but 
that brain acid proteinase activity was higher in treated rats on the fifth day of exposure to TCE. 
Honma et al. (1980) measured levels of neurotransmitters in the brain of rats after exposure to 
200, 400, or 800 ppmv TCE.  Following one month of treatment, biochemical effects were 
observed only in the rats exposed to 800 ppmv TCE.  Statistically significant (p < 0.05) 
reductions occurred in the acetylcholine content of the striatum and in the norepinephrine content 
of the cortex and hippocampus; only slight increases of dopamine were measured in the striatum. 
In addition, the serotonin content of the cortex and hippocampus were slightly elevated in the 
treated animals. 
Channel et al. (1998) observed that subchronic exposure to TCE caused lipid peroxidation and 
hepatocellular proliferation in male B6C3F1 mouse liver.  Animals (six per dose group) were 
dosed orally once daily, 5d/wk for 8 wk at 0, 400, 800, 1200 mg/kg-day TCE in corn oil. 
Peroxisomal proliferation, cell proliferation and apoptosis were evaluated at selected times. 
Lipid peroxidation, measured as thiobarbituric acid-reactive substances (TBARS), was 
significantly elevated at the two higher doses of TCE on days 6 through 14 of the study.  By day 
35 all treatment groups had TBARS values insignificantly different from the vehicle controls.  A 
significant increase in cell and peroxisomal proliferation was observed during the same period in 
the 1200 mg/kg-day group.  The greatest elevation occurred on day six (307% vs. controls) with 
modest increases on days 21, 42 and 56 (77, 30, 11% vs. controls, respectively).  Necrosis or an 
increase in apoptosis was not observed at any dose.  The authors note the temporal relationship 
between oxidative stress and cellular response of proliferation that both occur and resolve over 
the same relative time period suggests that TCE-induced mitogenesis may result from an altered 
liver microenvironment and selective advantage for certain hepatocyte subpopulations.  Further, 
the initial cellular response may be a characteristic of B6C3F1 mouse liver that may help explain 
the species and strain sensitivity to TCE-induced hepatic tumorigenesis. 
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A range of assays, covering a wide spectrum of genetic endpoints, has been performed to assess 
possible genotoxic effects produced by TCE or its metabolites.  DNA or chromosome-damaging 
effects have been evaluated in bacteria, fungi, yeast, plants, insects, rodents, and humans.  The 
genetic endpoints measured by these assays include: forward and reverse mutation, sister 
chromatid exchanges, gene conversion, chromosomal aberrations, micronuclei formation, and 
mitotic recombination.  Induction of DNA repair and covalent binding to DNA have also been 
examined.  The U.S. EPA (1985a) health risk assessment document for TCE presents a detailed 
review of the earlier literature on the genotoxicity of TCE.  The Genetic Activity Profile (GAP) 
database lists 36 entries for TCE with 12 positive results without activation and an additional two 
with exogenous activation (GAP version 4.01).  The positive responses included reverse 
mutation and gene conversion in Saccharomyces cerevisiae, gene mutation in the plant 
Tradescantia sp., cell transformation in rat embryo cells in vitro, mouse spot test and 
micronucleus test in vivo, and UDS and SCE in human lymphocytes in vitro.  Crebelli and 
Carere (1989) and more recently Fahrig et al. (1995) have also reviewed the genetic toxicity of 
TCE.  Crebelli & Carere concluded that TCE is weakly active both in vitro, where liver 
microsomes produce electrophilic TCE metabolites, and also in vivo in mouse bone marrow, 
where high rates of micronuclei, but no structural chromosome aberrations, are found.  Fahrig et 
al. reached somewhat similar conclusions in that the micronucleus tests were positive in 
mammalian cell cultures as well as bone marrow, whereas no chromosomal aberrations were 
found.  However, Fahrig et al. noted that TCE has a very specific genotoxic activity and is not 
typical of a genotoxic carcinogen (Table 4).  In vitro and in vivo, TCE induces recombination, 
including sister chromatid exchanges, and aneuploidies, including micronuclei.  However, TCE 
appears unable to induce gene mutations or structural chromosomal aberrations.  TCE was 
observed to induce increased DNA synthesis and mitosis in mouse liver in vivo (Dees & Travis, 
1993).  Despite its lack of “typical” genetic toxicity Fahrig et al. note that TCE could be involved 
in the expression of carcinogen-induced mutations due to its potential to induce recombination 
and aneuploidy.  Reciprocal recombinations have been shown to play a role in inherited 
mutations that lead to the development of human tumors (Cavenee et al., 1983). 
The genetic toxicity of TCE metabolites has also been evaluated.  Chloral hydrate is able to 
induce chromosomal aberrations (Degrassi & Tanzarella, 1988; Furnus et al., 1990), aneuploidies 
(Furnus et al., 1990; Vagnarelli et al., 1990; Natarajan et al., 1993; Sbrana et al., 1993), and 
micronuclei (Degrassi & Tanzarella, 1988; Migliore & Nieri, 1991; Bonatti et al., 1992; 
Hummelen & Kirsch-Volders, 1992; Lynch & Parry, 1993; Seelbach et al., 1993) in cultured 
mammalian cells in vitro. 
TCA was reported to induce chromosomal aberrations in human lymphocyte cultures in vitro 
(Kurinnyi, 1984).  TCA exposure of rodents in vivo resulted in strand breaks of hepatic DNA 
(Nelson & Bull, 1988; Nelson et al., 1989; Chang et al., 1992).  Induction of chromosomal 
aberrations by TCA in mouse bone marrow cells has given mixed results: positive by Bhunya & 
Behera (1987) and negative by Kurinnyi (1984).  Bhunya & Behera (1987) reported TCA-
induced increases in micronuclei frequencies in mouse bone marrow cells.  Tao et al. (1996) 
observed the loss of heterozygosity on chromosome 6 in TCA-promoted hepatic tumors in mice. 
Notwithstanding the contradictory chromosomal findings, TCA clearly has genotoxic potential. 
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but negative in another DNA repair test in S. typhimurium (Waskell, 1978).  DeMarini et al. 
(1994) found DCA active in a prophage induction test and mutagenic in S. typhimurium TA 100. 
Conflicting results have been obtained for DCA induced DNA damage as shown by the alkaline 
elution method (Nelson et al., 1989; Chang et al., 1992).  DCA did not induce loss of 
heterozygosity on chromosome 6 in DCA-promoted hepatic tumors in mice (Tao et al., 1996). 
Both TCA and DCA were found to induce hypomethylation of DNA in liver and tumors of 
female B6C3F1 mice (Tao et al., 1998).  The level of 5-methylcytosine in DNA of hepatocellular 
adenomas for animals promoted by DCA was 2.36 – 0.15% representing a 36% decrease 
compared to noninvolved liver tissue from the same animals (p < 0.05).  Both TCA and DCA 
promoted clonal expansion of anchorage-independent hepatocytes in vivo and in vitro (Stauber et 
al., 1998).  Pretreatment of male B6C3F1 mice with 0.5 g/L DCA in drinking water for two 
weeks resulted in a fourfold increase in in vitro colony formation above hepatocytes isolated 
from naïve mice.  A significant (p < 0.05) increase was seen at the lowest exposure level of 0.02 
mM DCA.  In naïve animals significant increases in colony formation were seen with TCA or 
DCA at 0.5 mM (p < 0.05), with DCA showing a greater effect than TCA at higher levels (1, 2 
mM (p < 0.05)). 
TCOH was inactive for gene mutation and DNA repair tests in S. typhimurium (Waskell, 1978). 
Crebelli et al. (1985) described TCOH-induced aneuploidy in Aspergillus nidulans.  A very weak 
induction of SCEs by TCOH was observed in human lymphocytes (Gu et al., 1981a,b cited in 
Fahrig et al., 1995). 
Dichlorovinylcysteine (DCVC) is mutagenic in bacteria (Dekant et al., 1986) and induces DNA 
repair in the cultured kidney cell line LLC-PK1 (Vamvakas et al., 1989).  DCVC induces DNA 
double-strand breaks followed by increased poly(ADP-ribosyl)ation of nuclear proteins in 
cultured renal cells in vitro (Vamvakas et al., 1992) and in rat kidney in vivo (McLaren et al., 
1994).  Increased poly(ADP-ribosyl)ation may play a role in the TCE-induced kidney cancers as 
has been suggested for hepatocarcinogenicity of N-nitrosodiethylamine and benzo[a]pyrene 
(Denda et al., 1988).  Muller et al. (1994) have investigated possible DNA adducts formed by 
halothioketenes and haloketenes from TCE.  When chloroketene was reacted with adenine, 
cytosine and guanine, four adducts were identified: 1, N
2-acetylguanine; 3, N
4-acetylcytosine 
(two isomers); and 1, N
6-acetyladenine.  Reactions with dichloroketene yielded adducts only with 
adenine and cytosine: N
4-dichloroacetylcytosine, N
6-dichloroacetyladenine.  The results are seen 
to confirm earlier findings of modified DNA formed from S-(1,2-dichlorovinyl)-L-cysteine by 
the action of b-lyase (Bhattacharya & Schultz, 1972).  The genetic toxicity findings for TCE and 
selected metabolites are summarized in Table 4. 
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Table 4.  Summary of Genetic Toxicity Findings for TCE and its Metabolites* 
Test Class  Positive Results  Negative Results 
Indicator tests in 
vitro 
Mutation tests in 
vitro 
Host-mediated assay 
•  Covalent binding to 
DNA 
•  Induction of C-mitoses 
•  Induction of 
recombination in yeast 
•  Weak induction of SCEs 
•  Induction of 
chromosome loss in 
fungi 
•  Weakly positive in 
mouse lymphoma assay 
•  Induction of 
aneuploidies at high 
concentration 
Induction of recombination 
in yeast 
•  No induction of 
chromosome damage in 
yeast 
•  No effects in bacteria 
•  No induction of UDS 
•  No relevant effects in 
bacteria 
•  No relevant effects in 
fungi 
•  No induction of 
chromosomal 
aberrations 
No induction of gene 
mutations in fungi 
Indicator tests in vivo 
Mutation tests in 
somatic cells in vivo 
•  Induction of DNA strand 
breaks 
•  Possible induction of 
sperm abnormalities 
•  Induction of increased 
DNA synthesis and 
mitosis in liver 
•  Weakly positive mouse 
spot test 
•  Induction of micronuclei 
•  Very low DNA binding 
capacity 
•  No induction of SCEs 
•  No induction of UDS 
•  No induction of 
chromosomal 
aberrations 
Germ cell tests  •  No induction of 
dominant lethals 
•  No induction of 
micronuclei in 
spermatids 
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Test Class  Positive Results  Negative Results 
Monitoring in 
humans 
Tests on metabolites: 
Chloral hydrate 
TCA 
DCA 
TCOH 
•  Positive in chromosomal 
aberration tests in vitro 
•  Possibly positive in 
aneuploidy tests in vivo 
•  Genotoxic potential in 
bacterial tests 
•  Loss of heterozygosity 
on chromosome 6 in 
mice in vivo 
•  Some positive DNA 
repair and gene mutation 
results in bacteria 
•  Positive aneuploidy tests 
in fungi 
•  Positive SCE tests in 
vitro 
•  No relevant induction of 
SCEs 
•  No induction of sperm 
abnormalities 
•  Most in vivo data 
inconclusive 
•  Inconclusive data on 
DNA damage in vivo 
•  No loss of 
heterozygosity 
•  Negative in bacterial 
gene mutation tests 
DCVC  •  Positive in gene 
mutation in bacteria 
•  Induces DNA repair in 
cultured kidney cells in 
vitro 
•  Induction of DNA 
double strand breaks and 
poly(ADP-ribosyl)ation 
in kidney in vitro and in 
vivo 
* Adapted from Fahrig et al., 1995. 
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Schwetz et al. (1975) evaluated the teratogenic potential of TCE in rats and mice exposed to 300
 
ppmv of TCE 7 hr/d on days 6 through 15 of gestation.  A statistically significant inhibition (p <
 
0.05) of maternal weight gain was observed in treated rats.  The exposure had no apparent effect
 
on the average number of implantation sites per litter, litter size, the incidence of fetal
 
resorptions, fetal sex ratios, fetal body measurements, or on the incidence of fetal tissue or
 
skeletal anomalies in either species.
 
Healy et al. (1982) exposed rats to 100 ppmv TCE (4 hr/d) during days 8 to 21 of gestation.
 
Compared to controls, there was a significant delay (p < 0.05) in fetal maturation (decreased fetal
 
weight) and in the number of resorptions in treated animals.  Beliles et al. (1980) conducted a
 
study to determine the teratogenic potential of workplace contaminants, including TCE.  Rats
 
and rabbits were exposed to 500 ppmv of TCE 7 hr/d, 5 d/wk prior to mating (3 wks) and during
 
gestation.  Separate groups of animals were exposed to TCE during gestation only.  No adverse
 
effects were noted in the offspring of rats.  However, fetuses from two litters of rabbits exhibited
 
hydrocephaly.  Although the incidence of this defect was not statistically significant, the authors
 
considered it to be of potential biological significance.
 
Kjellstrand et al. (1982b) studied the growth of neonatal Mongolian gerbils exposed to TCE.
 
The exposure regimens used in the study consisted of continuous exposure to 230 ppmv TCE for
 
7 d (21 to 28 d of age), 14 d (14 to 28 d of age), 21 d (7 to 28 d of age), or 28 d (0 to 28 d of age).
 
An age-related incidence of mortality was observed in the four groups (2, 13, 8, and 36%,
 
respectively).
 
Slacik-Erben et al. (1980) conducted a dominant lethal assay in mice to detect spermatocyte
 
anomalies induced by TCE.  Male mice were exposed to either 50, 200 or 450 ppmv of TCE for
 
24 hr.  Each male was then mated to 12 separate unexposed females over a 48-d period (this
 
regimen was designed to sample effects on all stages of spermatogenesis).  Females were
 
sacrificed on day 14 of gestation.  The following parameters were assessed to determine the
 
effects of the exposure:  number of implantations, fertilization  rate (percentage of females with
 
implantations in relation to the total number of mated females), post-implantation loss, pre­
implantation loss, and the frequency of dominant lethal factors.  None of these parameters was
 
observed to be significantly different between the exposed and the control group.
 
Manson et al. (1984) administered TCE at 1,000 mg/kg-day to rats by corn oil gavage and
 
observed indicators of maternal toxicity, significant fetal mortality, and decreased fetal weight,
 
but no teratogenic effects.  Dawson et al. (1993) exposed groups of 9-39 female rats to TCE in
 
drinking water (1.5 or 1,100 ppm) either before pregnancy (3 mo.), before and during pregnancy
 
(2 mo. + 21 d), or during pregnancy (21 d).  Maternal toxicity was not observed.  Fetal heart
 
defects were not observed in fetuses from dams exposed only before pregnancy.  Abnormal fetal
 
heart development was observed at both concentrations in dams exposed before and during
 
pregnancy (3% in controls; 8.2% at 0.18 mg/kg-day; 9.2% at 132 mg/kg-day).  In dams exposed
 
only during pregnancy fetal heart defects were seen only at the higher dose (10.4% vs. 3% in
 
controls).  The study is limited by widely spaced doses and lack of a useful dose-response.  The
 
study does seem to provide some support for human epidemiological findings of increased
 
congenital heart defects and TCE exposure.
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to TCE.  Postnatal exposure of male mice to 50 or 290 mg/kg-day TCE between the ages of 10 
and 16 d resulted in a significant reduction in rearing rate at both doses when tested at 60 d.  The 
study suggests that TCE affects brain maturation.  Based on the LOAEL of 50 mg/kg-day 
identified in this study, ATSDR developed an acute duration oral MRL of 0.2 mg/kg-day for 
TCE (ATSDR, 1997). 
NTP (1986) evaluated open-field activity in 21- and 45-day-old F1 rats that had been 
continuously exposed to TCE, in utero and throughout lactation, via maternal dietary exposure 
(microcapsules), at doses ranging from 75 to 300 mg/kg-day.  A significant dose-related trend 
toward increased time required for grid traversal was observed in the 21-day-old pups. 
Evaluation at 45 d was unremarkable suggesting a transient effect.  The 300 mg/kg-day dose was 
considered a NOAEL for the study. 
Other studies in which rats were exposed via drinking water from 14 days before mating 
throughout lactation to weaning have shown neurological effects.  A 40% decrease in the number 
of myelinated fibers was observed in 21-day-old offspring of rats given 312 mg/L TCE (37 
mg/kg-day) (Isaacson & Taylor, 1989).  A similar effect was seen at the higher concentration of 
625 mg/L (75 mg/kg-day).  Glucose uptake by the brain was reduced in 21-day-old offspring of 
rats given 312 mg/L TCE (Noland-Gerbec et al., 1986).  Activity measurements in 60-day-old 
rats showed increases in offspring of rats given 312 mg/L TCE (Taylor et al., 1985). 
The non-additive developmental toxicity of mixtures of trichloroethylene (TCE), di(2­
ethylhexyl)phthalate (DEHP), and heptachlor has been studied in 5 x 5 x 5 designs in Fischer­
344 rats.  Dose levels of 0, 10.1, 32, 101, 320 mg/kg-day for TCE, 0, 24.7, 78, 247, 780 mg/kg­
day for DEHP, and 0, 0.25, 0.8, 2.5, 8 mg/kg-day for heptachlor were administered by gavage on 
days 6-15 of gestation.  The dams were allowed to deliver and the pups were weighed and 
examined postnatally (Narotsky et al., 1995).  Three maternal and six developmental endpoints 
were evaluated.  Several significant two-way interactions but no significant three-way 
interactions were observed.  Maternal death exhibited no single chemical or main effects but 
DEHP and heptachlor were synergistic.  For maternal weight gain on gestational days 6-8, main 
chemical effects were seen for all three agents as well as TCE-DEHP synergism and DEHP­
heptachlor antagonism.  Maternal weight gain on gestational days 6-20 adjusted for litter weight 
showed effects for TCE and heptachlor, but no interactions.  Effects of all three agents were seen 
for full-litter resorptions and prenatal loss.  The heptachlor effects were unexpected, particularly 
as seen with pooled data (heptachlor only plus heptachlor combinations) for each heptachlor 
dose, with 23% of (253) dams with resorbed litters at 8 mg/kg-day and 18% of (247) dams at 2.5 
mg/kg-day vs. 12 % in the controls.  For full-litter loss, the TCE-heptachlor and DEHP­
heptachlor interactions were antagonistic.  For prenatal loss, the TCE-DEHP interaction was 
synergistic.  Postnatal loss showed DEHP and heptachlor effects but no interactions.  Analysis of 
pup weights on day 1 revealed TCE and DEHP effects and DEHP-heptachlor antagonism; on day 
6 DEHP and heptachlor effects and DEHP-heptachlor antagonism, and TCE-DEHP synergism 
were evident.  The authors note that some antagonistic interactions of prenatal loss and full litter 
resorptions may reflect a ceiling effect and, based on heptachlor main effects, that heptachlor 
potentiated the other two agents.  The authors thus regard all three two-way interactions to be 
synergistic for these related endpoints.  Microphthalmia and anophthalmia incidences showed 
TCE and DEHP effects but no interactions.  A dose related increase in micro- or anophthalmia 
that was statistically significant at 1,125 mg/kg-day TCE was observed.  Eye defects were 
observed in 1%, 5.3%, 9.2%, 11.7%, and 30% of pups from dams treated with 0, 475, 633, 844, 
and 1,125 mg/kg-day of TCE respectively (Narotsky et al., 1995). 
TRICHLOROETHYLENE in Drinking Water 
California Public Health Goal (PHG)  30  February 1999 Gennings (1996) analyzed a subset of the Narotsky et al. data to illustrate the use of ray designs 
in mixtures of chemicals.  Such ray designs provide a more economical way to study the effects 
of mixtures (Mantel, 1958; Bruden et al., 1988).  Mixtures of chemicals are evaluated along rays 
of fixed ratios.  For example, for a mixture of three chemicals with fixed ratios represented by 
Chemical 1:Chemical 2:Chemical 3, a 1:0:0 ratio represents a ray of Chemical 1 alone, while a 
1:1:1 ratio represents a ray of equal levels of the three chemicals.  A ray design for a small 
number of chemicals and many mixture rays can support the estimation of a response surface. 
However, the advantage of a ray design is that it can also be used with a mixture of many 
chemicals and a few mixture rays where a predictive univariate model is fit along each ray with 
total dose as the independent variable (Gennings, 1996). 
The selected response was prenatal loss.  The rays selected were one for each single chemical 
and one mixture ray.  The dose ratios for the rays were for (DEHP:heptachlor:TCE): (1:0:0); 
(0:1:0); (0:0:1); and (70:1:29).  A threshold model was fitted along each of the four rays 
simultaneously.  The author concluded that departure from additivity could not be claimed along 
the 70:1:29 ratio mixture ray. 
Zenick et al. (1984) studied the effects of TCE exposure on the reproductive function of male 
rats.  Rats were intubated with 10, 100 or 1000 mg/kg of TCE 5 d/wk for 6 wk and then were 
mated with ovariectomized, hormonally primed females.  At the end of 1, 5, and 10 wk after the 
start of the experiment, copulatory behavior and semen samples were evaluated.  All dose groups 
exhibited a statistically significant (p < 0.001) increase in body weight.  No significant effects 
were found in semen plug weights, sperm count, sperm motility, sperm morphology, or 
copulatory behavior.  Other data of Zenick et al. (1984) indicate that male reproductive organs 
are able to accumulate TCE and its metabolites.  Although this suggests that these substances 
may have the potential to interfere with normal reproductive function, Zenick et al. (1984) found 
little evidence of any direct effect of TCE on the male reproductive system. 
Manson et al. (1984) found that TCE had no effect on the reproductive performance of female 
rats.  Rats received 10, 100, or 1000 mg/kg of TCE daily for 6 wks (2 wks before mating, 
throughout mating (1 wk), and through day 21 of gestation).  Females in the high-dose group 
gained significantly less weight than those in other groups (p < 0.01).  The litters of these 
animals had a significantly greater number of deaths (p < 0.001) compared to controls, or to the 
other two treatment groups.  The authors attributed the high pup mortality to materna1 TCE-
induced toxicity, rather than to any direct neonatal action of TCE. 
Dorfmueller et al. (1979) examined whether exposure to TCE before mating and during 
pregnancy was more detrimental to reproductive outcome than exposure either before mating 
alone or during pregnancy alone in rats.  Three treatment groups were used: (1) TCE exposure 
before mating and during pregnancy, (2) TCE exposure before mating, and (3) TCE exposure 
during pregnancy.  Prior to mating, animals were exposed to 1800 ppmv TCE 6 hr/d, 5 d/wk for 2 
wk.  Exposure during pregnancy was for 6 hr/d, 7 d/wk and continued through day 20 of 
gestation.  Treatment had no significant effect on maternal rats, although the fetuses of rats 
exposed to TCE during pregnancy had an increased incidence of skeletal anomalies.  The 
incidence was not significantly different from controls, however. 
NTP (1986) conducted a continuous breeding study in which Fischer-344 rats were fed diets 
containing microencapsulated TCE that resulted in doses of approximately 0, 75, 150, or 300 
mg/kg-day from 7 days before mating through birth of the F2 generation.  There was an increase 
in relative left testis/epididymis weight in the F0 generation and a decrease in absolute left 
testis/epididymis weight in the F1 generation.  The findings were considered due to general 
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toxicity rather than specific to the reproductive system.  No histopathological changes were 
noted.  There was no effect on reproductive performance.  A similar fertility study (NTP, 1985) 
was conducted with CD-1 mice using the same dietary concentrations of TCE (up to 750 mg/kg­
day).  There were no treatment related effects on mating, fertility, and reproductive performance 
in either F0 or F1 mice, but sperm motility was reduced by 45% in F0 males and 18% in F1 males. 
TCE has not been listed as a reproductive toxicant under Proposition 65 (Safe Drinking Water 
and Toxic Enforcement Act of 1986). 
Immunotoxicity 
TCE induced a concentration-dependent decrease in the leukocyte count of dogs exposed to 200, 
500, 700, 1000, 1500, or 2000 ppmv of TCE for 1 hr.  In a second experiment, a group of dogs 
received 50 mg/kg TCE intravenously at the rate of approximately 1 mL/min through the right 
femoral vein.  No significant differences were noted in erythrocyte counts, thrombocyte counts, 
or in the hematocrit values of treated dogs.  Sanders et al. (1982) found a dose-related decrease in 
the cell-mediated immune response of mice given 24 or 240 mg/kg of TCE by gavage (daily for 
14 d).  In a follow-up study, the immune status in mice was evaluated after administration of 0.1, 
1.0, 2.5, or 5.0 mg/mL TCE in drinking water (4 or 6 months).  Humoral immunity was inhibited 
only at 2.5 and 5.0 mg/mL, whereas cell-mediated immunity and bone-marrow-stem cell 
colonization were inhibited at all four concentrations.  Lymphocyte proliferation was not affected 
when animals were challenged with T-cell mitogens. 
Wright et al. (1991) investigated the effects of TCE on hepatic and splenic lymphocytotoxic 
activities in Sprague-Dawley rats and B6C3F1 mice.  Rats were given 0.05, 0.5, and 5.0 mmol/kg 
TCE i.p. for three days.  Mice were similarly administered 10 mmol/kg.  The highest doses 
resulted in decreased splenocyte count and relative spleen weights in rats and mice, respectively, 
and inhibition of hepatic natural killer cell (NK), natural cytotoxic cell (NC), and NPK cell 
activities in both rats and mice. 
Kahn et al. (1995) studied TCE-induced autoimmune response in female autoimmune prone mice 
(MRL +/+).  Three groups of mice (5 weeks old) received i.p. injections of 10 mmol/kg of TCE, 
0.2 mmol/kg dichloroacetyl chloride (DCAC), or 0.1 mL corn oil.  Animals were dosed every 
fourth day for 6 weeks and sacrificed 24 hr following the final dose.  Spleen weights in the TCE 
and DCAC groups increased 36% with a similar increase in spleen weight/body weight ratio. 
Serum IgG in the TCE and DCAC groups increased 45 and 322%, respectively.  Using specific 
ELISA assays for mice, autoimmune antibodies (anti-nuclear, anti-ssDNA, anti-cardiolipin) were 
detected in the sera of TCE- and DCAC-treated mice.  These results suggest that TCE and its 
metabolite DCAC induce or accelerate autoimmune responses in female MRL +/+ mice.  The 
similar responses to DCAC at a 50-fold lower dose than TCE indicate a metabolite-mediated 
mechanism for TCE-induced autoimmunity. 
Neurotoxicity 
Several animal studies have demonstrated behavioral changes following TCE exposure. 
Grandjean (1960) exposed starved rats to 200 or 600 ppmv of TCE for 3 hr and noted the 
reaction time to a food-motivated, preconditioned response.  The average reaction time of the 
exposed rats was approximately the same as that of the controls.  However, the total number of 
times an animal responded to a test stimulus was significantly greater in treated animals (p < 
0.01) than in controls.  These data indicate that TCE may cause an increase in excitability or loss 
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400 ppmv of TCE for 49 d. 
Goldberg et al. (1964a) found that rats exposed to TCE (200, 560, 1568, or 4380 ppmv, 4 hr/d for 
10 d) exhibited a specific inhibition of the avoidance response.  This effect was not clearly 
concentration dependent, however.  Furthermore, animals exposed to 1568 ppmv showed "some 
evidence" of ataxia, while gross ataxia was observed in animals treated with 4380 ppmv TCE. 
Test results also indicated a slight increase in learning ability following exposure at 200 ppmv, 
while all other concentrations inhibited learning ability. 
To develop exposure protocols that were representative of episodes of TCE "sniffing," Utesch et 
al. (1981) exposed rats to high concentrations of TCE (i.e., 9000, 12,000, 14,000, or 15,000 
ppmv) for up to 15 min.  Animals displayed signs of CNS depression, such as difficulty in 
locomotion and loss of the righting reflex.  With the exception of animals exposed to 15,000 
ppmv, recovery was rapid.  In high-dose animals, the effects of exposure persisted for several 
hours.  In a separate experiment, the coupling of ethanol exposures and/or fasting regimens with 
exposure to TCE had no marked effects on neurological responses. 
Subchronic exposure of rats to TCE at 2600, 5000, or 8000 ppmv 30 min/d, 6 d/wk for 80 d 
caused a statistically significant (p < 0.05) decrease in open-field ambulation performance and 
response time (Ikeda et al., 1980b).  In a study conducted by Battig and Grandjean (1963), rats 
that were exposed to 400 ppmv TCE 8 hr/d, 5d/wk for 44 wk showed a decrease in swimming 
performance, exploratory activity, and learning ability (Hebb test or conditioned-avoidance 
response test).  Mikiskova and Mikiska (1966) demonstrated that TCE can also cause CNS 
depression with intraperitoneal (IP) administration.  Guinea pigs given a single IP dose of 880 
mg/kg (6.7 mmol/kg body weight) developed ataxia, a loss of muscle tone, and hyperalgesia. 
Eighteen female Sprague-Dawley rats were divided into three groups of six and administered an 
oil vehicle, TCE or dichloroacetylene (DCAC) by oil gavage, 5d/wk for 10 wk, then examined 
for impairment of the trigeminal nerve.  The daily doses were 2.5 g/kg for TCE and 17 mg/kg for 
DCAC.  Significant decreases of the internode length and of the mean fiber diameter were seen 
in the DCAC group, with diminished but not significant effects in the TCE group (Barret et al., 
1992). 
Arito et al. (1994) exposed rats by inhalation to 0, 50, 100, and 300 ppm TCE for 8hr/d, 5d/wk, 6 
weeks.  The endpoints of interest were reduced heart rate and wakefulness indicative of central 
nervous system (CNS) toxicity.  A LOAEL of 50 ppm was identified. 
Chronic Toxicity 
Histopathological changes in the GI tract were not seen in intermediate- and chronic-duration 
studies in rats and mice treated by oil gavage (NCI, 1976; NTP, 1988, 1990; Maltoni et al., 1986) 
or by chronic inhalation of TCE in rats (Maltoni et al., 1988).  Ingestion of TCE in drinking 
water for six months resulted in minor hematological changes in mice, including a 16% decrease 
in the red blood cell count in males exposed to 660 mg/kg (Tucker et al., 1982).  Liver 
enlargement is the primary effect seen in TCE-exposed animals after oral or inhalation exposure. 
Many of the studies were limited by lack or inadequate scope of pathological examinations, lack 
of measurement of hepatic enzymes, and/or failure to evaluate liver function indices (ATSDR, 
1997).  Renal enlargement has been associated with acute or intermediate duration exposures to 
TCE. Chronic experiments have also exhibited kidney toxicity.  Administration of high doses of 
TCE by gavage for 78 weeks to Osborne-Mendel rats and B6C3F1 mice resulted in treatment 
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related nephropathy with degenerative changes in the tubular epithelium (NCI, 1976).  In cancer 
bioassays in rats and mice, renal effects included toxic nephrosis (cytomegaly) at 500 and 1000 
mg/kg-day (NTP, 1983, 1990) and cytomegaly of the renal tubules and toxic nephropathy (NTP, 
1988).  Additional chronic effects in animals are discussed in the Carcinogenicity and Dose-
Response sections below and in recent reviews (ATSDR, 1997; Gist and Burg, 1995). 
Biochemical Toxicity 
Moslen et al. (1977a, 1977b) examined the effect of microsomal enzyme induction on TCE-
induced liver damage.  Hepatic damage occurred in rats anesthetized with TCE following 
pretreatment with five different inducers of microsomal enzymes.  Animals were given 400 
mmol/kg doses, in corn oil, of 3-methycholanthrene (3-MC), phenobarbital, hexachlorobenzene, 
spironolactone, pregnenolone-16-a-carbonitrile, or 150 to 300 mmole/kg of Aroclor 1254 by 
gavage, daily for 7 d.  Rats from all treatment groups were subsequently exposed to 1% TCE for 
2 hr by inhalation.  In vehicle control animals (corn oil pretreatment) exposure to TCE did not 
cause hepatic injury.  Moslen et al. (1977a) noted a striking increase in SGOT activity (p < 0.01 
to p < 0.001) accompanied by hepatic necrosis in all other animals (except those pretreated with 
spironolactone).  In a separate study, Moslen et al. (1977b) evaluated the effects of TCE on 
hepatic enzyme activity in rats pretreated with phenobarbital.  Rats were given an oral dose of 
400 mmol of phenobarbital or 5 mL/kg of vehicle daily for 7 d followed by a 2-hr exposure to 
TCE (1% by volume in air).  Liver homogenates from phenobarbital-treated animals had 
significantly lower levels of cytochrome P-450 (p < 0.001) and cytochrome b5 (p < 0.05) 
compared to controls.  Phenobarbital pretreatment caused hepatic glutathione (GSH) levels to 
decrease to half of control levels during the exposure, but GSH increased to above normal levels 
8 hr after the end of treatment.  Moslen et al. (1977b) also reported a marked increase in the rate 
of NADH-cytochrome c reduction following exposure to phenobarbital and TCE, but did not find 
any significant changes in the activity of other microsomal enzymes (N-demethylase 
aminopyrine, N-demethylase ethylmorphine, G-6-P, and zoxazolamine hydroxylase). 
Carlson (1974) studied the effects of TCE in rats treated with 3-MC or phenobarbital.  In one 
phase of this study, animals were exposed to 6900, 7800, 10,400, 12,000, or 16,000 ppmv TCE 
for 2-hr.  Forty-eight hours later, half of these animals were given an intraperitoneal (IP) 
injection of 40 mg/kg 3-MC (the remaining animals served as controls).  A separate group of rats 
received four IP injections of phenobarbital (50 mg/kg) daily for 4 d prior to a 2-hr exposure to 
10,400 ppmv TCE.  Isocitrate dehydrogenase activity was significantly greater (p < 0.05) in 
animals exposed to 7800 ppmv TCE, both with and without 3-MC treatment.  Carlson (1974) 
also measured a significant increase (p < 0.05) in SGPT and SGOT activity in animals exposed 
to 6900 or 10,400 ppmv TCE.  Treatment with 3-MC did not appear to affect the levels of these 
enzymes.  Pretreatment with phenobarbital followed by exposure to 10,400 ppmv TCE caused a 
significant decrease (p < 0.05) in G-6-P activity. 
Norpoth et al. (1974) measured a statistically significant (p < 0.05) increase in cytochrome P-450 
content in the liver homogenates of rats exposed to 470 ppmv of TCE 3 hr/d for 10 d. 
Aminopyrine demethylase activity was not significantly affected by this treatment.  Vainio et al. 
(1978) exposed rats to TCE at 7.9 mmol/L 6 hr/d for 4 or 5 days.  No effects were observed after 
4 d.  However, exposure to TCE for 5 d was associated with an increase in hepatic cytochrome P­
450 content (the statistical significance of this increase was not given).  Exposure to 500 to 1000 
ppmv of TCE 18 hr/d for three months produced no measurable effect on the liver function of 
rats, rabbits, or one dog (Nowill et al., 1954). 
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microscopic hepatic derangement.  Plaa et al. (1958) attempted to define an ED50 for TCE-
induced hepatic damage by using prolongation of sleeping time as an index.  Mice were injected 
subcutaneously with 749, 1130, 1314, 1840, or 2627 mg/kg of TCE (these doses were associated 
with "varying degrees of centrilobular necrosis").  Plaa et al. (1958) then measured the duration 
of the resulting anesthesia and used these data to develop a dose-response curve.  An ED50 of 
1445 mg/kg was estimated from this curve. 
Danni et al. (1981) studied the ability of TCE to induce peroxidation of liver microsomal lipids. 
Rats were given a single 678 mg/kg dose of TCE by gavage; hepatic lipids from these animals 
were analyzed for signs of peroxidation.  Lipid peroxidation in unsaturated fatty acids produces 
conjugated dienes, which can be measured spectrophotometrically.  However, no evidence of 
lipid peroxidation was found.  In a parallel study, male and female rats received 170 mg/kg TCE 
48 hr after an i.p. injection of 5 or 8 mg/kg of phenobarbital.  Statistically significant increases in 
hepatic triglycerides were measured in male and female rats (p < 0.025 and p < 0. 005 
respectively) at both doses of phenobarbital.  Rats that received only TCE showed no measurable 
adverse effects.  A third group of rats were given 85 or 339 mg/kg TCE orally.  No effect was 
found on hepatic or serum lipoproteins. 
Rats exposed to TCE, either by gavage or inhalation, excreted large amounts of formic acid in 
urine (Green et al., 1998).  Following a single 6-hr inhalation exposure to 500 ppm TCE, the 
excretion of formic acid was similar to that seen after a 500 mg/kg oral dose of formic acid. 
Formate excretion from TCE reached a maximum on day two and had a half-life of 4-5 days, 
whereas urinary excretion of administered formic acid was complete in 24 hr.  Formate is not a 
metabolite of TCE but rather results from inhibition of formate clearance by TCE metabolites. 
Long term exposure to formic acid is known to cause kidney damage and may contribute to TCE-
induced kidney toxicity seen in long-term studies with TCE. 
Carcinogenicity 
In a recent risk assessment of TCE by Bogen & Gold (1997), 35 long-term, chronic exposure 
experiments of TCE reported in the Carcinogenic Potency Database (Gold and Zeiger, 1997) 
were summarized.  These studies included dosing by gavage or inhalation in several strains of 
rats and mice, and in hamsters, and are listed in Table 5 below.  The main tumor findings were 
liver carcinomas in male mice by inhalation and in male and female mice by gavage 
administration, and lung carcinomas in female mice by inhalation.  In rats, kidney tubular cell 
carcinomas were seen in males by inhalation and gavage administration of TCE.  Benign 
testicular tumors were also seen in rats by inhalation and gavage administration of TCE. 
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Species  Tumor  Sex  Exposure/  Nonzero  Tumor  Tumor  Ref. 
Route  Site/ 
Strain 
Experi­
ment (wk) 
doses/ 
100 
Incidences 
Control (first value), 
Malignant 
Incidences 
Benign + 
Malignant 
Numerator 
Mouse  Liver 
Inhala­
tion 
(ppm) 
B6C3F1  F  78/154  1, 3, 6  3/88, 4/89, 4/88, 9/85 (p = 
0.05) 
1 
M  78/154  1, 3, 6  1/59, 1/31, 3/38, 6/37 (**)  1 
M  78/154  1, 3, 6  17/77, 19/47, 27/67, 21/63  1 
Han: 
NMRI 
F  78/129  1, 5  0/29 0/30, 0/28  (0, 0, 0)  2 
M  78/129  1, 5  1/30, 0/29, 0/30  2 
IC  F  104/107  0.5, 1.5,  0/49, 0/50, 0/50, 0/46  (0, 0, 0, 1)  3 
4.5 
Swiss  F  78/145  1, 3, 6  0/84, 0/89, 0/86, 1/86  1 
M  78/145  1, 3, 6  4/66, 2/53, 8/59, 13/61 
(**) 
1 
Gavage 
mg/kg­
day 
B6C3F1  F  78/90  9,18  0/20, 4/50, 11/50 (**)  (0, 4, 11) 
(**) 
4 
M  78/90  12, 24  1/20, 26/50, 30/50 (***)  (1, 26, 30) 
(***) 
4 
F  103/105  10  2/50, 13/50 (***)  (6, 22) (***)  5 
Mouse  Lung 
M  103/105  10  8/50, 31/50 (***) 
(p < < 1E-9) 
(14, 39) (***) 
(p < < 1E-7) 
5 
Inhala­
tion 
B6C3F1  F  78/154  1, 3, 6  0/90, 1/90, 0/89, 0/87  (2, 6, 7, 14) 
(**) 
1 
(ppm)  M  78/154  1, 3, 6  0/85, 0/86, 0/88, 0/88  (1, 2, 2, 1)  1 
M  78/135  1, 3, 6  0/90, 0/89, 0/90, 1/90  (12, 6, 7, 7)  1 
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Route  Site/ 
Strain 
Experi­
ment (wk) 
doses/ 
100 
Incidences 
Control (first value), 
Malignant 
Incidences 
Benign + 
Malignant 
Numerator 
Han: 
NMRI 
F  78/129  1,5  1/29, 3/30, 0/28  2 
M  78/129  1, 5  5/30, 3/29, 1/30  2 
IC  F  104/107  0.5, 1.5,  1/49, 3/50, 8/50, 7/46 (*)  (6, 5, 13, 11)  3 
4.5 
Swiss  F  78/145  1, 3, 6  2/88, 0/89, 0/88, 2/88  (15, 12, 12,  1 
16) 
M  78/145  1, 3, 6  0/78, 0/73, 0/78, 1/74  (10, 5, 12,  1 
12) 
Gav-
age, 
mg/kg­
B6C3F1  F  78/90  9, 18  0/20, 2/50, 2/50  (1, 4, 7)  4 
day  M  78/90  12, 24  0/20, 0/50, 1/50  (0, 5, 2)  4 
F  103/105  10  1/50, 0/50  (1, 4)  5 
M  103/105  10  3/50, 1/50  (7, 6)  5 
(p = 0.65)  (p = 0.089) 
Rat 
Inhala-
Kidney 
tubular 
F  104/159  1, 3, 6  0/101, 0/89, 0/88, 1/88  (0, 1, 0, 1)  1 
tion 
(ppm) 
cell car­
cinoma 
M  104/159  1, 3, 6  0/87, 0/86, 0/80, 3/85 (*)  1 
F  104/159  1, 3, 6  0/38, 0/39, 0/39, 0/39  (0, 0, 0, 0)  1 
Sprague 
Dawley 
M  104/159  1, 3, 6  0/33, 0/32, 0/36, 1/37  (0, 0, 0, 1)  1 
F  104/107  0.5, 1.5,  0/50, 0/50, 0/47, 1/51  (0, 0, 0, 1)  3 
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Route  Site/ 
Strain 
Experi­
ment (wk) 
doses/ 
100 
Incidences 
Control (first value), 
Malignant 
Incidences 
Benign + 
Malignant 
Numerator 
4.5 
Han: 
WIST 
F  78/156  1, 5  0/28, 0/30, 0/30  (0, 0, 1)  2 
Han: 
WIST 
M  78/156  1, 5  0/29, 0/30,1/30  2 
Gavage 
mg/kg-
ACI  F  103/104  5, 10  0/50, 1/50, 1/50  (0, 3, 1)  6 
day  ACI  M  103/104  5, 10  0/50, 1/50, 0/50  (0, 1, 0)  6 
Aug  F  103/104  5, 10  0/50, 2/50, 0/50  (1, 4, 0)  6 
Aug  M  103/104  5, 10  0/50, 1/50, 0/50  (0, 2, 1)  6 
Fischer 
344 
F  103/103  5, 10  0/50, 0/50, 1/50  (0, 0, 1)  5 
Fischer 
344 
M  103/103  5, 10  0/50, 0/50, 3/50 (*)  (0, 2, 3) (**)  5 
Mar­
shall 
F  103/104  5, 10  0/50, 1/50, 1/50  (1, 2, 1)  6 
Mar­
shall 
M  103/104  5, 10  0/50, 0/50, 1/50  (0, 1, 1)  6 
Osborne 
-Mendel 
F  78/110  5, 10  0/20, 0/50, 0/50  (0, 0, 0)  4 
Osborne 
-Mendel 
M  78/110  5, 10  0/20, 1/50, 0/50  (0, 1, 0)  4 
Osborne 
-Mendel 
F  103/104  5, 10  0/50, 0/50, 0/50  (0, 0, 1)  6 
Osborne 
-Mendel 
M  103/104  5, 10  0/50, 0/50, 1/50  (0, 6, 2)  6 
Sprague 
-Dawley 
F  52/140  0.5, 2.5  0/30, 0/29, 0/26  (0, 0, 0)  1 
Sprague  M  52/140  0.5, 2.5  0/22, 0/24, 0/21  (0, 0, 0)  1 
-Dawley  (p = 0.11)  (p = 0.0065) 
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Route  Site/ 
Strain 
Experi­
ment (wk) 
doses/ 
100 
Incidences 
Control (first value), 
Malignant 
Incidences 
Benign + 
Malignant 
Numerator 
Rat  Testis  M  104/159  1, 3, 6  5/81, 11/73, 24/71, 22/76  1 
Inhala- Tumor  (***) 
tion  Benign 
(ppm)  Sprague  M  104/159  1, 3, 6  1/33, 5/32, 6/36, 9/37 (*)  1 
-Dawley 
Han:  M  78/156  1, 5  4/29, 0/30, 3/30  2 
WIST 
Gavage  ACI  M  103/104  5, 10  36/50, 23/50, 17/50  6 
mg/kg­
day  Aug  M  103/104  5, 10  34/50, 30/50, 26/50  6 
Fischer  M  103/103  5, 10  46/50, 47/50, 32/50  5 
344 
Mar- M  103/104  5, 10  17/50, 21/50, 32/50 (***)  6 
shall 
Osborne  M  78/110  5, 10  0/20, 0/50, 0/50  4 
-Mendel 
Osborne  M  103/104  5, 10  0/50, 0/50, 1/50  6 
-Mendel 
Sprague  M  52/104  0.5, 2.5  0/30, 0/30, 1/30  1 
-Dawley  (p = 0.00002) 
Ham- All  F  78/129  1, 5  2/30, 3/29, 3/30  2 
ster  tumor 
Inhala­
tion 
bearing 
animals 
M  78/129  1, 5  6/30, 2/30, 4/30  2 
(ppm)  Syrian 
Golden 
Hepato­
cellular 
F  78/129  1, 5  1/30, 0/29, 0/30  (1, 1, 0)  2 
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Species 
Route 
Tumor 
Site/ 
Strain 
Sex  Exposure/ 
Experi­
ment (wk) 
Nonzero 
doses/ 
100 
Tumor 
Incidences 
Control (first value), 
Malignant 
Tumor 
Incidences 
Benign + 
Malignant 
Numerator 
Ref. 
carcino 
ma 
Syrian 
Golden 
M  78/129  1, 5  1/30, 0/30, 0/30  (1, 0, 0)  2 
Note: Adapted from Bogen and Gold (1997). In the first three columns are given the species, 
exposure route and exposure units, tumor site and strain of animal used.  In the fourth and fifth 
columns are the exposure periods and study length and the doses divided by 100 (e.g., 100, 300, 
and 600 ppm are listed as 1,3,6).  The sixth and seventh columns give the quantal tumor 
incidences and statistical significance for malignant and benign + malignant tumors respectively. 
The benign + malignant are given as numerators only since the denominators are the same.  The 
final column gives the reference to the study cited.  Doses, Inhalation = ppm in air 7 hr/d, 5d/wk; 
Gavage = mg/kg-day by gavage in oil 5d/wk; Studies, 1= Maltoni et al. (1986), 2 = Henschler et 
al. (1980), 3 = Fukuda et al. (1983), 4 = NCI (1976), 5 = NTP (1990), 6 = NTP (1988); Study 
specific p values test the null hypothesis that the dose-response slope is zero, tests for NCI and 
NTP studies are based on life-table analysis, and for other studies from Gold et al. (1984), 
asterisks indicate level of rejection of the null hypothesis, p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***) unless otherwise specified.  A global analysis of each tumor site using Fisher’s chi-square 
test (Fisher, 1973) was also performed by Bogen and Gold and p values are given in parentheses 
following each site. 
National Cancer Institute, 1976 
The National Cancer Institute (NCI, 1976) study was the first major long-term cancer bioassay of 
TCE and has led to several other investigations.  TCE was administered by gavage 5 d/wk for 78 
wk to B6C3F1 mice and Osborne-Mendel rats of both sexes.  The industrial grade of TCE used 
contained 1,2-epoxybutane (0.19%) ethyl acetate (0.04%), epichlorohydrin (0.09%), N­
methylpyrrole (0.02%), and diisobutylene (6.03%) as stabilizers. 
Following the dosing period, the animals were observed for 12 wk and they were sacrificed in the 
90th (mice) or 110th (rats) wk.  When the study began, the mice and rats were 5 wk and 7 wk of 
age, respectively.  Dose groups consisted of 50 male and 50 female mice and rats.  Twenty 
animals made up each matched control group.  Investigators also reported the tumor incidence in 
groups of colony controls. 
Preliminary acute and subchronic tests were used to determine a maximum tolerated dose (MTD) 
that could be given to the high-dose groups in chronic studies; the low-dose groups received half 
of the MTD.  Male mice received initial daily doses of 2000 mg/kg of body weight in the high-
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of the study resulting in corresponding experimental time-weighted average (TWA) doses of 
2339 and 1169 mg/kg.  Initial doses to female mice were 1400 and 700 mg/kg, and the 
corresponding experimental TWA doses were 1739 and 869 mg/kg.  Dose levels to rats were 
lowered during the study because of poor survival and decreasing body weights.  High-dose 
groups of both sexes initially received 1300 mg/kg, but a lower TWA dose of 1097 mg/kg.  The 
low-dose groups initially received 650 mg/kg, but a lower TWA dose of 549 mg/kg. 
The incidences of hepatocellular carcinoma in female mice were 0/20, 4/50, and 11/50 (p < 0.01) 
for control, mid and high dose respectively.  For male mice the incidences were 1/20, 26/50 (p < 
0.001), and 30/50 (p < 0.001), respectively.  Tests for linear trend on age-adjusted data were 
highly significant for hepatocellular carcinoma in males (p < 0.001) and females (p < 0.002). 
Metastases of the liver cancer to the lung were observed in four low-dose and three high-dose 
males.  The first hepatocellular carcinoma was observed among the high-dose males at 27 wk and 
among the low-dose males at 81 wk. 
In contrast to the positive results in the mouse study, analysis of tumor incidences in rats showed 
no significant difference in specific or total tumors between treated and control groups.  High-
dose male rats exhibited significantly (p = 0.001) decreased survival relative to that of controls. 
The response in rats to carbon tetrachloride, the positive control compound, appeared relatively 
low. 
Questions have been raised about the possible impact of the epichlorohydrin (ECH) impurity in 
the TCE used in the NCI mouse and rat bioassays.  The presence of this contaminant may have 
directly contributed to tumor induction observed in the NCI mice.  ECH is a direct-acting 
alkylating agent and is mutagenic (Kucerova et al., 1977; Bridges, 1978).  Van Duuren et al. 
(1974) demonstrated that ECH was carcinogenic in mice when injected subcutaneously.  A 
subsequent study by Laskin et al. (1980) showed that ECH induced neoplastic nasal cavity 
lesions in rats.  Most of these tumors were carcinomas of the squamous epithelium. 
Interestingly, 30-d exposures to 100 ppmv produced a much greater incidence of cancer than 
lifetime exposures of 30 ppmv (exposures were 6 hr/d, 5 d/wk).  Results from studies by Konishi 
et al. (1980) and Kawabata (1981) also showed that ECH fed discontinuously to rats in drinking 
water at a concentration of 1500 ppm (a lifetime TWA dose of approximately 40.2 mg/kg-day) 
induced a significantly increased incidence of papillomas and squamous cell carcinomas of the 
forestomach above that of control animals. 
The estimated quantity of ECH present in the TCE used in the NCI study is equivalent to lifetime 
TWA doses of 1.3 and 0.97 mg/kg-day for high-dose male and female mice, respectively.  These 
doses are only 3.2% and 2.4%, respectively, of the dose that elicited squamous cell carcinomas in 
rats referred to above.  Furthermore, ECH appears to initiate tumors at sites by a localized 
tumorigenic action where it is in direct contact with tissue, such as nasal or forestomach 
squamous-cell epithelium (U.S. EPA, 1984b).  No animal in the NCI mouse bioassay developed 
tumors at these sites. 
National Toxicology Program, 1983 
In order to clarify the question of contaminant effects in the 1976 NCI mouse study the National 
Toxicology Program (NTP, 1983) initiated a repeat series of carcinogenicity studies in mice and 
rats.  Dosing by gavage began when mice (B6C3Fl) and rats (F344/N) of both sexes were 8 wk of 
age.  The TCE used contained no epichlorohydrin and was stabilized with 8 ppm 
diisopropylamine.  Treated mice and high-dose rats received 1000 mg/kg 5 d/wk.  Low-dose rats 
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received 500 mg/kg 5 d/wk.  The dosing period lasted for 103 wk.  Survivors were killed within 4 
wk after treatment.  The incidences of renal tubular-cell adenocarcinoma in male rats dosed with 
either 500 mg/kg (0/49) or 1000 mg/kg (3/49) were not significant when compared to that of 
controls (3/49).  However, high-dose male rats that survived until the end of the experiment 
exhibited a statistically significant higher incidence (3/16) of renal tubular-cell adenocarcinoma 
than that of the controls (0/33) (p = 0.028) using the "Life Table" or "Incidental Tumor" tests 
referenced in NTP (1983).  These kidney tumors are considered uncommon occurrences in 
F344/N rats.  Only three of 748 (0.4%) male rats from historical vehicle gavage control groups 
have exhibited such tumors.  The incidence of mesotheliomas of the peritoneum among the low 
dose rats (5/50, 10%) significantly (p<0.05) exceeded concurrent (1/50, 2%) and historical 
controls (16/752, 2.1%).  However, toxic nephrosis that significantly reduced equivocal results 
that were considered "inadequate to evaluate the presence or absence of a carcinogenic response" 
of these rats to TCE (NTP, 1983). 
Significantly higher incidences of hepatocellular carcinoma in dosed male mice (13/49, p < 0.05) 
relative to those of their controls (8/48 and 2/48, respectively) confirmed the positive results of 
the 1976 NCI mouse study.  Dosed female mice were also found to have a statistically significant 
(p< 0.05) increase in the incidence of hepatocellular adenomas (8/49) relative to that of controls 
(2/48). 
National Toxicology Program, 1988 
In the 1987 National Toxicology Program study (NTP, 1988), four strains of rat (ACI, August, 
Marshall and Osborne-Mendel) received high (1000 mg/kg) or low (500 mg/kg) daily doses of 
TCE in corn oil by gavage 5 d/wk for 103 wk.  The TCE used contained no epichlorohydrin. 
Test groups consisted of 50 animals of each sex.  Male Osborne-Mendel rats exhibited a 
statistically significant higher incidence of renal cell adenomas (6/50) at the lower dose vs. 
controls (0/50) (p = 0.007).  Male Marshall rats exhibited a statistically significant higher 
incidence of testicular interstitial cell tumors at the higher dose (32/48) vs. the controls (17/46) 
(p = 0.002).  The incidence of these proliferative testicular lesions was also high in control 
groups of ACI rats (36/49), but dosed ACI rats showed a (nonsignificant) decrease in incidence 
(23/49 in the low-dose rats, 17/49 in the high-dose rats).  Therefore, the biological significance 
of the dose-related increase observed in this study is in question (DHS, 1990; Bogen et al., 1988). 
Consistent negative dose-response trends were observed in the incidence of adrenal 
pheochromocytomas in male ACI, female Marshall, and male and female August and Osborne-
Mendel rats in this study.  Results of audits conducted in the Fall of 1983 and the Spring of 1984 
(the in-life portion of the study was completed many years before the final report was issued) 
revealed that the documentation of animal breeding, animal identity, clinical observations, 
environmental conditions, and analytical chemistry data were inadequate to support any 
meaningful interpretation of the reported tumor incidence data (NTP, 1988). 
National Toxicology Program, 1990 (NTP, 1990) 
Carcinogenesis bioassays of epichlorohydrin-free TCE were conducted by corn oil gavage in 
groups of 50 male and 50 female F344/N rats and B6C3F1 mice.  Dose levels were 500 and 
1,000 mg/kg for rats and 1,000 mg/kg for mice.  TCE was administered five times per week for 
103 weeks, and surviving animals were sacrificed between weeks 103 and 107.  Groups of 50 
rats and 50 mice of each sex received corn oil by gavage and served as vehicle controls.  Groups 
of 50 male and 50 female rats were used as untreated controls.  Survival of treated animals was 
less than that of vehicle controls.  Mean body weights of treated animals were also lower than 
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the kidney was seen in 96/98 male and in 97/97 female rats given TCE, and in none of the 
vehicle controls.  Cytomegaly was observed in 45/50 male mice and 48/49 female mice given 
TCE, and in none in the vehicle controls.  Renal tubular cell adenocarcinomas were found in 
three high dose male rats killed at the end of the study (0/33, 0/20, and 3/16, 19%, p < 0.05). 
Renal cell adenocarcinomas are considered uncommon in F344/N rats with a 0.4% historical 
incidence in vehicle gavage controls.  Additional renal tumors in TCE-treated male rats included 
one transitional cell carcinoma of the renal pelvis at the high dose and two tubular cell adenomas 
in low dose and one carcinoma of the renal pelvis in a high dose animal.  No renal neoplasms 
were seen in vehicle control rats.  In female rats, one tubular cell adenocarcinoma was found in 
the high dose group.  The results in male rats were considered equivocal for detecting a 
carcinogenic response because both TCE-treated groups showed significantly reduced survival 
compared to the vehicle control (35/50, 70%; 20/50, 40%; 16/50, 32%) and because 20% of the 
animals in the high dose group were lost due to gavage dosing errors (NTP, 1990). 
TCE administration to mice caused increased incidences of hepatocellular carcinomas in males 
(8/48 vs.31/50, p < 0.001) and in females (2/48 vs. 13/49, p < 0.005).  Hepatocellular carcinomas 
metastasized to the lungs in five dosed male mice and one control male; none was observed in 
female mice.  The incidence of hepatocellular adenomas was increased in male mice (7/48 vs. 
14/50) and in female mice (4/48 vs. 16/49, p < 0.05).  Under the conditions of the studies, TCE 
caused renal tubular cell neoplasms in male F344/N rats, produced toxic nephrosis in both sexes, 
and shortened survival time of males.  The significance of these findings is compromised by 
inadequate survival.  No evidence of carcinogenicity was seen in female F344/N rats.  TCE was 
carcinogenic for B6C3F1 mice causing increased hepatocellular carcinomas in males and females 
and increased hepatocellular adenomas in females. 
Henschler et al., 1980 
Henschler et al. (1980) exposed three species of rodents (Han:NMRI mice, Han:WIST rats, and 
Syrian hamsters) to concentrations of pure TCE at 100 and 500 ppmv for 6 hr/d, 5 d/wk, for 78 
wk.  The ages of the animals when placed on study were not given.  Surviving mice and hamsters 
were sacrificed at the 130th wk.  Rats were not sacrificed until the 156th wk.  Neither rats, 
hamsters nor male mice were observed to have significantly increased tumor incidence.  Dosed 
female mice, however, exhibited significantly (p < 0.05) higher incidences of malignant 
lymphoma relative to that of the controls (100 ppmv, 17/30; 500 ppmv, 18/28; controls, 9/29). 
The time-to-tumor occurrence also decreased in a dose-related fashion.  Henschler et al. (1980) 
cited three studies that describe a high spontaneous incidence of malignant lymphoma in female 
NMRI mice.  The authors also referenced several studies that attribute the development of 
murine lymphoma to immunosuppressive agents that allow lymphoma induction by specific in­
born viruses.  In its review of this study, the U.S. EPA also suggests that immunosuppression by 
TCE or some other nonspecific agent provides a possible interpretation of the positive results of 
this study (U.S. EPA, l985a). 
Fukuda et al., 1983 
In a study by Fukuda et al. (1983), females of two species (Sprague-Dawley rats and ICR mice) 
were exposed to concentrations of 50, 150, and 450 ppmv of reagent grade TCE for 7 h/d, 5 
d/wk, for 104 wk.  The surviving animals were killed in the 107th wk.  Animals of both species 
were 7 wk old when placed on the study.  Size of the test groups varied between 49 and 51. 
Chemical analysis revealed the test sample to contain TCE (99.824%) along with carbon 
tetrachloride (0.128%), benzene (0.019%), epichlorohydrin (0.019%), and l,l,2-trichloroethane 
TRICHLOROETHYLENE in Drinking Water 
California Public Health Goal (PHG)  43  February 1999 (0.010%) in the vapor phase.  The incidence of lung adenocarcinomas among mice in the two 
higher exposure groups (150 ppmv, 8/50; 450 ppmv, 7/46) was significantly (p < 0.05) higher in 
both groups than that in the low dose (3/50) or controls (1/49).  The incidence of total lung 
tumors (adenomas and adenocarcinomas combined) in exposed mice was not significantly 
different (6/50,13/50,11/46) from that of the controls (6/49).  Statistical analysis of the tumor 
incidences among rats showed no significant increases or trends. 
Henschler et al., 1984 
Henschler et al. (1984) tested different samples of TCE with or without epichlorohydrin (ECH) 
and/or 1,2-epoxybutane for carcinogenicity in groups of 50 5-wk-old male or female ICR/Ha-
Swiss mice.  Treated animals received one large dose of TCE with or without epoxides  (males: 
2400 mg/kg; females: 1800 mg/kg) by corn oil gavage 5 d/wk times a week for 18 months. 
Dosing was interrupted during weeks 35 to 40, 65, and 69 to 78.  All doses were reduced to half 
the initial amount after the 40th wk.  We calculated experimental TWA daily doses of 1900 
mg/kg for males and 1400 mg/kg for females by dividing the sum of the product of the number of 
days dosed and the administered dose by the number of days dosed.  After the dosing period (61 
doses in 78 wk), the mice were observed for 26 wk and then sacrificed during the 104th wk. 
Mice dosed with purified, amine-stabilized TCE did not exhibit a statistically significant increase 
in the incidence of any tumor type.  The administration of TCE with ECH (0.6%, equivalent to 
lifetime TWA ECH doses of 8.1 and 6.0 mg/kg-day for males and females, respectively), or both 
ECH (0.25%) and 1,2-epoxybutane (0.25%) was associated with a significant (p<0.05) increase 
in forestomach papillomas or carcinomas in both sexes.  In particular, the incidence of these 
tumors in the control mice in this experiment versus that in the mice exposed to ECH-stabilized 
TCE was 1/50 vs. 8/50 in males and 1/50 vs. 12/50 in females.  The latter response in dosed 
females was the most significant (p = 0.0002, using an age-adjusted chi-squared test) increase in 
tumor incidence observed in the Henschler et al. (1984) study.  The administration of TCE with 
1,2-epoxybutane (0.8%) was associated with a significant (p < 0.05) increase in squamous cell 
carcinomas in males. 
Maltoni et al., 1986 
Maltoni et al. (1986) reported the results of a series of eight TCE carcinogenicity experiments 
performed between 1976 and 1983.  This project employed nearly 4,000 mice and rats that were 
observed until spontaneous death.  Inhalation was the primary route of administration.  The 
statistically and biologically significant results of these bioassays (BT301, 302, 303, 304, 304­
bis, 305, 306, and 306-bis) are summarized below. 
BT301 was the only noninhalation experiment in the project.  TCE was administered by stomach 
tube to Sprague-Dawley rats at dose levels of 50 or 250 mg/kg, 4 to 5 d/wk, for 52 wk.  Dosing 
began when the rats were 13-wk old.  Thirty rats of each sex were in each dosing group.  The 
TCE was epoxide free and contained 50 ppmv or less each of 1,2-dichloroethylene, chloroform, 
carbon tetrachloride and 1,1,2-trichloroethane.  A dose-related higher frequency of leukemia was 
observed in treated males, but this increase was not statistically significant. 
The U.S. EPA (1985a) reviewed this bioassay and remarked that the dosing period of 52 wk was 
below potential lifetime exposures.  They also stated that the older rats (13-wk old) would give 
no indication of the carcinogenic potential of TCE in developing animals. 
Maltoni et al. (1986) conducted two short-term inhalation bioassays with Sprague-Dawley rats 
(BT302) and Swiss mice (BT303).  The animals were exposed to 100 or 600 ppm TCE for 7 hr/d, 
5 d/wk, for 8 wk.  No statistically significant effect was observed.  Treated male mice 
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was not statistically significant at a 95% confidence level. 
BT304 and BT304-bis were both similar long-term inhalation experiments whose results were 
combined and evaluated together.  Sprague-Dawley rats were exposed to either 100, 300, or 600 
ppm TCE for 7 hr/d, 5 d/wk, for 104 wk.  A statistically significant exposure-related increase in 
the incidence of Leydig cell tumors of the testes was observed in treated rats: 31/130 (23.8%) at 
600 ppm (p < 0.01), 30/130 (23.1%) at 300 ppm (p < 0.01), 16/130 (12.3%) at 100 ppm (p < 
0.05), and 6/135 the (4.4%) in the control group. 
In experiment BT305 Swiss mice (90/sex/dose group) were exposed to TCE at a concentration of 
100, 300, or 600 ppm for 7 h/d, 5 d/wk, for 78 wk.  Males exposed to the two higher levels 
showed pulmonary tumors (27/90 at 600 ppm, p < 0.01; 23/90 at 300 ppm, p < 0.05) relative to 
that of the control group (11/90).  The increased incidence of pulmonary tumors included a slight 
increase in adenomas and adenocarcinomas, but the statistical significance of the increase in 
pulmonary tumors was clearly due to an increase in the number of animals with adenomatous 
hyperplasia or early adenomas (i.e., borderline adenomas).  Males exposed to 600 ppm TCE also 
had a higher frequency of hepatomas (13/90, p < 0.05) than that of controls (4/90).  Females did 
not show any significant response to TCE exposure in this bioassay. 
BT306 and BT306-bis were both conducted with B6C3Fl mice (90/sex/dose group) under similar 
conditions.  BT306-bis was added due to early high mortality in BT306 males.  Animals were 
exposed to 100, 300, or 600 ppm TCE for 7 hr/d, 5 d/wk for 78 wk.  The increase in the total 
numbers of malignant tumors in female mice was significant at all three dose levels: 64.4% at 
600 ppm (p < 0.01); 58.9% at 300 ppm (p < 0.01); 57.8% at 100 ppm (p < 0.05); and 46.7% in 
the controls.  A dose-related increase in the incidence of pulmonary tumors was observed in 
females, but was significant (p < 0.01) only at 600 ppm (14/87) relative to that in the control 
group (2/90).  The pulmonary tumors included no adenocarcinomas but consisted primarily of 
adenomas.  When males and females were considered together, a slight increase in the incidence 
of hepatomas was observed in treated animals and was significant (p < 0.01) at 600 ppm (15/180; 
controls: 4/180).  Males in BT306 (poor survival group) showed significant increases in 
hepatoma (1/59 control, 1/31, 3/38, 6/37, p < 0.01).  Males in BT306-bis (normal survival) didn’t 
show significant increases in hepatoma (17/77 control, 19/47, 27/67, 21/63).  Combined males 
from these two groups showed significant differences in hepatoma at all dose levels by Fisher’s 
exact test and a significant Mantel-Haenszel trend test [18/136 control, 20/78 (p = 0.02), 30/105 
(p = 0.0027), 27/100 (p = 0.0066), trend (p = 0.0024)]. 
Maltoni et al. (1986) reported statistically significant increases in pulmonary tumors (benign and 
malignant combined) and hepatomas (malignant) in treated mice and testicular tumors (benign 
and malignant combined) in treated rats.  An increased incidence of renal tubular cell 
adenocarcinoma was also observed in treated rats.  Although the incidence of this neoplasia was 
not statistically significant, Maltoni et al. (1986) considered the appearance of these tumors to be 
biologically significant because of their rarity in control animals (0/460). 
Summary of Evidence of Carcinogenicity in Animals 
The results of the rodent bioassays summarized in Table 5 indicate that TCE induces tumors in 
different tissues in mice and rats, and no tumors in hamsters.  The principal findings are: 1) liver 
carcinomas in male mice by inhalation and in both sexes by gavage administration; 2) lung 
carcinomas in female mice by inhalation; and 3) kidney tubular carcinoma in male rats by 
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inhalation and gavage dosing.  Results in both rats and mice are inconsistent across experiments 
and at each site and some tests are negative.  The strongest evidence for carcinogenicity is in 
B6C3F1 mouse liver with TCE administered by gavage. 
The results of the NCI (1976) bioassay of TCE administered by gavage show that oral exposure 
was associated with a statistically significant (p < 0.01) increased incidence of hepatocellular 
carcinoma in both sexes of B6C3F1 mice.  Factors such as dose-related increases of 
hepatocellular carcinoma in both sexes, a decrease in the time to tumor among males, and the 
occurrence of metastases to the lung in dosed mice support the NCI conclusion that TCE was 
hepatocarcinogenic in that strain of mouse under the conditions of the experiment. 
In the repeat experiment (NTP, 1983), oral administration of epoxide-free TCE was observed to 
be associated with increased incidences of hepatocellular carcinoma in both sexes, and of 
hepatocellular adenomas in females, confirming the results of the mouse bioassay by NCI (1976). 
An increased incidence of malignant lymphoma was observed in TCE-exposed female 
Han:NHRI mice (Henschler et al., 1980).  The EPA (U.S. EPA, 1985a) concluded that the 
biological significance of this observation is unclear because these tumors have a high rate of 
spontaneous occurrence, which may have increased as an indirect result of TCE dosing, possibly 
mediated by immunological sensitivity to the exposure regimen. 
In rats there is evidence of kidney carcinogenicity when TCE is administered by gavage, but not 
by inhalation.  When the multiple tests were analyzed together the incidence of malignant tumors 
of the kidney tubules was not statistically significant (p = 0.11).  Nearly all the significant results 
appeared in bioassays reported by the NTP (1983, 1988) that are considered by the NTP to be 
"inadequate" studies of carcinogenicity.  However, under the conditions of these studies, the 
administration of TCE was deemed by NTP to be "associated" with an increased incidence of 
renal tubular cell adenocarcinoma in the male F344/N rat (NTP, 1983), renal tubular cell 
adenoma in the male Osborne-Mendel rat, and testicular interstitial cell tumor in the male 
Marshall rat (NTP, 1988).  Malignant tumors in mouse lung were significantly increased (p = 
0.001) in only one of 12 experiments.  When analyzed as a group neither malignant or combined 
benign and malignant lung tumors were significantly increased (p > 0.05).  Increases in benign 
tumors of the testis occurred in some rat strains but not in others (Bogen and Gold, 1997). 
"Sufficient" evidence of carcinogenicity in animals is described by the U.S. EPA as evidence 
"which indicates that there is an increased incidence of malignant tumors or combined malignant 
and benign tumors: (a) in multiple species or strains; or (b) in multiple experiments (e.g., with 
different routes of administration or using different dose levels); or (c) to an unusual degree in a 
single experiment with regard to high incidence, unusual site or tumor type, or early age at onset" 
(U.S. EPA, 1986b). 
Based on only the positive results of the NCI (1976) bioassay, IARC (1979) determined that 
there was "limited evidence" that TCE is carcinogenic in animals.  Upon additional review of the 
data of Henschler et al. (1980), IARC's classification of evidence for carcinogenicity of TCE to 
animals remained "limited" (IARC, 1984).  In the latest evaluation IARC concluded that there is 
sufficient evidence in experimental animals for the carcinogenicity of TCE (IARC, 1995).  Based 
on the increased incidences of malignant liver tumors in B6C3Fl mice in two studies (NCI, 1976; 
NTP, 1983), the increased incidence of malignant lymphoma in NMRI mice (Henschler et al., 
1980), and the increased incidence of renal tumors in rats (NTP, 1983), the U.S. EPA (1985a) 
concluded that the above results constitute "sufficient" evidence for carcinogenicity in animals. 
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support for the U.S. EPA classification of "sufficient" evidence of carcinogenicity in animals 
because they showed statistically significant increases in malignant pulmonary tumors and liver 
tumors in treated mice.  The evidence is enhanced by the addition of a tumor type (lung 
adenocarcinomas from Fukuda et al., 1983) distinct from those observed in previous studies. 
Results from both studies further strengthen the classification by introducing the inhalation route 
of exposure, and by using different strains of mice. 
An increase in renal tubular cell adenocarcinomas found in treated Sprague-Dawley rats that was 
not statistically significant (Maltoni et al., 1986) may support the biological significance of the 
similar results observed in the NTP (1983) study.  Significant carcinogenic responses were 
observed in male B6C3Fl  mice exposed to high concentrations of the TCE metabolites, 
trichloroacetic acid (TCA) or dichloroacetic acid (DCA) in drinking water (Herren-Freund et al., 
1987; Pereira, 1996). 
Toxicological Effects in Humans 
Acute Toxicity 
Kleinfeld and Tabershaw (1954) reported the death of an individual following accidental 
ingestion of an unspecified quantity of TCE.  Prior to his death, the individual developed 
jaundice (elevated bilirubin levels); at autopsy, evidence of severe centrilobular necrosis was 
found.  Liver failure following TCE exposure was also implicated in a case reported by Joron et 
al. (1955).  TCE caused hepatitis and jaundice in an individual exposed to 27 to 294 ppmv in air. 
Liver damage progressed to massive liver necrosis, which was ultimately fatal.  Reports of recent 
TCE poisonings have included pharmacokinetic modeling of tissue concentrations (Perbellini et 
al., 1991; Ford et al., 1995).  In the latter study the most recent fatal case analyzed gave model 
predictions of TCE exposure concentrations in the 500-10,000 ppm range.  Blood TCE was 174 
mg/L and brain TCE was 809 mg/kg.  Previous fatalities analyzed showed values of 3-110 mg/L 
and 2-270 mg/kg, respectively. 
Bruning et al. (1998) evaluated clinical symptoms, toxicokinetics, metabolism, and biochemical 
parameters for renal damage in a 17-year old male who ingested about 70 mL of TCE.  The 
patient developed fever, tremor, general motor restlessness, and sinus tachycardia and lost 
consciousness five hr after TCE ingestion.  Medical management included hyperventilation and 
diuresis.  The highest TCE concentration in blood (4 mg/L) was observed 13 hr after TCE 
ingestion.  TCOH, TCA, N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, and N-acetyl-S-(2,2­
dichlorovinyl)-L-cysteine were quantified in urine samples.  Chloroacetic and dichloroacetic 
acids were also found in urine.  Normal levels of protein and glucose were seen in urine but a1­
and b2-microglobulin as well as b-NAG were significantly increased.  These increases are 
indicative of renal tubule damage.  Also seen via SDS-PAGE of urinary proteins were a number 
of low-molecular-mass proteins between 10,000 and 50,000 Da, clearly indicating renal tubular 
damage. 
Baerg and Kimberg (1970) described three cases of intentional intermittent exposure to TCE-
containing products that resulted in drowsiness, headache, vomiting, fever, chills, abdominal 
pain, jaundice, abnormal hepatic function, and hepatic necrosis.  In two of the three cases, 
hepatic damage occurred after inhalation of Carbona, a cleaning fluid (Carbona is composed of 
44% TCE and 56% petroleum distillates). 
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Occupational exposure to TCE from heated degreasing tanks was described by Thiele et al. 
(1982).  A worker reportedly became inebriated after periods of exposure to TCE fumes from the 
tank.  In addition to these intermittent exposures, the individual was inadvertently trapped several 
times in tanks that contained residual TCE.  Upon switching jobs, this worker was exposed to 
l,l,l-trichloroethane and began to suffer from fatigue, weight loss, anorexia, icterus, and 
abdominal swelling.  Results from liver tests were abnormal, and the worker was diagnosed as 
having hepatic cirrhosis.  There was no history of alcohol consumption or hepatitis, and Thiele et 
al. (1982) attributed the cirrhosis to repeated exposure to chlorinated hydrocarbons. 
The U.S. EPA (1985a) and the World Health Organization (1985) have reviewed a number of 
early occupational and medical reports on the hepatotoxicity of TCE.  Exposure to TCE has not 
consistently produced liver damage.  Of 248 patients anesthetized with TCE, none had evidence 
of hepatic injury (Brittain, 1948).  However, lethal hepatic failure has occurred in some instances 
following TCE-induced anesthesia (Ayre, 1945; Dodds, 1945; Elam, 1949; Werch et al., 1955). 
Accidental or occupational exposure to TCE has also caused liver disease, necrosis, and hepatic 
failure.  For example, Cotter (1950) found that accidental exposure to TCE induced 
hyperglobulinemia and hypercalcemia.  Secchi et al. (1968) reviewed seven cases of poisoning 
caused by ingestion of TCE.  Liver damage was documented in three of these individuals.  The 
authors noted, however, that this damage may have been due to the presence of contaminants. 
Phoon et al. (1984) described jaundice, hepatomegaly, and abnormal liver function in five 
individuals occupationally exposed to TCE for 2 to 5 wk (unknown concentration).  One of these 
workers eventually died from liver failure. 
Renal damage following TCE exposure is relatively uncommon.  However, Baerg and Kimberg 
(1970) diagnosed acute tubular necrosis in two individuals with a history of repeated inhalation 
of Carbona.  These authors cited a number of other case reports that also implicated TCE 
exposure in renal damage.  Gutch et al. (1965) documented hyperkalemia and elevated blood 
urea nitrogen levels in an individual occupationally exposed to TCE (‡ 2 hr).  A kidney biopsy 
revealed abnormalities of the glomeruli and tubular degeneration.  An acute occupational 
exposure to TCE (unknown concentration) reportedly caused oliguria and hepatorenal 
insufficiency (Suciu and Olinici, 1983).  Kleinfeld and Tabershaw (1954) reported that one of 
five deaths they attributed to TCE exposure was caused by acute renal failure. 
The use of TCE as a surgical anesthetic has provided a number of case reports that have 
documented its adverse effects on the cardiovascular system.  TCE's cardiotoxicity has been 
reviewed by Norris and Stuart (1957), Defalgue (1961), and by the U.S. EPA (1985a).  In 
addition, the World Health Organization (WHO, 1985) published a comprehensive review of 
foreign-language articles on the cardiovascular effects of TCE in humans.  These effects 
reportedly include cardiac arrest, atrial and ventricular extrasystole, tachycardia, and ventricular 
fibrillation. 
Inhalation or ingestion of TCE has resulted in a number of instances of sudden death, presumably 
due to heart failure.  There are also case reports of nonlethal cardiac arrest due to TCE exposure. 
For the most part, the concentration of TCE and the duration of exposure that caused these 
effects have not been clearly established (Kleinfeld and Tabershaw, 1954; Bernstine, 1954; 
Norris and Stuart, 1957; Dhuner et al., 1957; James, 1963; Defalque, 1961; U.S.EPA, 1985a). 
TCE can cause sensitization of the cardiac muscle to epinephrine.  Concurrent administration of 
TCE and epinephrine has caused arrhythmia and tachycardia (reportedly fatal in some instances) 
(Defalque, 1961; U.S. EPA, 1985a). 
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of patients (Atkinson, 1960; U.S. EPA, 1985a).  However, the primary respiratory problem 
associated with the medical use of TCE has been a pronounced increase in the rate of respiration 
(tachypnea).  Although Atkinson (1960) stated that the magnitude of this effect was dose related, 
the effective concentrations of TCE were not given.  TCE-induced tachypnea has commonly 
been associated with the onset of shallow respiration.  Coleridge et al. (1968) attempted to 
determine the physiologic basis for TCE-induced alterations in respiration.  Earlier work (cited 
by Coleridge et al., 1968) had indicated that an increase in excitability of the pulmonary stretch 
receptors may be responsible for the decrease in depth of respiration during TCE anesthesia. 
This study found that the frequency of discharge of the pulmonary stretch receptors increased 
when cats and dogs were exposed to 1.0 or 3.0% TCE for five minutes.  In concurrent 
experiments, TCE did not produce any change in the impulse frequency of the pulmonary 
endings of vagal nerve fibers. 
Subchronic Toxicity 
McCunney (1988) reports various effects of TCE exposures varying from a few days to 18 
months.  The cases studied represent diverse manifestations of TCE toxicity secondary to acute 
and subchronic exposures.  Encephalopathy characterized by impaired short term memory, a 
sense of inebriation, irritability, and personality changes developed after low dose exposure, 
primarily by dermal absorption.  Urinary TCA levels dropped within one week of removal from 
the worksite, indicating a half-life of 40 hr.  Symptoms persisted even at lower TCA levels 
suggesting other toxic metabolites with longer residence contributed to the symptoms.  Chloral 
hydrate, an intermediary metabolite of TCE, has hypnotic effects.  Air measurements were 
repeatedly within recommended limits (e.g., < 25 ppm).  Hepatitis from exposure to TCE in 
occupational settings is extremely rare.  In a review of 288 cases of industrial poisoning by TCE 
only five showed symptoms of hepatic toxicity.  When TCE was used as an anesthetic, numerous 
cases were reported.  Hepatitis has also been attributed to the inhalation of spot remover that 
contained 45% TCE.  Of ten cases reported, five showed liver function abnormalities, two 
exhibiting proteinuria and a rise in blood urea nitrogen.  A review of cases of TCE-associated 
hepatitis indicates that dose had little effect on development or prognosis.  In nine of twelve 
hepatitis cases there was renal impairment.  Liver biopsies of TCE induced hepatitis usually 
show centrilobular necrosis in both fatal and non-fatal cases. 
Although rare, serious skin diseases secondary to occupational TCE exposures have been 
reported (Nakayama et al., 1988; Yanez Diaz et al., 1992). 
Genetic Toxicity 
The demonstration of TCE-induced genetic toxicity in humans has been largely inconclusive. 
Four studies of SCE tests in peripheral lymphocyte cultures from exposed workers show no or 
only minor effects on SCE frequencies (Seiji et al., 1990; Nagaya et al., 1989; Gu et al., 1981a,b 
cited in Fahrig et al., 1995; Brandom et al., 1990). 
Three studies have been conducted that measured chromosomal effects on humans 
occupationally exposed to TCE.  Peripheral lymphocytes were scored for hypodiploid cells and 
chromosome breaks by Konietzko et al. (1978) and for sister chromatid exchanges (SCE) by Gu 
et al. (1981a,b).  The incidence of hypodiploid cells (cells containing less than the diploid 
number of chromosomes) was found to be higher in the exposed group of 28 workers compared 
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(1978) also found a greater frequency of chromosome breaks in cells from the exposed group. 
Although this increase was not considered biologically significant, no statistical evaluation of the 
data was provided. 
Gu et al. (1981a,b) compared an occupationally exposed group of six workers to a control group 
of nine individuals and reported a statistically significant (p < 0.01) increase in SCE in cultured 
peripheral lymphocytes (9.0 – 0.4 vs. 7.9 – 0.2, respectively).  Exposed workers showed a 
positive correlation between the average number of SCE/cell and levels of trichloroacetic acid 
and trichloroethanol in the blood.  These studies indicate that TCE or a metabolite may cause 
chromosomal aberrations or SCE in chronically exposed humans.  However, exposure to 
additional compounds, including TCE contaminants, cannot be ruled out as possible causative 
agents in these studies. 
Rasmussen et al. (1988) evaluated genotoxicity in 15 metal workers exposed to TCE.  For 
workers exposed to high doses of TCE there was no difference (vs. unexposed) with respect to 
sperm count and morphology, and a small (insignificant) increase of two fluorescent Y-bodies 
(an indicator of two Y chromosomes) in spermatozoa.  In contrast, there was a highly significant 
increase in the frequency of structural aberrations (breaks, gaps, translocations, deletions, 
inversions) and hyperdiploid cells in cultured lymphocytes from TCE degreasers.  Of 1261 
metaphases analyzed, 21.7 % exhibited gaps (vs. 2.8%, p < 0.001), 1.9% breaks (vs. 0.85%, p < 
0.001), sum of translocations, deletions and inversions 1.35% (vs. 0.15%, p < 0.001), and 
hyperdiploid cells 0.79% (vs. 0.24%, p <0.0013).  Chromosomal aberrations in cultured 
circulating lymphocytes are a reliable indicator of mutagenic exposure.  Lymphocytes reflect 
cumulative exposure, having half lives between 12 mo. and 20 yr.  Urinary TCA was also 
measured in the TCE exposed degreasers with a mean value of 3.7 mg/L (range 0.02-26.9).  The 
cumulative exposure for the group averaged 4.6 yr (range 0.8-22.0).  The authors noted the lack 
of an adequate negative control group so these findings are inconclusive. 
Developmental and Reproductive Toxicity 
Tola et al. (1980) conducted an epidemiologic study on the mortality of Finnish workers exposed 
to TCE.  As part of this study, these investigators consulted the Finnish Registry of Congenital 
Malformations.  No malformed babies had been born to women exposed to TCE during the 13 yr 
covered by this study.  Based on the national incidence, three malformed infants would have 
been expected. 
A survey of 80,938 live births and 594 fetal deaths in an area of New Jersey with TCE-
contaminated public drinking water (mean concentration of 55 ppb) found an association 
between TCE concentrations >10 ppb and oral clefts, CNS defects, neural tube defects, and 
major cardiac defects (Bove et al., 1995).  Small numbers of cases and exposure classifications 
are limitations of the study.  A study of subjects exposed to solvent contaminated well water 
including 267 ppb TCE in Massachusetts suggests that the combination of eye and ear anomalies 
and the combination of CNS, chromosomal, and oral cleft in newborns were associated with 
contaminated water exposure (Lagakos et al., 1986).  The groupings for statistical analysis have 
been questioned on the basis of a lack of connection in embryological development.  Additional 
studies of the same population (MDPH, 1994) indicated increased prevalence in choanal atresia, 
a rare respiratory effect, and hypospadias/congenital chordee.  A small increase in eye defects 
was seen but there was no relation between TCE exposure and heart defects.  In an Arizona 
population exposed to TCE (6-239 ppb), dichloroethylene, and chromium in drinking water 
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children whose parents were exposed in the month before conception and the first trimester of 
pregnancy (Goldberg et al., 1990).  The rate of heart defects in the exposed group was about 2.5 
times higher than among children from the unexposed referent group.  A study in Michigan 
communities exposed to chlorinated solvents including up to 14,890 ppb TCE in drinking water 
found no increase in congenital defects (Freni & Bloomer, 1988).  The size of the study 
population was small, however. 
Taskinen et al. (1989) conducted a nested case-control study of 120 cases of spontaneous 
abortion (SAB) and 251 controls in a file of 6000 Finnish workers biologically monitored for 
solvent exposure.  No association was found between parental occupational exposure to TCE and 
SAB (crude odds ratio (OR), 1.0; 95% C.I. 0.6-2.0).  Pregnancies occurring among 3265 women 
biologically monitored for solvent exposure in 1965-83 were identified in a Finnish database 
(Lindbohm et al., 1990).  Only one pregnancy per woman was included, resulting in 120 cases of 
SAB; 336 age-matched controls were randomly selected from women who had normal births 
during the study period.  The OR for SAB, adjusted for previous SABs, parity, smoking, alcohol 
use, and exposure to other solvents, was 0.6 (95% C.I., 0.2-2.3) for exposure to TCE. 
Windham et al. (1991) compared 852 cases of SAB in Santa Clara Co., CA with 1618 controls 
randomly selected from county residents.  All participants were surveyed about occupational use 
of 18 solvents and products used during the first 20 weeks of pregnancy.  An excess risk for SAB 
was observed for women who reported exposure to TCE (crude OR, 3.1; 95% C.I., 0.92-10.4). 
Four of the seven women exposed to TCE also reported PCE exposure. 
Information on 7316 pregnancies was obtained from a hospital discharge register of 9186 women 
identified as working in Finnish laboratories (Taskinen et al., 1994).  The pregnancies resulted in 
5663 births, 687 SABs and 966 induced abortions.  A case referent study was conducted within 
the cohort.  The 206 women with only one SAB and 329 randomly selected normal birth controls 
were included in the study.  The OR for SAB and exposure to TCE was 1.6 (95% C.I., 0.5-4.8) 
adjusted for employment, smoking, alcohol consumption, parity, previous miscarriages, failed 
birth control, and febrile disease during pregnancy.  The OR for exposure to halogenated solvents 
as a group were 0.6 (0.4-1.1) for exposure 1-2 d/wk and 1.8 (0.9-3.7) for 3-5 d/wk. 
Chia et al. (1996) evaluated semen parameters of workers exposed to TCE.  Eighty-five workers 
were analyzed for volume, sperm density, viability, motility, and morphology.  Urine samples 
were analyzed for TCA.  Personal monitoring of 12 subjects showed a mean air concentration of 
29.6 ppm (range 9-131).  The mean urine TCA was 22.4 mg/g creatinine (range 0.8-136.4).  One 
of the sperm parameters to show a significant difference between low (< 25 mg/g urine TCA) 
and high exposure subjects was sperm density at 56.9 million/mL vs. 63.6 million/mL (p = 
0.044).  The authors also report an apparent dose-response relation between TCA in urine and 
hyperzoospermia or sperm densities > 120 million/mL.  The prevalence ratios vs. the low 
exposure group were: 50 to <75, 2.36 (0.92-6.07); 75 to <100, 3.00 (1.00-9.02); ‡100 mg TCA/g 
creatinine, 3.58 (1.09-11.80).  Hyperzoospermia has been implicated in infertility. 
Endocrine Toxicity 
Goh et al. (1998) examined serum levels of insulin and selected adrenal steroid hormones in men 
chronically exposed to low doses of TCE.  Eighty-five workers had urine collected and analyzed 
for TCA (UTCA) and on the same day blood samples were analyzed for serum testosterone, sex 
hormone-binding globulin (SHBG), androstenedione, cortisol, aldosterone, and insulin.  The 
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creatinine (range 0.8-136.4).  No significant alterations in adrenal steroid hormone production 
were noted.  However, UTCA was significantly correlated with serum insulin levels.  Insulin and 
SHBG responded in tandem with the highest levels found in workers exposed for less than two 
years, while levels of both were significantly lower in those exposed for more than 2 years.  A 
triphasic response in insulin levels vs. duration of TCE exposure was observed.  An initial acute 
rise (41 mIU/L) was followed by a fall to normal levels (12 mIU/L) in those exposed 2-4 yr and 
then a more gradual rise in those exposed 4-6 yr (16 mIU/L), and >6 yr (20 mIU/L).  The 
mechanism of this dynamic response is unknown but may be related to TCE-associated increases 
in SHBG.  Although none of the subjects had a history of diabetes, the clinical significance of 
such transient TCE-induced insulin levels is unknown and needs further study. 
Immunotoxicity 
Kilburn &Warshaw (1992) investigated the prevalence of symptoms of systemic lupus 
erythematosus (SLE) and of fluorescent antinuclear antibodies associated with chronic exposure 
to TCE and other chemical contaminants in well water.  Criteria for recognition of SLE were 
applied to 362 subjects exposed to TCE, trichloroethane, inorganic chromium, and other 
chemicals in a contaminated aquifer in Tucson, AZ.  TCE concentrations in the affected wells 
ranged from 6-500 ppb for a period of up to 25 years.  Antinuclear antibodies were measured by 
fluorescence in serum (FANA).  Frequencies of each of 10 criteria symptoms were higher in the 
exposed subjects than in any comparison group (AZ control group, published studies, laboratory 
controls) except those with clinical SLE.  The number of subjects with four or more symptoms 
was 2.3 times higher than referent subjects.  FANA titers >1: 80 were about 2.3 times higher in 
exposed women but equivalent in men and laboratory controls.  The symptom criteria and FANA 
were rank correlated with a coefficient of 0.125, r
2 = 0.0205 (p < 0.059).  In control men and 
women neither correlation was significant.  The study indicates an association between exposure 
to chemical contaminants, particularly TCE, in drinking water and the development of symptoms 
of SLE in a manner similar to drug-induced lupus or scleroderma. 
Neurotoxicity 
TCE is a central nervous system (CNS) depressant and has been used as an anesthetic and 
analgesic.  TCE’s popularity as an anesthetic declined with the accumulation of evidence that 
documented severe (and occasionally fatal) neurotoxic effects (Defalque, 1961; Atkinson, 1960; 
Tomasini and Sartorelli, 1971; Thierstein et al., 1960; Nomura, 1962).  Occupational exposure to 
TCE has resulted in nausea, headache, loss of appetite, weakness, dizziness, ataxia, and tremors 
(Longley and Jones, 1963; Milby, 1968; Mitchell and Parsons-Smith, 1969; Okawa and Bodner, 
1973).  Acute exposure to high concentrations of TCE has caused irreversible nerve damage 
(Mitchell and Parsons-Smith, 1969; Buxton and Hayward, 1967; Barret et al., 1982) and death 
(Kleinfeld and Tabershaw, 1954; James, 1963; Buxton and Hayward, 1967).  Evidence from 
experimental human and animal studies indicates that TCE induces a variety of adverse effects 
on the CNS. 
In a controlled experiment conducted by Salvini et al. (1971), six individuals were exposed to 
110 ppmv of TCE vapor for two 4-hr periods.  Volunteers had a statistically significant (p < 
0.001) reduction in performance on various psychophysiological function tests, such as 
perceptiveness, immediate memory, and complex reaction time.  In an attempt to remove a 
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Similar decrements in test performance were also noted in these individuals. 
Vernon and Ferguson (1969) evaluated the effects of TCE exposure (100 to 1000 ppmv TCE for 
two hr) on the psychophysiologic performance of eight volunteers.  Exposure to 1000 ppmv TCE 
caused a statistically significant (p < 0.05) decrease in performance on the Howard-Dolman, 
steadiness, and pegboard tests.  Stopps and McLaughlin (1967) also reported a decline in 
psychophysiologic test performance following exposure to 500 ppmv TCE for approximately 
three hr. 
Triebig et al. (1982) did not detect any change in motor or sensory nerve-conduction velocity in 
persons occupationally exposed to TCE (400 ppmv, 1 month to 36 yr).  However, other reports 
have documented trigeminal nerve impairment in workers who were chronically exposed to TCE 
(exposure concentration and duration were not provided) (Barret et al., 1982; Mitchell and 
Parsons-Smith, 1969). 
Alcohol intolerance associated with exposure to TCE has been described by Defalque (1961) and 
Muller et al. (1975).  The experimental data of Muller et al. (1975) indicate that simultaneous 
exposure to TCE and ethanol results in a marked inhibition of TCE's metabolism.  This leads to 
an accumulation of TCE in blood, which increases the extent of CNS depression. 
Buxton and Hayward (1967) described an industrial incident involving four men who were 
exposed to TCE (actual concentrations are not known).  Of the four men, two developed severe 
multiple cranial nerve palsies, and one of them died after 51 d.  An autopsy revealed damage to 
the brainstem, cerebral cortex, and spinal cord.  Cavanagh & Buxton (1989) have suggested that 
cranial neuropathy of TCE may result from reactivating a latent herpes virus. 
Rasmussen et al. (1993) conducted a historical cohort study of 99 metal degreasers whose 
occupational exposures were mainly to TCE.  Cumulative exposure to solvents was categorized 
in three groups where the mean full time exposure was: low, 0.5 yr; medium, 2.1 yr; and high, 
11.0 yr.  The dominant exposure for 70 workers was TCE with a mean exposure time of 7.1 yr 
and 35 hr/wk and for 25 workers Freon 113 (CFC 113) 4.2 yr and 15.1 hr/wk.  Present and recent 
TCE exposures were assessed by blood and urine analyses of TCA and TCOH metabolites.  The 
mean urinary TCA in the highly exposed group was 7.1 mg/L with a maximum of 26.1 mg/L. 
Historical data during the 1947-87 period indicate a fairly constant and high exposure level 
corresponding to a urinary TCA of 40-60 mg/L from the mid 1950’s to the mid 1970’s, the 
period relevant to the study population.  A variety of neurological tests was performed to assess 
cranial nerve, olfactory nerve, and facial nerve functions, coordination and vibration threshold. 
The most marked finding was a highly significant dose-response relation between solvent 
exposure and motor dyscoordination.  No significant cranial nerve dysfunction was found. 
Kilburn & Warshaw (1993) studied neurobehavioral impairment in a population of human 
subjects exposed to TCE (6-500 ppb) and other contaminants in their drinking water for 1-25 yr. 
The 170 well-water exposed subjects were compared to 68 referent subjects for 
neurophysiological (NPH) and neuropsychological (NPS) tests.  Also, 113 histology technicians 
were referents for the blink latency test.  Exposed subjects were statistically significantly 
impaired when compared to referents for NPH tests.  The impairments included sway speed with 
eyes open and closed, blink reflex latency, eye closure speed, and two-choice visual reaction 
time.  NPS status was significantly impaired for Culture Fair (intelligence) scores, recall of 
stories, visual recall, digit span, block design, recognition of fingertip numbers, grooved 
pegboard, and Trail making A and B.  Profile of Mood States (POMS) scores were also elevated. 
In a subsequent study 116 subjects exposed to TCE and polychlorinated biphenyls (PCBs) via 
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contaminated well water were compared to 46 reference subjects with uncontaminated water in 
two tests of balance or postural sway (Kilburn et al., 1994).  A head and trunk tracking device 
and a force platform were used simultaneously.  Speed, mean radius, and distance of sway were 
equally reproducible by both methods.  Correlation coefficients were 0.672 with eyes closed and 
0.588 with eyes open.  The balance of the exposed group was significantly worse than that of the 
referent group by both head tracking (1.50 – 0.71 cm/s vs. 1.27 – 0.36 cm/s, p < 0.034) and the 
force platform (4.93 – 1.56 N vs. 4.29 – 1.14 N, p < 0.013) with the eyes closed.  The differences 
were also significant with the eyes open.  Exposure information in this study is sketchy; well 
water analyses for PCBs in the 1980’s claimed values up to 3500 ppm and TCE concentrations 
exceeded the federal MCL of 5 ppb.  Subjects in the exposed group lived in the area with 
contaminated water for at least four years between 1956 and 1981. 
White et al. (1997) also examined residents exposed to TCE in well water for neurobehavioral 
effects.  Three groups of subjects were studied.  The first group in Woburn, MA was exposed to 
water initially showing concentrations of 267 ppb TCE, 21 ppb PCE, 12 ppb chloroform, 29 ppb 
dichloroethylene, and 23 ppb trichlorotrifluoroethane.  The mean TCE concentrations of wells 
during the two-year study were: 256 ppb (range 184-400 ppb) and 111 ppb (range 63-188 ppb). 
A total of 28 subjects were assessed.  Exposure durations were < 1 to 12 yr.  The second group 
from Alpha, OH was exposed to well water with up to 760 ppb TCE and up to 2569 ppb 1,1,1­
trichloroethane.  Three subjects also had PCE (16.5 ppb), cis-1,2-dichloroethane (23.9 ppb), and 
1,1-dichloroethane (21.7 ppb) in their well water.  Twelve subjects were assessed for exposures 
of 5-17 yr duration.  The third group of 14 subjects from Minnesota (MN) were exposed to TCE 
concentrations in well water ranging from 1220 to 2440 ppb for periods of 0.25 to 25 yr.  For the 
MA group peripheral nerve conduction studies generally were normal although subclinical 
peripheral neuropathy was indicated in several patients.  Neuropsychological assessment of the 
MA group showed that the behavioral domain most commonly affected was memory with 89% 
of subjects showing impairments on at least one memory test.  In the OH group evidence of 
peripheral nerve involvement included nerve-conduction abnormalities greater than 2 SD from 
the mean in 3/12 subjects.  Blink reflex in this group was normal.  Neuropsychological 
assessment of this group showed that the most commonly affected domain was 
attention/executive function in 10/12 (83%).  Digit Span, Wisconsin Card Sorting Test, and 
Visual Spans were especially difficult for these patients.  Memory was abnormal in 7/12 (58%). 
In the MN group peripheral neuropathy was diagnosed in 5/14 (36%) subjects.  A family of six 
underwent neuropsychological assessment.  All six showed signs of impaired memory.  All six 
also performed below expectation on tests of attention/executive functions.  The children in the 
family had long term developmental exposure to TCE and academic testing and language were 
carefully assessed.  The mother had normal test results and no evidence of academic disability 
and the father had reading difficulty due to a childhood head injury.  All four children performed 
below average.  Three of the children showed naming deficits on the Boston Naming Test.  All 
six were diagnosed with TCE-induced encephalopathy.  The authors caution that the results 
presented are from a clinical/diagnostic study and not a prospective epidemiological 
investigation.  Nevertheless the results suggest that chronic environmental exposure to solvents 
at ppb concentrations can be associated with significant behavioral deficits as measured by 
neuropsychological tests.  The data also indicate that the younger the individual is at the time of 
exposure, the greater is the range of neuropsychological deficits detected. 
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Information from medium to long term TCE exposures via inhalation and dermal routes is 
presented elsewhere in this report and in ATSDR (1997).  These studies indicate that the nervous 
system is the most sensitive target.  The studies also indicate that the liver and kidneys are targets 
of TCE chronic toxicity.  The liver effects noted include liver enlargement and increases of 
serum levels of liver enzymes.  The kidney effects include increased N-acetyl-b-D­
glucoaminidase.  Other chronic effects include cardiovascular, immunological, and cancer (see 
next section). 
Carcinogenicity 
The evidence of TCE-induced cancers in humans has been reviewed in depth by IARC (1995). 
Three cohort studies were considered to be relevant to TCE evaluation.  Two of these studies in 
Sweden and Finland (Axelson et al., 1994; Anttila et al., 1995) involved people who had been 
monitored for exposure to TCE by measurement of TCA in urine.  The third study in the U.S. 
(Spirtas et al., 1991) covered workers exposed to TCE during maintenance of military aircraft 
and missiles, some of whom were also exposed to other solvents.  A fourth cohort study included 
all workers in an aircraft manufacturing company in the U.S. (Garabrant et al., 1988).  This study 
was considered less relevant, since only one-third of the workers had jobs that exposed them to 
TCE.  In none of the available cohort studies was it possible to control for potential confounding 
factors, such as social class (with regard to cervical cancer) and smoking (with regard to urinary 
bladder cancer). 
The results of the three better cohort studies consistently indicated an excess relative risk for 
cancer of the liver and biliary tract, with a total of 23 observed vs. 12.87 expected.  The results 
for liver cancer only in the Finnish and U.S. studies were 7 observed vs. 4.00 expected.  With 
respect to non-Hodgkin’s lymphoma the results of the three cohort studies were consistent: a 
modest increase in relative risk with 27 cases observed vs. 18.9 expected.  A twofold risk for 
cervical cancer was observed in two cohort studies.  The occurrence of kidney cancer was not 
elevated in the cohort studies.  However a study of German workers exposed to TCE yielded five 
cases of renal cancer vs. none in a comparison group (IARC, 1995).  The incidence of urinary 
bladder cancer was not increased in the two cohort studies from Sweden and Finland.  However, 
slightly increased numbers of deaths were seen in the two U.S. cohorts.  The incidence of bladder 
cancer was not increased in subjects assumed to be exposed to TCE in a case-control study from 
Montreal, Canada (IARC, 1995). 
Morgan et al. (1998) investigated mortality rates in a cohort of 20,508 aerospace workers 
followed up over the period 1950-1993.  Of these, 4733 workers had occupational exposures to 
TCE.  TCE was also present in some washing and drinking water at the work site.  Standardized 
mortality ratios (SMRs) were calculated for the entire cohort and the TCE exposed subcohort. 
SMRs for nonmalignant respiratory diseases were near or less than 1.00 for TCE exposure 
groups.  Elevated SMRs for ovarian cancer were observed for workers with peak TCE exposure 
at medium and high levels, relative risk (RR) = 2.74, 95% C.I. = 0.84-8.99, and among women 
with high cumulative exposure (RR = 7.09, 95% C.I. = 2.15-23.54).  Among those workers with 
peak exposures at medium and high levels, slightly elevated SMRs were seen for kidney cancer 
(RR = 1.89, 95% C.I. = 0.85-4.23); urinary bladder (RR = 1.41, 95% C.I. = 0.52-3.81); 
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high exposure groups gave (RR = 0.31, 95% C.I. = 0.04-2.36) and (RR = 1.59, 95% C.I. = 0.68­
3.71), respectively.  A meta-analysis of four occupational studies including Anttila et al. (1995), 
Axelson et al. (1994), and Spirtas et al. (1991) gave the following meta-SMRs: liver cancer, 1.32; 
prostate cancer, 1.09; kidney cancer, 1.09; bladder cancer, 1.15; and non-Hodgkin’s lymphoma, 
1.25.  However, small numbers of cases (except for prostate cancer), even aggregated across four 
studies, limits the interpretation of these findings.  Other limitations include narrowly defined 
exposure groups, lack of data on potential confounders such as smoking, diet, and exposure to 
other solvents, and no direct measure of personal exposure. 
Blair et al. (1998) reported an extended followup of mortality and cancer incidence of 14,457 
aircraft maintenance workers exposed to TCE and other organic solvents and chemicals. 
Workers exposed to TCE showed non-significant excesses for non-Hodgkin’s lymphoma (RR = 
2.0), and cancers of the esophagus (RR = 5.6), colon (RR = 1.4), primary liver (RR = 1.7), breast 
(RR = 1.8), cervix (RR = 1.8), kidney (RR = 1.6), and bone (RR = 2.1).  None of these cancers 
showed an exposure-response relation.  The authors conclude that the findings do not support a 
causal link with TCE due to lack of significance and dose-response.  The study has a number of 
limitations including lack of information on lifestyle and other non-occupational risk factors for 
various diseases, such as tobacco use and diet. 
Henschler et al. (1995a,b) conducted a retrospective cohort study in a cardboard factory in 
Germany where workers in one part of the plant were exposed to TCE.  The study group 
consisted of 169 men who had been exposed to TCE for at least one year.  The average 
observation period was 34 years.  By the close of the study 50 members of the study group had 
died, 16 from malignant neoplasms.  In 2/16 cases, kidney cancer was the cause of death (SMR = 
3.28, vs. local population).  Five workers were diagnosed with kidney cancer: four with renal cell 
cancer and one with a urothelial cancer of the renal pelvis.  The standardized incidence ratio 
(SIR) was 7.77 (95% CI:2.50-18.59).  After the close of the observation period, two additional 
kidney tumors (one renal and one urothelial) were diagnosed in the study group.  The control 
group consisted of 190 unexposed workers from the same plant.  By the close of the study 52 
members of this group had died, 16 from malignant neoplasms, but none from kidney cancer.  No 
case of kidney cancer was diagnosed in the control group.  For the 7 cases of kidney cancer the 
average exposure duration was 15.2 years (range 3-19.4).  Comparisons with cancer registries in 
Denmark and the former German Democratic Republic gave SIR values of 11.15 (95% CI: 4.49­
23.00) and 13.53 (95% CI: 5.44-27.89) respectively.  The statistical significance (internal study 
comparison) was p < 0.005 (Mantel-Haenszel test) and p < 0.006 (Binomial test).  No exposure 
data were obtained but the authors summarized: “all workers enrolled in the study were 
repeatedly, in part continuously, exposed over long periods of time both via the lungs and 
through the skin to moderate to very high TCE concentrations, and extremely high exposure 
episodes occurred at regular weekly to biweekly intervals, when the major cleaning operations 
were conducted.”  The occupational threshold limit values of 100 ppm (U.S.) and 50 ppm 
(German) were probably exceeded during episodic exposures.  “The workers often left the work 
area ‘to get fresh air and to recover from drowsiness and headaches’” (Henschler et al., 1995a). 
This is the only study of kidney cancer in humans that claims a causal link with TCE exposure. 
A recent case-control study by Bruning et al. (1997b) investigated the role of glutathione-S­
transferase (GST) polymorphisms on the incidence of renal cell cancer in two occupational 
groups exposed to high levels of TCE.  Forty-five cases with histologically verified renal cell 
cancer and TCE exposure were studied.  The reference group was 48 workers from the same 
region with similar occupational exposures to TCE but free of any cancer.  GSTM1 and GSTT1 
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the 45 cancer patients, 27 carried at least one functional GSTM1 gene (GSTM1+) and 18 at least 
one functional GSTT1 gene (GSTT1+).  Among the 48 reference workers, 17 were GSTM1+ and 
31 were GSTT1+.  Odds ratios for renal cell cancer were 2.7 for GSTM1+ individuals (95% CI, 
1.18-6.33; p < 0.02) and 4.2 for GSTT1+ individuals (95% CI, 1.16-14.91, p < 0.05), 
respectively.  The data indicate a higher risk for development of renal cell cancer if TCE-exposed 
persons carry either the GSTT1 or GSTM1 gene.  The GSTM1 isozyme is thought to detoxify 
epoxides of aromatic (polycyclic) hydrocarbons while the GSTT1 is primarily involved in the 
metabolism of some aliphatic epoxides and halogenated hydrocarbons (Their et al., 1996).  The 
nephrocarcinogenicity of TCE has been attributed to metabolites derived from the glutathione 
dependent pathway (Henschler et al., 1995a).  These results tend to support this view of the mode 
of action of TCE-induced kidney cancer at least in humans. 
Cancer occurrence in populations exposed to drinking water contaminated with various 
concentrations of TCE has been compared in several studies.  The interpretation of these studies 
is complicated by methodological problems.  Lagakos et al. (1986) studied childhood leukemia in 
a community in Massachusetts where water from two wells was contaminated with TCE.  In 
1979 the well showed a TCE concentration of 267 ppb.  Twenty cases of childhood leukemia 
were diagnosed in 1964-83 and were associated with exposure to water in the two contaminated 
wells vs. the community at random (observed 21.1 vs. expected 10.6, p = 0.03).  A study in New 
Jersey during 1979-87 included 75 towns (Cohn et al., 1994).  TCE concentrations were 
measured during 1984-85, and an average level assigned to each town, the highest being 67 ppb. 
The water supply of six towns contained > 5 ppb TCE (average, 23.4 ppb).  Women in these 
towns had significantly higher total incidence of leukemia than inhabitants of towns with average 
TCE concentrations in drinking water < 0.1 ppb (relative risk, 1.4; 95% CI, 1.1-1.9); no effect 
was seen in men (1.1, 0.84-1.4).  The risk among women was particularly elevated for acute 
lymphocytic leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia.  The 
risk for acute lymphocytic leukemia in children was also significantly increased in females but 
not in males.  Increased risks for non-Hodgkin’s lymphoma were also seen in the towns with the 
highest TCE contamination (1.2, 0.94-1.5 for males; 1.4, 1.1-1.7 for females).  Other human 
studies are also reviewed by IARC (1995). 
Overall the most important human observations are the elevated risk for liver and biliary tract 
cancer, the moderately elevated risk for non-Hodgkin’s lymphoma, the suggested marginally 
increased risk for non-Hodgkin’s lymphoma in areas with TCE-contaminated drinking water 
(IARC, 1995), and finally the recent occupational findings of renal cell carcinomas in cardboard 
workers exposed to TCE (Henschler et al., 1995a,b).  The IARC (1995) concluded  that “there is 
limited evidence in humans for the carcinogenicity of trichloroethylene.”  A strikingly different 
assessment of these studies was provided by McLaughlin and Blot (1997) who concluded: 
“although exposure to TCE and PCE can induce cancers in some species of rodents, it is not 
clear that these solvents pose a risk for renal-cell cancer in humans.”  Their critique of the 
Henschler et al. (1995a) study included the following points: (a) they claim that some cases (3) 
were identified prior to the initiation of the study and should be excluded, reducing the 
observations to non-significance; (b) that the occurrence of the much rarer urothelial cancer cases 
indicates a different mode of action than assumed for renal cell cancer and either undercuts a 
chief conclusion of the study or reveals a confounding exposure to another agent or non­
occupational factors; and (c) a possible discrepancy in the reported incidence and mortality rates 
for kidney cancer.  Notwithstanding these criticisms as to whether the Henschler et al. (1995a) 
study is a true cohort or a cluster analysis, it is impossible to ignore these findings (see authors’ 
response to published critiques, Henschler et al., 1995b).  Assumptions about the mode(s) of 
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and cannot be used to exclude potentially relevant public health findings relating to TCE 
exposures even when the latter are somewhat poorly defined. 
DOSE-RESPONSE ASSESSMENT 
The risk assessment of TCE with respect to induced tumors has witnessed enormous change in 
the last decade.  A summary of some risk assessments reviewed for this document (Table 6) 
reveals differences in virtually safe concentrations of TCE in drinking water of over eight (8) 
orders of magnitude.  According to the U.S. EPA’s proposed 1996 Guidelines for Carcinogen 
Risk Assessment (U.S. EPA, 1996), the preferred approach for dose response assessment is one 
based on a relevant biologically based model or a case-specific model for tumor responses in 
both the observed range and in the extrapolated range.  The default procedure, in the absence of 
specific models, is to fit the data in the observed range with a curve-fitting model.  The choice 
between a nonlinear extrapolation, a linear extrapolation, or a combination of linear and 
nonlinear is based on the view of the mode of action (MOA) as, for example, when the MOA 
clearly indicates linearity through direct alterations in DNA.  A linear default approach is 
recommended when MOA information is insufficient to support a nonlinear approach.  From the 
curve-fitting model the point of departure for low dose extrapolation is the 95% lower bound on 
the dose yielding a 10% tumor incidence, the so-called LED10.  A nonlinear approach is used 
when adequate data on the MOA show that linearity is not the most reasonable judgment and 
there is sufficient evidence to support a nonlinear MOA, e.g., a clearly nonlinear overall dose 
response or a sharp reduction in tumor incidence with decreasing dose.  In this case the default 
approach would employ either a margin of exposure (MOE) analysis using an LED10 from tumor 
data or related biological response data as the point of departure, or if a specific numerical value 
is required the LED10 could be used as a benchmark dose or LOAEL.  Evidence of a receptor 
mediated MOA per se may not be sufficient to justify a nonlinear MOE approach.  Factors to be 
considered in determining the margin of exposure for the analysis include: the dose response 
slope at the LED10; the severity of the effect chosen; extent of human variability; the persistence 
in the body following exposure; interspecies differences in sensitivity, and distinguishing 
pharmacodynamic differences from pharmacokinetic factors which may already be included in a 
human equivalent LED.  Where a MOE approach is adopted it is still useful to show the 
comparable value if the linear approach had been used. 
An important task for the TCE risk assessor is to evaluate the evidence supporting claims of a 
nonlinear MOA.  This is particularly critical in view of the differences in magnitude of assessed 
risks by nonlinear and linear approaches and the fact that the consequences of underestimation 
versus overestimation of risk are not equal. 
Mode of Action 
Noncarcinogenic Effects 
The acute toxicity of TCE in rodents and humans is low.  After repeated high doses of TCE to 
rodents, damage is seen in liver and kidney (mice and rats) and in lung (mice only).  TCE is a 
more potent peroxisome proliferator in livers of mice than of rats.  Repeated exposure of humans 
to TCE in the workplace appears to have some toxic effects on kidney or liver (see discussion 
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above).  Available data show no consistent effect of TCE on the human reproductive system. 
TCE is metabolized to TCA in the placenta or fetus of many species but there is little evidence of 
toxic effects in developing rats or mice (IARC, 1995). 
Carcinogenic Effects 
Orally administered TCE induces benign and malignant liver tumors in mice but not in rats.  In 
two oral studies, the incidence of uncommonly occurring renal-cell tumors was significantly 
increased in male rats.  In one study an increased incidence of testicular interstitial-cell tumors 
was seen.  Of four inhalation studies in mice, one showed increased incidence of lymphomas, 
one showed increased incidence of liver tumors, and three showed increased incidences of lung 
tumors.  One of three TCE inhalation studies in the rat showed an increased incidence of 
testicular tumors and a marginal increase of renal-cell tumors in males (IARC, 1995).  No 
increased tumor incidences were found in hamsters with TCE inhalation exposures.  No skin 
tumors or local sarcomas were observed after topical or s.c. injection of TCE or trichloroethylene 
oxide in mice (IARC,1995). 
TCE is rapidly absorbed by oral and respiratory routes in rodents.  The metabolic fate of TCE is 
largely via cytochrome P450 oxidation leading to the formation of chloroacetic acids.  Mice 
show consistently more oxidative biotransformation than rats.  A minor pathway in rodents and 
humans involves the production of mercapturic acids.  [1,2-
14C]TCE or metabolites were found 
to bind to mouse liver protein and DNA in a linear dose-dependent manner in vivo (Kautiainen et 
al., 1997).  Most genetic toxicity studies of TCE are negative or inconclusive.  Pure TCE 
apparently does cause an induction of micronuclei and DNA single-strand breaks/alkaline labile 
sites.  In mammalian cells in vitro pure TCE induced cell transformation, sister chromatid 
exchange and gene mutation, but not chromosomal aberrations.  In one study with human cells in 
vitro impure TCE slightly increased SCE frequencies and unscheduled DNA synthesis. In fungi 
TCE induced aneuploidy, gene mutation and mitotic recombination and induced gene conversion 
with exogenous metabolic activation.  Humans exposed to TCE occupationally or in drinking 
water may have elevated risk for cancer of the liver and biliary tract, for renal tumors, and for 
non-Hodgkin’s lymphoma (IARC, 1995; Henschler et al., 1995a). 
The following elements need to be considered in the development of the MOA of TCE: 
•	  While TCE does not have a typical genotoxic profile for a mutagenic or direct-acting 
carcinogen, it (or its metabolites) does have some genotoxic ability to damage chromosomes, 
e.g., as indicated by micronuclei tests.  Thus a genotoxic MOA, albeit atypical, cannot be 
ruled out on the basis of current data; 
•	  While the evidence of TCE induced cancer in humans is limited, the possible target sites 
reflect some of the findings in animal bioassays, i.e., liver tumors, renal tumors, and 
lymphoma; 
•	  The demonstration of dose dependent mouse liver DNA and protein adducts with doses as 
low as 2.0 mg/kg equivalent to ~ 4 adducts/10
11 base pairs; 
•	  Rodent species and strain susceptibility to TCE induced tumors seems to be related to the 
degree of metabolic transformation of TCE; 
•	  The principal products of TCE metabolism, the chloroacetic acids, are cytotoxic and 
carcinogenic.  In particular TCA may play a key role in the tumorigenicity of TCE; 
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•	  Other minor products such as chloral hydrate, DCVC and other TCE conjugates may also 
play a role in cytotoxicity and tumorigenicity of TCE; 
•	  Since TCE induces tumors at more than one site, there may well be more than one MOA 
operating; 
•	  While TCE-induced tumors in rodents were observed in studies with necessarily high doses, 
in some cases showing toxicity, it remains to be established that the tumors at all sites were a 
direct result of the cell/tissue toxicity and not the result of parallel exposure to one or more 
genotoxic metabolites; 
•	  Evidence of carcinogenicity from human epidemiological studies, while limited, would have 
resulted from exposures with little on no overt toxicity; 
•	  The only human cancer with a claimed causal link to TCE exposure, kidney cancer in male 
cardboard workers, was also observed in male rats exposed to TCE. 
•	  The role of glutathione-S-transferase polymorphisms may be important in assessing 
variability in human renal cell cancer risk from TCE exposures; 
•	  The shape of the dose-response curves for cytotoxic effects may figure in the carcinogenic 
process, i.e., hepatic cytomegaly, nephropathy etc. 
Liver 
Bogen & Gold (1997) have summarized the key findings supporting a cytotoxic MOA and non­
linear dose response for TCE-induced liver tumors in mice.  They noted that: 
•	  TCE-induced cytotoxicity occurs primarily in the liver, the main site of TCE metabolism; 
•	  Liver toxicity positively correlates with the total amount of TCE metabolized; 
•	  Liver and kidney weights were increased and liver-related serum enzymes (SGPT) were 
elevated as indicators of toxicity; 
•	  Toxic effects were noted at doses lower than those given in the cancer bioassays; 
•	  The main TCE metabolites (chloral hydrate, TCA, DCA) all induce liver cancer in mice 
when given in buffered drinking water; 
•	  TCE is hepatocarcinogenic in mice but not rats correlating with species differences in the 
rate of TCE metabolism; mouse strain differences in carcinogenic susceptibility also 
correlate with metabolism; 
•	  TCA or DCA administered in water caused lipoperoxidative-stress-induced cell killing in 
liver (similar to that of CCl4) at doses of 300 mg/kg and higher; 
•	  Substantial peroxisome proliferation is observed in mice, but the effect is weaker in rats; 
•	  Acute and subchronic TCE administration in corn oil gavage significantly increases S-phase-
DNA synthesis and proliferation in mouse hepatocytes; 
•	  In mice exposed to either TCA or DCA in drinking water, hepatocellular DNA-labeling 
index was significantly elevated after 5 days, but not 12 or 33 d of exposure; 
•	  DCA or TCA induced hepatocellular carcinomas in B6C3F1 mice have a ras oncogene 
mutation frequency approximating those seen in spontaneous tumors, indicating tumor 
promotion rather than initiation. 
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Kidney 
For kidney cancer Bogen & Gold (1997) give the following supporting evidence for a cytotoxic 
mode of action: 
•	  Most rats chronically exposed to TCE in the NCI and NTP bioassays developed toxic 
nephrosis and greater than 90% of rats (and mice) developed cytomegaly, which was most 
evident in male rats; 
•	  Kidney tumors were increased only in male rats and this presumably correlates with greater 
cytomegaly in males; 
•	  The dichlorovinylcysteine TCE conjugates (1,2-DCVC and 2,2-DCVC) and the 
corresponding mercapturic acids (1,2-DCV-Nac and 2,2-DCV-Nac) are all rodent (and 
possible human) nephrotoxicants that can produce proximal tubular necrosis and other 
lesions in rat kidney after conversion to reactive mutagenic intermediates by cytosolic 
cysteine conjugate b-lyase (Goeptar, 1995); 
•	  1,2-DCVC induces c-fos and c-myc proto-oncogene expression in cultured rat kidney cells 
which indicates direct mitogenic action for this TCE metabolite similar to the tumor 
promoter 12-O-tetradecanoylphorbolacetate; 
•	  TCE-conjugation metabolites like DCV-Nac occur as minor metabolites in rodents and in 
human workers exposed to TCE; 
•	  TCE conjugation with cysteine and GSH become significant upon saturation of the main 
oxidative cytochrome P450 metabolic pathway in rats, but not in mice highly exposed to 
TCE. 
Lung 
As noted above lung tumors were induced in female mice by inhalation exposure to TCE.  Odum 
et al. (1992) studied inhalation toxicity of TCE in female mice.  A specific lesion, characterized 
by vacuolization of Clara cells, was only seen in mice.  Mice exposed to 100 ppm chloral had a 
similar lesion.  Only mild effects were seen with inhaled TCOH and none with intraperitoneally 
administered TCA (500 mg/kg).  These results suggest that acute lung toxicity of TCE may be 
due to accumulation of chloral in Clara cells, the result of low glucuronidation capacity and low 
metabolism to TCOH.  Since chloral is also genotoxic, the toxicity observed with intermittent 
exposures is likely to exacerbate any genotoxic effect through compensatory cell proliferation. 
Green et al. (1997) studied the activity of TCE metabolizing enzymes in mouse, rat and human 
lung.  Metabolism of TCE to chloral was significant in the mouse lung, 23-fold lower in rat lung, 
and non-detectable in human lung microsomes.  Immunolocalization of cytochrome P450 2E1 in 
lung sections showed high concentrations in mouse lung Clara cells with lesser amounts in type 
II cells.  Low levels of enzyme were detected in rat lung, but not in human lung sections. 
Dose-response approach 
The three tumor types mentioned above have complex modes of action with contributions from: 
(1) non-genotoxic processes related to cytotoxicity; (2) possibly receptor-mediated mitogenic 
stimulation; (3) genotoxic metabolites such as chloral, DCVC and related metabolites, and; (4) 
possibly reactive oxygen species related to peroxisomal induction in the liver.  While the role of 
cytotoxicity seems to play an important role in TCE induced cancer in rodents, particularly liver 
cancer, it is uncertain what role it plays in human cancers induced by TCE at exposure levels 
below those expected to cause frank toxicity.  The demonstration of linear dose-dependent DNA 
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14C]TCE in mice, in vivo, would tend to support a 
genotoxic MOA, at least in mice.  The potential role of several mutagenic and/or carcinogenic 
metabolites of TCE cannot be ignored, particularly in renal cell carcinoma, with additional 
supporting evidence of human GST isozyme dependence and DNA adducts formed from 
genotoxic DCVC metabolites.  Bruning et al. (1997a) have found evidence supporting the role of 
VHL tumor suppressor gene mutations in TCE-induced renal cell cancer in humans. 
For liver cancer the preferred approach is to apply both linear and non-linear methods.  For the 
rodent data the dose metric of AUC TCA + AUC DCA based on current rodent PBPK modeling 
is probably a reasonable approach, although a metric based on the metabolism of TCE (AMET) 
should also be evaluated to account for a possible epoxide mediated dose response.  The LED10 
point of departure would be used: a) to calculate a potency or Carcinogen Slope Factor (CSF) for 
low dose extrapolation (linear method); and b) as a LOAEL with appropriate uncertainty factors 
to calculate a virtually safe dose or water concentration of TCE (non-linear method). 
For kidney cancer the linear approach would appear to be the most appropriate notwithstanding 
the arguments in favor of a wholly cytotoxic MOA, or arguments based on the potential role of 
a-2m-globulin a male rat specific factor (Goldsworthy et al., 1988).  As noted above there is 
enough evidence indicating the importance of TCE glutathione conjugates in human TCE-
induced renal cancer to justify this approach.  A preferred dose metric would be based on 
prolonged exposure to DCVC and possibly other TCE-conjugates, i.e., AUC DCVC or total TCE 
metabolized via the GST pathway (e.g., TCOG and related metabolites in urine). 
For lung cancer the relative importance of cytotoxicity and genotoxicity in rodents is uncertain as 
is the implication for human cancer since TCE-induced lung cancer has not yet been observed in 
humans.  In this case as in liver both linear and non-linear approaches based on chloral hydrate 
dose metrics seem appropriate.  There is considerable uncertainty about the comparability of 
TCE pharmacodynamics in humans vs. rodents. 
The best approach, not mentioned above, would be to use the available human data to develop a 
safe water concentration for TCE.  Unfortunately the current epidemiological database, with very 
limited exposure and dose response information, allows only rough, at best semi-quantitative, 
estimates.  Human risk estimates should include the possibility of subpopulations at greater risk 
due to GST polymorphisms. 
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 Lifetime Concentrations in Air and/or Drinking Water.
1 
Study  Dose Metric Used  Nonlinear/MOE 
Approach 
Linear/LMS Approach 
Page et al., 1997; 
Clewell et al., 
1995 
PBPK metrics incl. 
mg DCVC/ kg 
kidney/d 
MOE = 1000 
Lung: 9-6000 ppb 
air; 900-600,000 
ppb in water 
Liver: 12.5-88 ppb 
air; 56-390 ppb in 
water 
Kidney: 36-15,000 
ppb air; 540-225,00 
in water 
Lung: 0.06-41 ppb air; 
6-4000 ppb in water 
Liver: 0.05-0.35 ppb in 
air; 0.8-5.6 ppb in 
water 
Kidney: 0.64-300 ppb 
in air; 9.6-4500 ppb in 
water 
Bogen & Gold, 
1997 
Cronin et al.,1995 
PBPK peak 
concentration 
metrics: 
Liver, 
Max(CTCA) ppm; 
Kidney, Max(B)/Km 
PBPK/Monte Carlo: 
Liver AMET mg/kg­
day, AUCTCA mg­
hr/L/day 
16 ppb in air 
continuous; 700 
ppb in air brief; 
210 ppm in water at 
2 L/day intake 
AMET: 
Intermittent inhalation 
exposure: 25-120 ppb 
in air 
Continuous inhalation 
exposure: 5-26 ppb in 
air 
Drinking water: 5-69 
ppb in water 
AUCTCA: 
Intermittent inhalation 
exposure: 0.07-13.3 
ppb in air 
Continuous inhalation 
exposure: 0.01-6.3 ppb 
in air 
Drinking water: 0.09­
5.3 ppb 
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Approach 
Linear/LMS Approach 
Fisher & 
Allen,1993 
Brown et al.,1990 
DHS,1990 
PBPK metrics: 
AMET, AUCTCA 
See Bogen et al. 
below 
227 mg/d 
MOE=10,000 
AMET:15-69 ppb in 
air; 7-39 ppb water 
AUCTCA: 0.1-0.2 ppb 
in air; 4 ppt in water 
0.1-1.7 ppb in water 
0.022-0.22 ppb in air 
TCA oral 
DCA oral 
Liver: 9.0 ppb in water 
Liver: 0.25 ppb 
in water 
Fan, 1988 
Bogen et al., 
1988 
PBPK adjusted 
metabolized doses, 
7.0 Leq/d water 
intake for multiroute 
exposure, range of 6 
studies analyzed. 
TCA oral 
DCA oral 
5 ppb in water 
Liver: 0.28-1.0 ppb in 
water 
Kidney: 2.5 ppb in 
water 
Lymph: 0.1 ppb in 
water 
Lung: 0.53 ppb in 
water 
Liver: 0.56 ppb in 
water 
Liver: 0.15 ppb in 
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Approach 
Linear/LMS Approach 
U.S. EPA, 1986  water 
0.33 ppb in water 
U.S. EPA, 1985  Values adjusted for 
partial lifetime, 2 L/d 
water intake 
1.8-6.0 ppb in water 
1 Notes: Page et al. ranges are for best and worst case estimates; MOE is margin of exposure; 
AMET is TCE metabolized dose metric; AUC is the area under the blood concentration x time 
curve or tissue concentration x time curve; Max(CTCA) is the peak concentration of TCA in blood 
plasma; Max(B)/Km peak concentration metric which, when >>1, indicates saturation of 
oxidative TCE metabolism.  This metric is a measure of effective kidney cytotoxic dose. 
PBPK/Monte Carlo, a probabilistic simulation of model parameters, was incorporated into a risk 
assessment using a PBPK model; the values in the table above are ranges from the analysis of 
male and female mice; LMS is the linearized multistage model of low dose extrapolation of 
cancer risk. 
Noncarcinogenic Effects 
The results of a number of studies discussed in this section are summarized in Table 7. 
Animal Studies 
Clewell et al. (1997) have incorporated PBPK modeling into a noncancer risk assessment of TCE 
employing benchmark doses (BD) based on animal data sets.  For intermediate term inhalation 
exposure Clewell et al. (1997) used the data of Arito et al. (1994) on CNS effects (decreased 
wakefulness, reduced heart rate) in rats.  The animals were exposed to 0, 50, 100, and 300 ppm; 
8 hr/d, 5 d/wk, for 6 wk.  The continuous data were fitted with a polynomial model and the 
Weibull (power) model.  The dose metrics chosen were peak concentration or the AUC of TCE 
in the blood.  The lowest benchmark dose based on a 10% response (BD10) was 56 ppm, which 
exceeded the LOAEL of 50 ppm determined by pairwise significance testing.  This was due to 
poor fitting of the model to the data.  Excluding the highest dose, an improved BD10 of 31 ppm 
for decreased wakefulness was obtained.  The continuous equivalent of this value is 7 ppm (31 
ppm x 8/24 hr x 5/7 d).  The authors considered the 7 ppm a NOAEL and applied a UF of 30 to 
obtain a minimum risk level as defined by the ATSDR (MRL) of 0.25 ppm. 
For an intermediate term oral BD the teratogenicity data of Dawson et al. (1993) were used.  Rats 
were given 0, 1.5 or 1100 ppm in drinking water.  The observed critical toxic endpoint was 
cardiac abnormalities.  Female rats were exposed either before and during pregnancy (80-90d), 
during pregnancy only (18-20d), or before pregnancy only (80-100d).  A study LOAEL of 0.18 
mg/kg-day was identified for the 1.5 ppm group exposed before and during pregnancy.  There 
was no apparent dose response relationship.  Also the reporting of this study is unclear.  For 
example, the number of animals per test group was not specified (116/9 groups assumed) and the 
number of fetuses per maternal rat are much higher (5.4 vs. 17.6) than in a previous study using 
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impossible to test for litter effects.  The quantal responses for the heart abnormalities were: 
control, 7/238, 2.9%; 1.5 ppm TCE, 21/257, 8.2%; 1100 ppm TCE 40/436, 9.2%. 
Notwithstanding the difficulties presented by these study data, Clewell attempted to analyze the 
quantal data.  The dose metrics employed were the AUC of TCE and TCA in blood.  The models 
used in fitting the data were the polynomial and the Weibull.  Modeling of the administered dose 
yielded the lowest BD10 of 65 mg/kg-day, well above the LOAEL, again due to poor fit by the 
models.  Removing the top dose gave an improved BD10 of 0.24 mg/kg-day.  The use of the 
PBPK dose metrics did not linearize the data and probably represents saturation of response 
rather than nonlinear pharmacokinetics.  Without the high dose the BD10 values of 0.0027 mg 
hr/L (AUC TCE) and 2.26 mg hr/L (AUC TCA) were obtained.  With a PBPK model for 
continuous human exposure the target dose metrics are produced by doses of 0.018 mg/kg-day 
TCE and 0.009 mg/kg-day TCA.  The authors employed an uncertainty factor of 3 to account for 
human variability to give an MRL range of 0.003-0.006 mg/kg-day for TCE.  They assumed that 
the human PBPK model would account for interspecies differences.  It might be argued that the 
uncertainties inherent in the problem data set should also rate an uncertainty factor.  Also in view 
of the severity of effect (teratogenicity), the human BD10 value of 0.009 mg/kg-day probably 
represents a LOAEL, not a NOAEL.  The authors caution against quantitative use of these data 
due to shortcomings in reporting of the original study data.  The study and analysis are included 
here for the sake of completeness and because there are relatively few studies of this type in the 
literature. 
Haag-Gronlund et al. (1995) applied the benchmark dose method to a risk assessment of TCE. 
They used polynomial models for both quantal and continuous data sets.  Toxicity data on liver, 
kidney and CNS effects, and tumor data were selected for evaluation.  Benchmark doses were 
estimated at the 1%, 5%, and 10% response levels.  For kidney effects in the NTP (1988) rat 
study, BD10 values for cytomegaly ranged from 11-24 mg/kg-day for different sexes and strains 
of rat.  The BD10s for nephropathy ranged from 50-210 mg/kg-day.  These values are lower than 
the study LOEL of 500 mg/kg-day.  The lowest BD10 values for liver, kidney, and CNS effects in 
inhalation experiments (Henschler et al., 1980; Fukuda et al., 1983; Maltoni et al., 1988) were 
23, 122, and 10 ppm respectively.  Overall, all NOELs were higher than the BD01, and 42% of 
the NOELs and 93% of the LOELs were higher than the BD10.  The authors noted that the 
polynomial regression models often failed to fit the experimental data at the desired level of 
significance in the C
2 “goodness of fit” test (p > 0.05). 
Barton & Das (1996) conducted a similar assessment for chronic noncancer effects from oral 
exposures to TCE.  Four dose response models for quantal data and one for continuous data were 
employed.  The analysis considered liver effects, kidney toxicity, and developmental effects.  For 
liver endpoints the BD05 values ranged from 82-289 mg/kg-day.  The lowest value was based on 
liver weight/body weight ratio changes (LW/BW) in B6C3F1 mice (Elcombe et al., 1985) and the 
highest value on LW/BW in F344 rats (Melnick et al., 1987).  For kidney, toxicity data from 
NTP (1988) and Maltoni et al. (1986) were evaluated.  For rat kidney cytomegaly, BD05 values 
with superior fits (p > 0.1) ranged from 0.14 to 24 mg/kg-day for 8 data sets.  For toxic 
nephrosis, BD05s ranged from 5 to 276 mg/kg-day.  For eye defects (Narotsky et al., 1995) in rats, 
BD05s ranged from 231 to 308 mg/kg-day and the BD01s ranged from 48 to 60 mg/kg-day.  The 
authors noted high model dependence in the BD values generated.  They used the LOAEL of 10 
mg/kg-day and the BD of 82 mg/kg-day for liver effects in a calculation of safe drinking water 
concentrations of 1 and 10 ppm, respectively.  The kidney LOAEL and developmental NOAEL 
gave similar values. 
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Table 7. Benchmark Dose Estimates and LOAELs for TCE and Noncancer Endpoints 
Study  Species  Duration & 
Exposure 
Route 
Site 
Toxic Endpoint 
LOAEL 
BD10 or 
BD05* 
Authors’ 
Suggested 
UF 
Clewell et  Rat  Subchronic  CNS  7 ppm  30 
al., 1997  Inhalation  Decreased 
wakefulness 
50 ppm 
Rat  Subchronic 
Oral 
Cardiac 
abnormalities in 
offspring 
0.24 mg/kg­
day 
10 
0.18 mg/kg-day  0.009-0.018 
mg/kg-day in 
human PBPK 
3 
Haag- Rat  Chronic  Kidney  11-24  100 
Gronlund 
et al., 1995 
Oral  Cytomegaly 
500 mg/kg-day 
mg/kg-day 
Rat  Chronic 
Oral 
Kidney 
Nephropathy 
500 mg/kg-day 
50-210 
mg/kg-day 
100 
Mouse  Chronic 
Inhalation 
Tumors 
Lung 100 ppm 
Liver 100 ppm 
141 ppm 
594 ppm 
5000 
Mouse  Chronic 
Inhalation 
Liver effects
 35 ppm 
Kidney effects 
75 ppm 
CNS effects
 25 ppm 
23 ppm 
122 ppm 
10 ppm 
1000 
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Exposure 
Route 
Site 
Toxic Endpoint 
LOAEL 
BD10 or 
BD05* 
Authors’ 
Suggested 
UF 
Barton & 
Das, 1996 
Mouse  Chronic 
Oral 
Liver 
LW/BW 
100-800 mg/kg­
day 
82-289 
mg/kg-day* 
300 
Mouse  Chronic 
Oral 
Kidney 
Cytomegaly 
500 mg/kg-day 
0.14-24 
mg/kg-day* 
1000 
Mouse  Chronic 
Oral 
Kidney 
Toxic nephrosis 
250 mg/kg-day 
5-276 
mg/kg-day* 
1000 
Rat  Short term 
Gestation 
days 6-15 
Oral 
Eye defects 
101 mg/kg-day 
231-308 
mg/kg-day* 
1000 
Kahn et al., 
1995 
Mouse  Subchronic 
Intra-
peritoneal 
Autoimmune 
response 
328 mg/kg-day 
single dose frank 
effect? 
none  10,000 
Chia et al., 
1997 
Human  Subchronic 
Inhalation 
Endocrine 
effects trends: 
DHEAS ›; 
SHBG ﬂ; serum 
testosterone ﬂ 
5.4 mg/kg-day 
none  100 
Chia et al., 
1996 
Human  Subchronic 
Inhalation 
Increased 
hyperzoospermia 
ED10 = 0.2** 
mg TCA 
excreted/kg­
day 
30 
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Exposure 
Route 
Site 
Toxic Endpoint 
LOAEL 
BD10 or 
BD05* 
Authors’ 
Suggested 
UF 
Isaacson &  Rat  Subacute  Developmental  10,000 
Taylor, 
1989 
Oral in 
drinking 
water 
effect, decrease 
in myelinated 
fibers in the 
hippocampus 
LOAEL = 37 
mg/kg-day 
Maltoni et  Rat  Subchronic  Kidney toxicity  300 
al., 1986  Oral  NOAEL = 50 
mg/kg-day 
Fredriksson  Mouse  Subacute  Developmental  3000 
et al., 1993  Oral  effect, reduced 
rearing at 60 d 
LOAEL = 50 
mg/kg-day 
Note: DHEAS = dehydroepiandrosterone sulfate; SHBG = sex hormone binding globulin; 
** estimated by linear regression of % hyperzoospermia vs. level of TCE exposure 
indicated by urinary TCA in mg/g creatinine.  The TCA dose metric was adjusted to 
mg/kg-day assuming excretion of 25 mg creatinine/kg/day and 70 kg body weight.  The 
regression was % hyperzoospermia = 0.06 + 0.204(mg TCA/kg-day), R
2 = 0.98.  BD05 
values indicated by * 
Human Studies 
Clewell et al. (1997) also evaluated the data of Stewart et al. (1970) on humans exposed to 200 
ppm TCE for 7 hr/d for 5 days.  The endpoint was behavioral effects (mental fatigue and 
sleepiness).  A LOAEL of 200 ppm was reported for the study.  Clewell et al. (1997) concluded 
that benchmark modeling could not be performed on the study due to inadequate reporting of the 
data.  Using human PBPK modeling of the LOAEL (200 ppm x 7 hr), a blood peak concentration 
and AUC TCE target dose metrics were estimated.  These metrics were then divided by a 30 UF 
to obtain target dose metrics for the MRL.  The PBPK model was then run with varying 
continuous exposure conditions until the target dose metrics were obtained.  These values were 
reached at 8 ppm for the peak TCE concentration and two ppm for AUCTCE.  These MRLs are 
much higher than the current acute MRL value of 0.1 ppm.  This disparity is due to differences in 
calculating human equivalence since the latter depends on ratios of pulmonary ventilation and 
body weight whereas the former PBPK-based estimate is essentially based on the ratio of 
blood/air partition coefficients for TCE. 
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Animal Studies 
The data sets selected for dose response analysis were the liver tumors in the NCI (1976) study in 
B6C3F1 mice, the liver and lung tumors from Maltoni et al. (1986) in B6C3F1 mice, and the lung 
tumors from Fukuda et al. (1983) in ICR mice.  The NCI study used oral gavage administration 
of TCE while the other two studies used inhalation exposure.  Each of these data sets had at least 
two non-zero dose groups. 
For the dose response assessment of TCE in mice the PBPK modeling results of Abbas and 
Fisher (1997) were employed to estimate the following dose metrics: AUC of chloral hydrate 
(CH) for lung tumors and AUC of TCA+DCA for liver tumors.  Abbas and Fisher’s results are 
based on male B6C3F1 mice dosed orally with 300, 600, 1200, and 2000 mg/kg TCE.  The model 
predictions for CH in lung and the dose metric of AUC CH in mg hr/L d were regressed against 
applied dose to give the relation AUC CH = 0.05496 (mg/kg-day) - 3.46, R= 0.9976.  The AUC 
values were estimated by triangulation from the tabular Cmax values and the graphs of CH lung 
concentration vs. time in the paper as AUC (mg hr/L d) = Cmax-0.1 Cmax mg x 20 hr/2 L d.  A 
similar process on the liver TCA + DCA AUC produced the following relation: AUC TCA 
+DCA = 0.476 (mg/kg-day) + 191.2, R = 0.92.  For values below 300 mg/kg-day the relation was 
forced through the origin with a slope of 0.575 (mg/kg-day)/(mg hr/L d).  Using these 
relationships, bioassay doses could be converted to AUC dose metrics adjusted for lifetime 
exposure, converted back to oral equivalents and fitted to the tumor incidence data.  The metrics 
are summarized in Table 8 and the results of the analysis are shown in Table 9. 
Using the AUC TCA+DCA metric, the human equivalent LED10 values for liver tumors in both 
sexes in two studies by two routes of administration vary by 15 fold, i.e., 4.5-70 mg/kg-day.  For 
lung tumors with the AUC CH metric the LED10 values from two inhalation studies varied by a 
factor of two, i.e., 12-28 mg/kg-day.  The geometric mean (Gmean) CSF for the four liver data 
sets is 4.9 x 10
-3 (mg/kg-day)
-1 and for the two lung data sets is 5.5 x 10
-3 (mg/kg-day)
-1.  If the 
total TCE metabolism dose metric (AMET) (Cronin et al., 1995) is used, the LED10 values are 
lower at 1.3-29.1 mg/kg-day (CSFs of 0.021, 0.0047, 0.077, 0.0034 in Table 9) corresponding to 
a higher geometric mean CSF of 0.013 (mg/kg-day)
-1.  The three geometric mean CSFs vary by 
less than a factor of three.  Since the AMET dose metric gave a better fit on 2/4 data sets and fit 
all four with acceptable significance (p > 0.05), the CSF based on this metric, namely 0.013 
(mg/kg-day)
-1, is considered the most appropriate for use in calculating possible PHG values. 
While carcinogenic potencies based on the linearized multistage model (LMS) varied somewhat 
from CSFs depending on the specific data set, the geometric mean potency estimate for liver 
tumors with the AMET dose metric was identical to that derived from the CSFs.  Different 
authors have published different quantal responses for some of the data sets listed in Table 8, 
particularly for the Maltoni et al. (1986) liver tumor data.  The calculations noted above were 
performed on the Maltoni mouse liver tumor values noted by Bogen & Gold (1997) (Table 5) and 
Fisher & Allen (1993) for both dose metrics.  While the latter are used in the current analysis, the 
Bogen & Gold values gave only slightly higher CSFs of 6.1 x 10
-3 (mg/kg-day)
-1 for the AUC 
based Gmean and 0.014 (mg/kg-day)
-1 for the AMET based Gmean. 
Not included in Table 9 are the dose response results from the combined male mouse groups 
from Maltoni et al. (1986) (BT306 and BT306-bis).  For the AMET dose metric this combined 
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-1 with adequate fit statistics.  The AUC metric did not 
give an adequate fit with this data set (chi squared = 8.24, p = 0.02).  These are not considered 
significant differences from the values given above in the context of this risk assessment. .  The 
CSF value of 0.013 (mg/kg-day)
-1 is consistent with previous estimates of carcinogenic potency 
from OEHHA (DHS, 1990ab; Cal/EPA, 1994). 
Table 8. Summary of Dose Metrics and Doses Used in the TCE Cancer Dose Response 
Study, Site  Sex, Species  Dose Metric [a]  Oral or Oral Equivalent 
Continuous Lifetime Doses 
mg/kg-day 
NCI, 1976 
Liver 
Tumors 
Male Mouse  AUC TCA + DCA  0, 172.4, 697.3 
Female Mouse  AUC TCA + DCA  0, 139.4, 456.7 
Male Mouse  AMET  0, 69.2, 84.0 
Female Mouse  AMET  0, 57.7, 73.1 
Maltoni et 
al. 1986 
Liver 
Tumors 
Male Mouse 
Female Mouse 
AUC TCA + DCA  0, 50.6, 88.9, 542.5 
Male Mouse  AMET  0, 58.7, 150.6, 190 
Female Mouse  AMET  0, 58.4, 125.5, 155.5 
Lung 
Tumors 
Female Mouse  AUC CH  0, 67.7, 82.0, 103.8 
Fukuda et al. 
1983 
Female Mouse  AUC CH  0, 27.6, 115.4, 571.9 
Note:[a] AUC TCA + DCA is the area under the liver concentration x time curve for the sum of 
TCA and DCA; AMET is the total amount of TCE metabolized by the liver; AUC CH is the area 
under the curve for the chloral hydrate metabolite in the lung. 
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Table 9. Carcinogenic Dose Response Estimates for TCE Based on PBPK Dose Metrics and 
Mouse Bioassays 
Study, sex, 
route, site 
Applied 
Doses[a] 
AUC or 
AMET 
Lifetime Dose 
Metrics 
Quantal Tumor 
Incidence; 
C C
2 , p, k [d] 
ED10/LED10 
mg/kg-day 
Human 
equivalent[e] 
CSF [f] 
q1* [g] 
(mg/kg-day)
-1 
NCI, 1976  0, 869,  [b] 0, 242*,  0/20, 4/50,11/50;  29.1/10.2  9.8 x 10
-3 
female, 
gavage, liver 
1739
 mg/kg­
day 
408.6 mg hr/L 
d; 
[c] 0, 57.7, 
0.03, 0.87, 2;  5.7 x 10
-3 
73.1 mg/kg-day  1.16, 0.28, 2  8.1/4.8  2.1 x 10
-2 
2.4 x 10
-2 
male,  0, 1169,  [b] 0, 299.8*,  1/20, 26/50,30/50;  13.3/4.5  2.2 x 10
-2 
gavage, liver 
tumors 
2339 
mg/kg­
day 
523, mg hr/L d;  9.34, 0.002, 2;  1.3 x 10
-2 
[c] 0, 69.2, 
84.0 mg/kg-day 
0, 1, 2  2.0/1.3  0.077 
0.089 
Maltoni  et  0, 100,  [b] 0, 134, 255,  2/90, 3/90, 4/89,  102/53.6  1.9 x 10
-3 
al., 1986, 
female, 
inhalation, 
liver tumors 
(Fisher & 
300, 600 
ppm 
436 
mg hr/L d; 
9/87; 
0.12, 0.94, 3 
2.1 x 10
-3 
Allen, 1993)  [c] 0, 58.4, 
125.5, 155.5 
0.63, 0.73, 3  27.2/21.4  4.7 x 10
-3 
mg/kg-day 
4.3 x 10
-3 
(Bogen & 
Gold,1997) 
[b]0, 134, 255, 
436 mg hr/L d 
3/88, 4/89, 4/88, 
9/85; 
116/57.2  1.7 x 10
-3 
0.03, 0.99, 3; 
2.0 x 10
-3 
[c]0, 58.4, 
125.5, 155.5 
0.89, 0.64, 3 
27.8/22.7 
4.4 x 10
-3 
mg/kg-day  4.2 x 10
-3 
male,  0, 100,  [b] 0, 134, 255,  1/85, 1/86, 3/88,  144/71.4  1.4 x 10
-3 
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Study, sex, 
route, site 
Applied 
Doses[a] 
AUC or 
AMET 
Lifetime Dose 
Metrics 
Quantal Tumor 
Incidence; 
C C
2 , p, k [d] 
ED10/LED10 
mg/kg-day 
Human 
equivalent[e] 
CSF [f] 
q1* [g] 
(mg/kg-day)
-1 
inhalation,  300, 600  436 6/88;  1.6 x 10
-3 
liver tumors  ppm  mg hr/L d;  0.76, 0.69, 3 
(Fisher & 
Allen, 1993) 
[c] 0, 58.7,  0.07, 0.97, 3  356/29.4  3.4 x 10
-3 
150.6, 190.0 
mg/kg-day 
2.6 x 10
-3 
(Bogen & 
Gold, 1997) 
[b]0, 134, 255, 
436 mg hr/L d 
1/59, 1/31, 3/38, 
6/37; 
51.0/27.0  3.7 x 10
-3 
4.2 x 10
-3 
0.86, 0.65, 3 
[c]0, 58.7, 
150.6, 190.0 
0.14, 0.71, 3  25.9/16.1  6.2 x 10
-3 
7.0 x 10
-3 
female,  0, 100,  0, 4.75, 19.1,  2/90, 6/90, 7/89,  14.4/12.0  8.3 x 10
-3 
inhalation, 
lung tumors 
300, 600 
ppm 
40.8 
mg hr/L d 
14/87; 
0.22, 0.90, 3 
9.0 x 10
-3 
Fukuda et  0, 50,  0,1.52*, 9.8,  1/49, 3/50, 8/50,  62.1/27.8*  3.6 x 10
-3 
al., 1983, 
female, 
inhalation, 
150, 450 
ppm 
34.9
 mg hr/L d 
7/46; 
5.2, 0.07, 3 
3.8 x 10
-3 
lung tumors 
Gmean  48.8/20.4  4.9 x 10
-3 
Liver  AUC 
[b] 
4.5 x 10
-3 
38.9/16.3  6.1 x 10
-3 
5.0 x 10
-3 
Gmean  19.9/7.9  0.013 
Liver 
AMET [c] 
0.012 
10.4/6.9  0.014 
0.016 
Gmean  29.9/18.3  5.5 x 10
-3 
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route, site 
Applied 
Doses[a] 
AUC or 
AMET 
Lifetime Dose 
Metrics 
Quantal Tumor 
Incidence; 
C C
2 , p, k [d] 
ED10/LED10 
mg/kg-day 
Human 
equivalent[e] 
CSF [f] 
q1* [g] 
(mg/kg-day)
-1 
Lung 
AUC [b] 
5.9 x 10
-3 
Notes: 
[a] Unadjusted applied doses. 
[b] AUC dose metrics from linear regressions of AUC values for CH (lung) or TCA+DCA (liver) 
vs. oral mg/kg-day (Abbas & Fisher, 1997); inhalation applied doses first converted to mg/kg-day 
(DHS, 1990), adjustments made to AUC doses to produce lifetime average daily AUC doses 
(DHS, 1990).  Lifetime AUCs were converted back to oral mg/kg-day equivalent using 
regression (* in three low doses the slope was forced through zero) and the oral equivalent AUC 
doses were then fit to the tumor incidence data using Tox_Risk v.3.5. 
[c] AMET dose metric from Cronin et al. (1995) is the total amount of TCE metabolized, in 
mg/kg-day, converted to a continuous lifetime daily dose. 
[d] Quantal tumor responses for respective doses, fit statistics by Tox_Risk v. 3.5 using 
multistage polynomial in bold face, values of p greater than 0.05 are considered acceptable fits. 
[e] LED10 human equivalents are produced by the Tox_Risk v. 3.5 program using (body 
weight)
3/4 interspecies scaling. 
[f] Carcinogen slope factor (CSF) is calculated as 0.1/LED10. 
[g] q1* carcinogenic potency determined by the linearized multistage model (Tox_Risk v.3.5). 
For Maltoni et al. (1986) data sets quantal tumor responses as reported by Fisher & Allen (1993) 
and by Bogen & Gold (1997) were analyzed and included in separate Gmeans. 
Human Studies 
The study of Henschler et al. (1995a) on kidney cancer in TCE exposed cardboard workers may 
provide a useful estimate of TCE carcinogenic potency, although there are few exposure or dose-
response data as such.  If we assume continuous exposure to TCE during the working hours at 
the German threshold limit value of 50 ppm for the average exposure duration of 15.2 yr, it 
seems unlikely that the total TCE intake would be seriously underestimated notwithstanding 
episodic exposures to several times this value.  If we also assume 50% of inhaled TCE is 
absorbed we can estimate the daily continuous intake of TCE as follows: 
50 ppm x 5.37 mg/m
3/ppm x 20 m
3/d/70 kg x 5 d/7 d x 8 hr/24 hr x 0.5 = 9.13 mg/kg-day. 
TRICHLOROETHYLENE in Drinking Water 
California Public Health Goal (PHG)  74  February 1999  
The kidney cancer incidence in the Henschler et al. study was 7/169 = 0.0414.  The background 
rate of kidney cancer based on the standardized incidence ratio (SIR = observed kidney 
cancers/expected kidney cancers) of 13.53 from the German Cancer Registry was about 0.003, 
indicating a TCE-induced incidence of 0.038.  Adjusting this value to an incidence resulting from 
a 70 yr lifetime exposure gives 0.038 x (70/15.2) = 0.175.  Assuming linearity of dose-response a 
potency estimate of 0.175/9.13 = 0.019 (mg/kg-day)
-1 is obtained. 
Bruning et al. (1997b) have studied the influence of glutathione transferase (GST) 
polymorphisms on risk of kidney cancer in workers with long-term high occupational exposure to 
TCE (see study summary above).  Their data indicate that persons with the combined genotypes 
for GSTM1 and GSTT1 (+/+), representing about 40% of the European (Caucasian) population, 
are at higher risk of developing kidney cancer from TCE exposures.  The odds ratio (OR) for the 
(+/+) combined genotype vs. the other combinations (-/+, +/-, -/-) was 3.75.  If we assume the 
study population in Henschler et al. was balanced with a 40% (+/+) frequency, then the relative 
potency in this sensitive sub-population would be about 0.035 (mg/kg-day)
-1 vs. 0.009 (mg/kg­
day)
-1 for the other genotype combinations.  Similarly the 47% of the population with GSTM1 
(+/+, +/-) had an OR of 2.74 and an average TCE potency of 0.03 (mg/kg-day)
-1 compared to the 
85% subpopulation with the GSTT1 (+/+, -/+) with an OR of 4.16 and a potency of 0.017 
(mg/kg-day)
-1.  The frequency of the genotypes in the Bruning et al. study of 93 subjects was: 
(+/+) 40 %; (-/+) 45%; (+/-) 7.5%; and (-/-) 7.5%. 
CALCULATION OF PHG 
Calculations of concentrations of chemical contaminants in drinking water associated with 
negligible risks for carcinogens or noncarcinogens must take into account the toxicity of the 
chemical itself, as well as the potential exposure of individuals using the water.  Tap water is 
used directly as drinking water and for preparing foods and beverages.  It is also used for bathing 
or showering, and in washing, flushing toilets and other household uses resulting in potential 
dermal and inhalation exposures. 
Noncarcinogenic Effects 
Calculation of a public health-protective concentration (C, in mg/L) for TCE in drinking water 
for noncarcinogenic endpoints follows the general equation: 
C  =  NOAEL/LOAEL x BW x RSC
 UF x W 
where, 
NOAEL/LOAEL  =	  No-observed-adverse-effect-level or lowest-observed-adverse-effect­
level, or an appropriate benchmark dose (e.g., BD10) 
BW  =	  Adult body weight (a default of 70 kg for average human, 60 kg for 
female, and 10 kg for a child) 
RSC  =	  Relative source contribution (a default of 20%, 40%, or 80%). 
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UF  =  Uncertainty factors (typical defaults of 10 to account for LOAEL to 
NOAEL, 10 for inter-species extrapolation, 10 for subchronic study to 
lifetime exposure, and 10 for inter-individual variation in sensitivity to 
toxic chemicals) 
W  =  Adult daily water consumption rate; default of 2.0 L/day for a 70 kg 
adult and 1.0 L/day for a 10 kg child.  Higher liter equivalents/day 
(Leq/day) are used to account for inhalation and dermal exposures to 
volatile organic compounds (VOCs) through showering, bathing, 
flushing of toilets and other typical household uses of tap water. 
In Table 10, the value of C in the equation above was calculated for a number of selected 
noncancer toxic endpoints (see Table 6 above for details).  In these calculations a relative source 
contribution of 20% (0.2) was used since TCE residues have been measured in a number of food 
products.  In addition a multi-route tap water intake value of 7.1 Leq/day (Bogen et al., 1988; 
Bogen et al., 1992) was used to account for ingestion, dermal and inhalation exposures from 
typical household uses of TCE contaminated tap water.  This value was based on the equivalent 
lifetime daily fluid intake by a 70 kg adult or the sum of 2.2 L ingestion absorption, 2.9 Leq 
inhalation absorption, and 2.0 Leq dermal absorption.  Bogen et al. (1988) also give upper bound 
estimates of 3.8 L, 11.9 Leq, and 2.6 Leq respectively for a total upper bound exposure of 18.3 
Leq/day.  Note that the earlier mentioned study of Weisel and Jo (p. 14) measured showering and 
bathing exposures only and not other household exposures which would be expected to add to 
the inhalation exposure.  Their results would indicate lower estimates of 2 L, 3 Leq and 3 Leq (8 
Leq total) and upper estimates of 2 L, 6 Leq, and 6 Leq (14 Leq total) for ingestion, inhalation 
and dermal intakes, respectively.  An alternative analysis was performed using CalTOX�, a 
multimedia total exposure model (v. 1.5, DTSC, 1994).  For tap water containing 5 ppb TCE the 
CalTOX model predicts lower dermal and inhalation doses relative to ingestion, namely 12% 
dermal, 40% inhalation, and 48% ingestion, at 0.022 L/kg-day tap water ingestion.  Overall the 
estimates of Bogen et al. (1988) seem best suited to use in this calculation.  Other assumptions 
are given in Table 10 below. 
Among the studies listed in Table 10 the kidney nephropathy endpoint in a chronic rat study is 
judged to be the most reliable and relevant for human risk assessment because the kidney is an 
important target of TCE toxic action.  The value of C based on this endpoint could be rounded to 
1 mg/L or 1 ppm: 
C  =  50 mg/kg-day  x  70 kg  x  0.2  =  0.986 mg/L  =  1.0 mg/L (rounded)  =  1.0 ppm 
100  x  7.1 Leq/day 
In this calculation we employ the BD10 as a chronic NOAEL with 10-fold uncertainty factors 
(UF) for interspecies and interindividual differences.  No additional uncertainty factor is added 
for potential carcinogenicity in the kidney.  A relative source contribution default of 0.2 (20%) 
and the total water intake from ingestion, dermal and inhalation exposures of 7.1 Leq/day are 
applied. 
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Table 10. Estimated Health Protective Drinking Water Concentrations [C] Based on 
Noncancer Toxicity Endpoints 
Study  Species 
Duration 
Route 
Toxicity 
Endpoint 
BD10/05 or 
LOAEL/ 
NOAEL 
Uncertainty 
Factor (UF) 
C, mg/L, 
ppm 
Chia et al.,  Human,  Hyperzoo­ 0.2 mg/kg-day  30  0.013 
1996  subchronic 
inhalation 
spermia  [a] 
Clewell et  Rat,  Cardiac  0.009 mg/kg-day  3-10  0.0017­
al., 1997  subchronic 
oral 
abnormalities  [b]  0.005 
Haag- Rat, chronic  Kidney  50 mg/kg-day  100  0.98 
Gronlund et  oral  nephropathy  [c] 
al., 1995 
Barton &  Mouse,  Liver effects,  82 mg/kg/d [c]  1000  0.16 
Das, 1996  subchronic 
oral 
LW/BW 
Barton &  Rat  Eye defects  101 mg/kg-day  1000  0.17 
Das, 1996  subacute oral  [d] 
Notes:  [a] ED10 based on linear regression of urinary TCA vs. % hyperzoospermia; [b] 
BD05 value includes human pharmacokinetic adjustment; [c] BD10; [d] LOAEL. 
Carcinogenic Effects 
For carcinogens, the following general equation can be used to calculate the public health-
protective concentration (C) for a carcinogenic chemical in drinking water (in mg/L): 
C  =  BW  x  R  =  mg/L 
CSF  x  W 
where, 
BW  =	  Adult body weight (a default of 70 kg) 
R  =	  De minimis level for theoretical lifetime excess individual cancer risk (a 
default of 10
-6) 
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CSF  =	  Cancer slope factor, CSF, is a potency derived from the lower 95% 
confidence limit on the 10% tumor dose (LED10).  CSF = 0.1/ LED10. 
The q1*, included for comparison, is the upper 95% confidence limit on 
the low dose slope calculated by the LMS model.  Both potency 
estimates are converted to human equivalent [in (mg/kg-day)
-1] using 
BW
3/4 scaling from the animal data. 
W  =	  Daily volume of water consumed by an adult.  A default of 2.0 L/day is 
used for a 70 kg adult and 1.0 L/day for a 10 kg child.  Larger values of 
L equivalents/day (Leq/day) are used to account for multi-route 
exposures to volatile organic chemicals (VOCs). 
The purpose of comparing two potency estimates for a carcinogen is based on the fact that our 
current experience-base is largely with the LMS model whereas the new methodology, proposed 
by U.S. EPA (1996) in its draft guidelines for carcinogen risk assessment, is based on the LED10 
which has a more limited experience-base.  The LMS model focuses on the linear low dose 
extrapolation, and analysts (e.g., U.S. EPA) have often accepted relatively poor fits to the 
observed tumor incidence data.  The new method places a higher premium on fitting the observed 
data to estimate the ED10 and the 95% lower bound (LED10), the point from which the low dose 
extrapolation is made (U.S. EPA, 1996). 
Using the Gmean CSF from the AMET dose metric for mouse liver tumors of 0.013 (mg/kg-day)
­
1 from the NCI (1976) and the Maltoni et al. (1986) studies, and a value of 7.1 Leq/day for water 
consumption, the water concentration corresponding to a negligible cancer risk, C, is calculated 
as follows: 
C  =  70 kg  x  10
-6	  =  7.6 x 10
-4 mg/L
 0.013 (mg/kg-d)
-1  x  7.1 Leq/day
 =  0.8 ppb 
If we assumed that the dose response is nonlinear we could treat the LED10 for liver tumors as a 
chronic LOAEL.  In this case appropriate uncertainty factors would be 10 for LOAEL to 
NOAEL, 3 for interspecies extrapolation (since the LED10 estimate incorporates an interspecies 
adjustment), 10 for interindividual variation, and 10 for severity of effect, possibly cancer, giving 
a total UF of 3,000.  Note that the relative source contribution (RSC) is included in this 
calculation. 
C  =  7.9 mg/kg-d  x  70 kg  x  0.2  =  5.2 x 10
-3 mg/L 
3,000  x  7.1 Leq/day 
=  5 ppb 
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Since the values for the cancer endpoint are lower than the values calculated for noncancer 
endpoints in Table 10, the PHG should be based on the more health protective cancer endpoint. 
Of the dose response approaches for the cancer endpoint, the linear default is appropriate to use 
for TCE because the nonlinear MOA is insufficiently supported by the data, and in view of the 
specifications of the PHG, namely in cases when “the currently available scientific data is 
insufficient to determine the amount of a contaminant that creates no significant risk to public 
health, the public health goal shall be set at a level that is protective of public health.”  Thus the 
value of 0.8 ppb is the PHG for TCE.  This value is lower than current state and federal MCLs 
of 5 ppb and is identical to the value calculated from current Cal/EPA oral and inhalation 
potencies for TCE of 0.015 and 0.01 (mg/kg-day)
-1 respectively, namely 0.8 ppb (Cal/EPA, 
1994).  It is also similar to the estimate based on the occurrence of kidney cancer in human 
cardboard workers with occupational exposures at or above the German TLV.  This study would 
indicate a health-protective water concentration of 0.5 ppb (range 0.3 -1.1 ppb), albeit with less 
certainty than the mouse based value, based on an estimated potency of 0.019 (range 0.009 to 
0.035) (mg/kg-day)
-1 (Henschler et al., 1995a). 
RISK CHARACTERIZATION 
The PHG of 0.8 ppb was calculated from the cancer slope factor (CSF) of 0.013 (mg/kg-day)
-1 
based on the geometric mean of CSF values of liver tumors from the NCI (1976) and Maltoni et 
al. (1986) studies using the AMET dose metric.  In calculating the PHG, a de minimis theoretical 
excess individual cancer risk level of 10
-6 was assumed.  The corresponding levels for cancer risk 
levels of 10
-5 or 10
-4 are 8 and 80 ppb, respectively. 
Some of the uncertainties involved in the present assessment can be listed as follows: 
•	  CSF based on the LED10 vs. the q1* based on the linearized multistage model.  Since the 
Gmeans for the tumor site and dose metric of choice, i.e., liver by AMET, are identical, there 
is no difference between the methods.  For lung tumors the CSF is 7% lower and for liver 
tumors using AUC metric the CSF is 23% higher.  For the sum of lung and liver by AUC the 
CSF is 5% higher than a LMS based potency.  Typically CSF and q1* values differ by 5­
10%. 
•	  Use of the AMET dose metric based CSF vs. the AUC-based values.  The difference is a 2.5­
fold greater estimate of theoretical extra lifetime risk for a single site.  However if the sum of 
liver and lung tumors by AUC is chosen the difference is only 17% higher.  The AUC values 
are based on estimates made from published graphs of blood or tissue concentrations of 
metabolites versus time and are thus less accurate than the published AMET values.  The 
AUC values are probably underestimates by 10% or more. 
•	  Use of an average value vs. a CSF based on the most sensitive tumor site.  The highest CSF 
calculated was 0.077 and the lowest was 0.0014 (mg/kg-day)
-1, a 55-fold range.  The selected 
value was six-fold less than the highest individual value and nine-fold higher than the lowest 
individual value. 
•	  Use of (body weight)
3/4 interspecies scaling vs. (body weight)
2/3  scaling, no scaling, or the 
use of a human PBPK model.  Scaling from mouse to human using the ¾ power increases the 
CSF value about 6.5-fold vs no scaling.  Previous scaling using the 2/3 power would increase 
the value by 13-fold.  The scaling factor is used to account for metabolic and tumor response 
differences between rodents and humans where humans are generally considered the more 
sensitive species.  Calculations made by Fisher (1993) using a human PBPK model and the 
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AMET dose metric as described above yielded a safe drinking water concentration of 7 ppb 
(see also Fisher & Allen, 1993; Allen & Fisher, 1993).  The methods of Fisher and Allen 
only address pharmacokinetic differences in the interspecies extrapolation and not possible 
pharmacodynamic differences or significant interindividual differences (see Fisher et al., 
1998). 
•	  Use of linear dose response for cancer risk assessment vs. a nonlinear approach.  If instead of 
the linear approach we applied the nonlinear approach as described above we would obtain a 
value of 5 ppb or six-fold higher than the proposed value of 0.8 ppb.  In this calculation an 
uncertainty factor of 3,000 was applied to the LED10 of 8 mg/kg-day (see above). 
•	  Use of animal data vs. human data.  The estimates based on human data including sensitive 
subpopulations with specific GST polymorphisms range from three-fold higher to two-fold 
lower CSFs vs the mouse based values.  However the human exposure estimates are too 
uncertain to rely on fully but are in fair agreement with the mouse based CSF.  In view of the 
uncertainty in the human exposure data, it is an open question whether mouse liver-based 
CSF estimates adequately protect humans against TCE-induced renal cancer.  In general, 
tumor concordance between species is poor.  In addition there may be other sensitivity 
factors besides GST polymorphisms related to age and disease conditions.  Also the GST 
polymorphisms have only been studied in limited subpopulations. 
•	  Stochastic Analysis.  A number of the factors noted above were included in a stochastic 
analysis to forecast a PHG distribution based on distributions of the component variates. 
Included in the analysis were: adult human body weight, a lognormal distribution with a 
mean and standard deviation of 71.0 – 15.9 kg (range 45-115 kg); relative source 
contribution, a triangular distribution, minimum = 0.1, maximum = 0.8, likeliest = 0.2; water 
consumption (multiroute) in Leq/day, triangular distribution, min. =1.0 L/day, max. = 18 
Leq/day, likeliest = 7.1 Leq/day; and a fixed CSF of 0.013 (mg/kg-day)
-1.  The Monte Carlo 
analysis was performed using Microsoft Excel v. 4.0 and Crystal Ball v. 4.0 
(Decisioneering).  The forecast mean values based on 20,000 trials with Latin hypercube 
sampling were: PHG = 0.28 ppb; body weight = 71.17 kg; RSC = 0.37; water intake = 8.8 
Leq/day.  Fifty percent of the forecast PHG values fell between 0.14 and 0.35 ppb and the 
95
th percentile of the distribution was 0.7 ppb.  Note that the stochastic analysis includes the 
RSC, unlike the calculation noted in the text above.  If interspecies scaling power (triangular 
distribution, min. = 0.67, max = 1.0, likeliest = 0.75) and LED10 values for all cancer sites 
(triangular distribution, min. = 1.3, max. = 71.4, likeliest = 7.9 mg/kg-day) were included in 
the Monte Carlo simulation, the forecast PHG values were: mean = 0.9 ppb, median = 0.58 
ppb, with 50% of the predicted values falling between 0.29 and 1.1 ppb.  If the calculation 
was extended to include the range of ED10 values, the forecast values were 4.2 ppb, 2.5 ppb, 
and 1.1-5.2 ppb, respectively.  Current OEHHA recommendations for stochastic analysis 
apply only to exposure variates (OEHHA, 1997).  Overall the results of this brief stochastic 
analysis are similar to the range of safe water concentrations in the main analysis above, i.e., 
about 0.5 to 5.0 ppb. 
TCE may have synergistic or antagonistic interactions with other chemicals (e.g., DEHP or 1,1­
DCE) but these effects were noted at higher doses, unlikely to be relevant to drinking water 
exposures to TCE.  However this is an area of limited data and further studies need to be 
conducted with other common water contaminants. 
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related to showering, bathing, flushing toilets and other typical household uses of tap water.  An 
estimate of such exposures is included in the calculation of the PHG.  The range of estimates 
from Bogen et al. (1988) is 2.2 L/day for ingestion of water only, to 18.3 Leq/day for the upper 
bound on the sum of ingestion (3.8 L/day), inhalation, and dermal absorption.  Predictions of the 
CalTOX� program ranged from total intakes of 4.2 Leq/day for average exposure to 26.5 Leq/d 
for high exposure.  For these calculations water ingestion values were 1.36 L/day (CalTOX 
default), 1.68 L/day (high point estimate, OEHHA, 1997), and 2.29 L/day, the average for 
lactating women (Ershow et al., 1991).  The body weight was 62 kg (CalTOX default) and it was 
assumed that 50% of inhaled dose was absorbed and 100% of ingestion and dermal doses were 
absorbed. 
The relative source contribution (RSC) chosen for TCE is the 20% default, indicating anticipated 
exposure via other sources besides drinking water, notably ambient air and food.  A larger RSC, 
based on a more detailed exposure assessment, would possibly give a higher PHG value. 
OEHHA scientists have determined that the 80% default is not appropriate for use in the case of 
TCE. 
For PHGs, our use of the RSC has, with a few exceptions, followed U.S. EPA drinking water risk 
assessment methodology.  U.S. EPA has treated carcinogens differently from noncarcinogens 
with respect to the use of RSCs.  For noncarcinogens, RfDs (in mg/kg-day), drinking water 
equivalent levels (DWELs, in mg/L) and MCLGs (in mg/L) are calculated using uncertainty 
factors (UFs), body weights and water consumption rates (L/day) and the RSC respectively.  The 
RSC defaults are 20% for agents with expected non-water sources or 80% for agents whose 
anticipated exposure is mainly from water (0.2, 0.8) other values are used depending on the 
strength of scientific evidence supporting them. 
For approaches that use low-dose extrapolation based on quantitative risk assessment, U.S. EPA 
does not factor in an RSC.  The use of low-dose extrapolation is considered by U.S. EPA to be 
adequately health-protective without the additional source contributions.  In developing PHGs, 
we have adopted the assumption that RSCs should not be factored in for carcinogens grouped in 
U.S. EPA categories A and B, and for C carcinogens for which we have calculated a cancer 
potency based on low-dose extrapolation.  This is an area of uncertainty and scientific debate and 
it is not clear how this assumption impacts the overall health risk assessment. 
OTHER REGULATORY STANDARDS 
The U.S. EPA has established a National Primary Drinking Water Standard or maximum 
contaminant level (MCL) of 0.005 mg/L (5 ppb) and a maximum contaminant level goal 
(MCLG) of zero mg/L for TCE.  They have also set a drinking water equivalent level (DWEL) of 
0.3 mg/L and a 1E-4 cancer risk level of 0.3 mg/L.  U.S. EPA (1985a) has classified TCE as a 
probable human carcinogen, B2.  Subsequently U.S. EPA’s Science Advisory Board concluded 
that TCE was on a continuum between a possible human carcinogen, C, and a probable human 
carcinogen, B2.  U.S. EPA is currently reassessing TCE for oral and inhalation reference doses, 
cancer classification, etc. 
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drinking water standard (MCL) of 0.005 mg/L (5 ppb) for TCE (Section 64444, California 
Health & Safety Code).  Under Proposition 65 risk specific intake levels of 50 mg/day for 
ingestion and 80 mg/d for inhalation have been established for TCE (DHS, 1990; OEHHA, 1996). 
The Agency for Toxic Substances and Disease Registry (ATSDR) has derived an acute duration 
inhalation MRL of 2 ppm with an uncertainty factor of 30 for TCE based on neurological effects 
in humans (Stewart et al., 1970), and an intermediate duration MRL of 0.1 ppm with an 
uncertainty factor of 300, based on neurological effects in rats (Arito et al., 1994).  An acute 
duration oral MRL of 0.2 mg/kg-day with an uncertainty factor of 300 was derived based on 
developmental effects in mice (Fredriksson et al., 1993; ATSDR, 1997). 
The International Agency for Research on Cancer (IARC) designated TCE as Group 2A, 
probably carcinogenic to humans (IARC, 1995). 
The World Health Organization (WHO) has set a drinking water guidance level of 0.03 mg/L 
based on the carcinogenic endpoint (WHO, 1984). 
The American Conference of Governmental Hygienists (ACGIH) has recommended a TLV 
TWA of 50 ppm TCE and a STEL of 100 ppm TCE (ACGIH, 1996). 
U.S. EPA has set the following Ambient Water Quality Criteria for Protection of Human Health: 
for consumption of water and aquatic organisms, 2.7 mg/L for 10
-6 lifetime risk.  For ingestion of 
organisms only, 80.7 mg/L for 10
-6 lifetime risk. 
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